2024-03-28T22:31:02Z
http://www.ijcto.org/index.php/IJCTO/oai
oai:ojs.ijcto.org:article/23
2014-03-18T16:01:57Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Saha
2014-03-18T16:01:57Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 2 (2013): November - December
Assessment of pulmonary toxicities in breast cancer patients undergoing treatment with anthracycline and taxane based chemotherapy and radiotherapy- a prospective study
Saha, Aramita; Apollo Gleangles Cancer Hospital
Chattopadhyay, Subrata; Medical College,Kolkata
2013-11-22 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Saha
Oncology
Anthracycline, Taxane, Radiotherapy, Pulmonary, FEV1/FVC
Breast Cancer
en
Background: Anthracycline based regiments and/or taxanes and adjuvant radiotherapy; the main modalities of treatment for breast cancers are associated with deterioration of pulmonary functions and progressive pulmonary toxicities. Aim: Assessment of pulmonary toxicities and impact on pulmonary functions mainly in terms of decline of forced vital capacity (FVC) and the ratio of forced expiratory volume (FEV) in 1 Second and FEV1/FVC ratio with different treatment times and follow ups in carcinoma breast patients receiving anthracycline and/or taxane based chemotherapy and radiotherapy. Materials and methods: A prospective single institutional cohort study was performed with 58 breast cancer patients between January 2011 to July 2012 who received either anthracycline based (37 patients received 6 cycles FAC= 5 FU, Adriamycin, Cyclophosphamide regime) and radiotherapy or anthracycline and taxane based chemotherapy (21 patients received 4cycles AC= Adriamycin, Cyclophosphamide; followed by 4 cycles of T=Taxane) and radiotherapy. Assessment of pulmonary symptoms and signs, chest x-ray and pulmonary function tests were performed at baseline, midcycle, at end of chemotherapy, at end radiotherapy, at 1 and 6 months follow ups and compared. By means of a two-way analysis of variance (ANOVA) model, the course of lung parameters across the time points was compared. Results and Conclusion: Analysis of mean forced vital capacities at different points of study times showed definitive declining pattern, which is at statistically significant level at the end of 6th month of follow up (p=0.032) .The FEV1/FVC ratio (in percentage) also revealed a definite decreasing pattern over different treatment times and at statistically significant level at 6th month follow up with p value 0.003. Separate analysis of mean FEV1/FVC ratios over time in anthracycline based chemotherapy and radiotherapy group as well as anthracycline and taxane based chemotherapy and radiotherapy group showed a similar declining pattern.-------------------------Cite this article as:Saha A, Chattopadhyay S. Assessment of pulmonary toxicities in breast cancer patients undergoing treatment with anthracycline and taxane based chemotherapy and radiotherapy- a prospective study. Int J Cancer Ther Oncol 2013; 1(2):01021.DOI: http://dx.doi.org/10.14319/ijcto.0102.1
oai:ojs.ijcto.org:article/95
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Casesnoves
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Geometrical determinations of IMRT photon pencil-beam path in radiotherapy wedges and limit divergence angle with the Anisotropic Analytic Algorithm (AAA)
Casesnoves, Francisco; Society for Industrial and Applied Mathematics (SIAM) (Individual Researcher), Denver, Colorado, USA.
2014-05-18 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Casesnoves
Medical Physics
Radiotherapy; Intensity Modulated Radiation Therapy; Static Alloy Wedges; Analytic Geometry; Treatment Planning Optimization (TPO); Analytic Anisotropic Algorithm (AAA); Superposition-Convolution Models (SCM)
en
Purpose: Static wedge filters (WF) are commonly used in radiation therapy, forward and/or inverse planning. We calculated the exact 2D/3D geometrical pathway of the photon-beam through the usual alloy WF, in order to get a better dose related to the beam intensity attenuation factor(s), after the beam has passed through the WF. The objective was to provide general formulation into the Anisotropic Analytical Algorithm (AAA) model coordinates system (depending on collimator/wedge angles) that also can be applied to other models. Additionally, second purpose of this study was to develop integral formulation for 3D wedge exponential factor with statistical approximations, with introduction for the limit angle/conformal wedge.Methods: The radiotherapy model used to develop this mathematical task is the classical superposition-convolution algorithm, AAA (developed by Ulmer and Harder). We worked with optimal geometrical approximations to make the computational IMRT calculations quicker/reduce the planning-system time. Analytic geometry/computational-techniques to carry out simulations (for standard wedges) are detailed/developed sharply. Integral developments/integral-statistical approximations are explained. Beam-divergence limit Angle for optimal wedge filtration formulas is calculated/sketched, with geometrical approximations. Fundamental trigonometry is used for this purpose.Results: Extent simulation tables for WF of 15º, 30º, 45º, and 60º are shown with errors. As a result, it is possible to determine the best individual treatment dose distribution for each patient. We presented these basic simulations/numerical examples for standard manufacturing WF of straight sloping surface, to check the accuracy/errors of the calculations. Simulations results give low RMS/Relative Error values (formulated) for WF of 15º, 30º, 45º, and 60º.Conclusion: We obtained a series of formulas of analytic geometry for WF that can be applied for any particular dose delivery model. Simulations results gave acceptable trigonometrical approximations/data that can be used for LINAC applications/planning-system software. The integral formulas presented are practical for dose delivery calculations/3D-approximations when using WF/other similar types of beam modification devices. Limit angle formulation and conformal wedge concept was also presented...................................................Cite this article as: Casesnoves F. Geometrical determinations of IMRT photon pencil-beam path in radiotherapy wedges and limit divergence angle with the Anisotropic Analytic Algorithm (AAA). Int J Cancer Ther Oncol 2014; 2(3):02031. DOI:10.14319/ijcto.0203.1
oai:ojs.ijcto.org:article/170
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.14
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
A decision tool to adjust the prescribed dose after change in the dose calculation algorithm
http://www.ijcto.org/index.php/IJCTO/article/download/170/2099
Chaikh, Abdulhamid; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
Giraud, Jean-Yves; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
Marguet, Maud; Institute of Radiation Physics, CHUV Lausanne University Hospital, Vaud
Silva, David DA; University of California, Davis, California
Perrin, Emanuel; University Claude Bernard Lyon 1, Villeurbanne
Balosso, Jacques; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
2014-10-12 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.14
Dose Calculation; Prescribed Dose; Gamma Index; Radiotherapy
en
Purpose: This work aims to introduce a method to quantify and assess the differences in monitor unites MUs when changing to new dose calculation software that uses a different algorithm, and to evaluate the need and extent of adjustment of the prescribed dose to maintain the same clinical results. Methods: Doses were calculated using two classical algorithms based on the Pencil Beam Convolution PBC model, using 6 patients presenting lung cancers. For each patient, 3 treatment plans were generated: Plan 1 was calculated using reference algorithm PBC without heterogeneity correction, Plan 2 was calculated using test algorithm with heterogeneity correction, and in plan 3 the dose was recalculated using test algorithm and monitor unites MUs obtained from plan 1 as input. To assess the differences in the calculated MUs, isocenter dose, and spatial dose distributions using a gamma index were compared. Statistical analysis was based on a Wilcoxon signed rank test. Results: The test algorithm in plan 2 calculated significantly less MUs than reference algorithm in plan 1 by on average 5%, (p < 0.001). We also found underestimating dose for target volumes using 3D gamma index analysis. In this example, in order to obtain the same clinical outcomes with the two algorithms the prescribed dose should be adjusted by 5%.Conclusion: This method provides a quantitative evaluation of the differences between two dose calculation algorithms and the consequences on the prescribed dose. It could be used to adjust the prescribed dose when changing calculation software to maintain the same clinical results as obtained with the former software. In particular, the gamma evaluation could be applied to any situation where changes in the dose calculation occur in radiotherapy.
oai:ojs.ijcto.org:article/229
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.14
2015-03-29T11:59:32Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Malignant minor salivary gland tumors: A retrospective study of 28 cases: Clinical experience of a single institution
Anter, Abeer Hussien; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University
Hamed, Rasha Hamdy; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University
2015-01-01 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.14
Radiation oncology
Minor Salivary Gland tumours; Postoperative Radiation; Adenoid Cystic Carcinomas
en
Purpose: This retrospective study was done to report our experience with the management of patients with primary malignant tumors of minor salivary glands that were treated with various combinations of surgery, radiation, and chemotherapy and to review treatment outcome. Methods: The records of all patients with malignant minor salivary gland tumors presenting for treatment at our department between 2000 and 2010 were retrospectively reviewed. Variables were collected and outcome measures were defined in terms of overall survival, disease-free survival. Descriptive statistics were compiled and statistically evaluated. Survival was described using the Kaplan-Meier method. Results: Twenty eight patients (10 males and 18 females) ranging in age from 18 to 80 years (median, 64 years) met the criteria for inclusion in the study. The majority of tumors were located in the oral cavity (n = 20), followed by nasal cavity and paranasal sinuses (n = 8). Adenoid cystic carcinoma was the most common neoplasm (n = 18). All patients were treated with surgery as the primary modality. Neck dissection was performed in 18% of patients, and all patients (n = 28) were treated with adjuvant external beam radiation therapy to a dose of 50 to 60 Gy. The disease-free survival rate and overall survival at 5 years were 80% and 85%, respectively. Conclusion: Postoperative radiation therapy is effective in preventing local recurrence in most patients with minor salivary gland tumors after gross total excision.
oai:ojs.ijcto.org:article/307
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.7
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
An analysis of the demographic profile, clinical manifestations, investigations and outcome of paediatric myelodysplastic syndrome: A single centre, cross-sectional study
http://www.ijcto.org/index.php/IJCTO/article/download/307/3096
http://www.ijcto.org/index.php/IJCTO/article/download/307/3097
Lingegowda, Appaji; Department of Pediatric Oncology, Kidwai Memorial Institute of Oncology, Bangalore
Kuntegowdenahalli, Lakshmaiah; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore
Komaranchath, Ashok; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore
Devi, Lakshmi; Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore
Kumari, Prasanna; Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore
Kamath, Mangesh; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore
2015-06-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.7
Paediatric Oncology, Haematology
Pediatric Myelodysplastic Syndrome; MDS
Paediatric Haematology
NIL
en
Purpose: Pediatric myelodysplastic syndrome (MDS) is a relatively rare entity, with distinct clinical features and more aggressive course than its adult counterpart. The aim of this study was to analyze the incidence of pediatric myelodysplastic syndrome at a tertiary cancer care center in southern India along with clinical manifestations, investigations and outcome.Methods: On retrospective analysis of 1094 cases of pediatric hematological malignancies over a five-year period from September 2009 to August 2014, a total of seven cases of pediatric myelodysplastic syndrome were identified. Presenting complaints, physical examination, investigations including haemogram, biochemistry, bone marrow examination and cytogenetics were reviewed. The diagnosis of MDS was made if there was dysplasia in at least 10% of cells in two or more cell lineages. All patients were risk stratified using the revised IPSS. Results: Out of 1094 cases of pediatric hematological malignancies presenting at our institute within the study period, there were only seven cases of pediatric MDS with an incidence of 0.65%. There were no genetic predispositions nor any cases of therapy related MDS. The most common presentation was with fever and all patients had significant splenomegaly. All patients had anemia (Median-6.2 gm / dL) with elevated WBC counts (Median-30,900 / uL) and thrombocytopenia (Median-50,000 / uL). The marrow cytogenetics was normal in five patients. Most patients fell into the high and very high-risk category of the revised IPSS, with only two patients of low risk. All seven patients were given only supportive care but one progressed to AML for which he was treated with remission induction. Only two patients were alive at the time of analysis and median survival was 9 months. Conclusion: Pediatric MDS is a rare disease with a short clinical history, aggressive course and generally poor outcomes as compared to the adult variant. A hematopoietic stem cell transplant may be the only viable option for survival.
oai:ojs.ijcto.org:article/402
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.9
2016-01-03T12:17:08Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Dosimetric comparison among different head and neck radiotherapy techniques using PRESAGE® dosimeter
Rehman, Jalil; Department of Physics, Faculty of Science, University of Gujrat, Hafiz Hayat Campus, Gujrat
Iqbal, Tahir; Department of Physics, Faculty of Science, University of Gujrat, Hafiz Hayat Campus, Gujrat
Tailor, Ramesh; Department of Radiation Physics, University of Texas MD Anderson Cancer Center Houston Texas
Majid, Abdul; Department of Physics, Faculty of Science, University of Gujrat, Hafiz Hayat Campus, Gujrat
Ashraf, Jahenzeb; Department of Physics, The Islamia University of Bahawalpur, Bahawalpur
Khan, Isa; Department of radiation Physics, Women University A & J Kashmir, Bagh
Afzal, Muhammad; Department of Physics, The Islamia University of Bahawalpur, Bahawalpur
Ibbott, Geoffrrey; Department of Radiation Physics, University of Texas MD Anderson Cancer Center Houston Texas
2015-11-06 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.9
Radiation oncology; Medical Physics
RPC; 3DCRT; IMRT; VMAT; EBT2 FILM; TLD; PRESAGE®
HEC Pakistan
en
Purpose: The purpose of this analysis was to investigate dose distribution of Three Dimensional Conformal Radiation Therapy (3DCRT), Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) for Head and Neck cancer using 3-dimensional PRESAGE® dosimeter. Method: Computer Tomography (CT) scans of Radiological Physics Center (RPC) Head and Neck anthropomorphic phantom with both RPC standard insert and PRESAGE® insert were acquired separated with Philipp’s CT scanner and both CT scans were exported via DICOM to the pinnacle treatment planning system (TPS). Each plan was delivered twice to the RPC phantom first containing the RPC standard insert having Thermoluminescent detectors (TLD) and film dosimeters and then again containing the PRESAGE® insert having three dimensional dosimeter (PRESAGE®) by using a Varian True beam linear accelerator. After irradiation, the standard insert including point dose measurement (TLD) and planner GafChromic® EBT film measurement was read using RPC standard procedure. The 3D dose distribution from PRESAGE® was read out with the Duke Midsized optical scanner dedicated to RPC (DMOS-RPC). Dose volume histogram (DVH), mean and maximal doses for organ-at-risk (OARs) were calculated and compared among each Head and Neck technique. The prescription dose was same for all Head and Neck radiotherapy techniques which was 6.60 Gy per friction. Beam profile comparison and gamma analysis were used to quantify agreement among film measurement, PRESAGE® measurement and calculated dose distribution. Quality assurances of all plans were performed by using ArcCHECK method. Results: VMAT delivered the lowest mean and maximal doses to organ at risk (spinal cord and parotid) than IMRT and 3DCRT. Such dose distribution was verified by absolute dose distribution using TLD system. 2D gamma 5%/3 mm criteria of Pinnacle vs. EBT2 film 3DCRT (92.34%), IMRT (92.3%) and VMAT (96.63%) in axial plan respectively. It was also found that agreement between PRESAGE® and pinnacle along the axial, sagittal and coronal plans VMAT agreement was better than IMRT and 3DCRTplan excludes a 7 mm rim at the edge of the dosimeter using 2D gamma map criteria (±5%/3 mm) with 5% threshold dose. Profile showed good agreement for all plans between film, PRESAGE® and pinnacle. 3D gamma was performed for planning target volume (PTV) and organ at risks (OARs) VMAT and 3DCRT endow with better agreement than IMRT. Conclusion: VMAT delivered lowered mean and maximal doses to organ at risk and better PTV coverage. TLD, EBT film and PRESAGE® dosimeter has suggested that VMAT would be superior modality for the treatment of Head and Neck cancer than IMRT and 3DCRT.
oai:ojs.ijcto.org:article/458
2016-07-16T06:09:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.2
2016-07-16T06:09:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 2 (2016): April - June
Body mass index versus bladder and rectal doses using 2D planning for patients with carcinoma of the cervix undergoing HDR brachytherapy
Talluri, Anil Kumar; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
Yarrama, Aparna; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad
Ahamed, Shabbir; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
Madhusudhana Sresty, Narayana Venkata Naga; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
2016-04-27 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.2
Medical Physics
Body Mass Index, Rectum, Bladder, Cervical Cancer
Brachytherapy
en
Purpose: To assess bladder and rectum doses in relation to body mass index of patients undergoing high dose rate brachytherapy for the treatment of carcinoma of the cervix.Methods: The cohort consists of fifty subjects with carcinoma of the uterine cervix presented with grade II and III. Patient’s height and weight was measured before the insertion of applicator in situ. Body mass index (BMI) of the patient was calculated in accordance to World Health Organization definition (weight in Kg/ height in m2). Adequacy of position and orientation of the applicator was confirmed with the help of orthogonal X-ray images and the same were transferred to the treatment planning system (TPS) to generate treatment plan. Prescription doses were optimized to Point A and to reference lines placed at 0.5 cm apart from the surface of ovoids. The following dose reference points were identified on orthogonal x-ray images for analysis using the rectal marker and Foleys bulb inflated with radio opaque dye Rectal points at the level of femoral heads (RL) and pubis symphysis (RLP), Anorectum Junction (AR Jn) point and Rectosigmoid (RS) point and Bladder point (BL). Pearson regression analysis was used to analyze data from TPS.Results: The mean BMI was 22.7 kg/m2 and average age was 49.9 years. Analysis showed that RL point dose and BMI were inversely correlated with a coefficient -0.45 (p = 0.001). The trend continued along the rectal tube in cranio-caudal direction, as RLP and AR Jn points showed inversion co-efficiency with increase in BMI,-0.48 (p < 0.01) and -0.51 (p < 0.01) respectively. Bladder point showed weak positive correlation to BMI, 0.12 (p = 0.38).Conclusion: Significant rectal dose reduction is observed with increase in BMI. Bladder dose did not show statistically significant correlation with BMI. Based on the findings, BMI constitutes a confounding factor in the treatment of carcinoma of cervix.
oai:ojs.ijcto.org:article/549
2017-02-12T15:24:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.2
2017-02-12T15:24:26Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
A phantom study for in-vivo dosimetry of high dose rate brachytherapy applicators
Gadhi, Muhammad Asghar; Department of Radiation Physics, The University of Texas, MD Anderson Cancer Center, Houston, Texas
Buzdar, Saeed Ahmad; Medical Physics Research Group, The Islamia University of Bahawalpur, Bahawalpur
Arshad, Muhammad; Department of Medical Physics, Bahawalpur Institute of Nuclear Medicine and Oncology (BINO), Bahawalpur
Akram, Muhammad; Medical Physics Research Group, The Islamia University of Bahawalpur, Bahawalpur
Aziz, Farooq; Medical Physics Research Group, The Islamia University of Bahawalpur, Bahawalpur
Rehman, Aziz-Ur
Fatmi, Shahab
2016-12-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.2
Medical Physics; Radiation Oncology; Radiation Dosimetry
Brachytherapy, In-vivo dosimetry, Phantom, Ir-192, HDR
HDR Brachytherapy
Higher Education Commission, Pakistan, Pakistan Atomic Energy Commission
en
Purpose: The aim of the current investigation was to calibrate the diode in-vivo dosimetry (IVD) system for high-dose-rate (HDR) brachytherapy and to design a phantom study for in-vivo dosimetry of HDR brachytherapy applicators.Methods: Gamma Med Plus with Abacus 3.1 treatment planning system (TPS), and diode dosimetry system has been used in this study. Calibration and different correction factors of diode have been measured in water phantom. Treatment simulation, planning of different applicators for esophagus, rectum/vagina and cervix (fletcher & ring), dose delivery and finally in-vivo verification at prescription point using diode in water phantom has been performed.Results: The mean calibration factor for diode for Ir-192 HDR source is 1.256 (N=15) with σ ± 0.0015. The overall average percentage difference between TPS dose and diode dose was 1.87% (σ ± 2.64) for all measurements, 1.86% (σ ± 2.73) for esophagus, 1.86% (σ± 2.94) for rectum/vagina and 1.67% (σ ±2.81) for fletcher and 2.07% (σ ± 2.26) for ring applicators, respectively. These results advocate that the dose calculated by TPS and dose measured using diode for the various clinical situations deliberated here are in good agreement (~2%) at the points of clinical importance.Conclusion: The in-vivo phantom dosimetry study gives both a confidence that the treatments are being delivered as prescribed and enhance the reliability of the HDR brachytherapy treatment. This may be used for acceptance testing/commissioning of new treatment planning system and to validate the new brachytherapy techniques in the clinics.
oai:ojs.ijcto.org:article/596
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.6
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
The comparison between TP53 gene polymorphisms (c.[215G>C]) homozygotes and heterozygotes in Breast Cancer Patients: A clinicopathological analysis
http://www.ijcto.org/index.php/IJCTO/article/download/596/4731
http://www.ijcto.org/index.php/IJCTO/article/download/596/4732
http://www.ijcto.org/index.php/IJCTO/article/download/596/4733
http://www.ijcto.org/index.php/IJCTO/article/download/596/4734
Huszno, Joanna; Clinical and Experimental Oncology Department. Maria Sklodowska Curie Memorial Cancer Centere and Institute of Oncology. Gliwice Branch Poland.
Grzybowska, Ewa; Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
Nycz Bochenek, Marta; Genetic Outpationt Clinic. Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch 44-101 Gliwice, Wybrzeze Armii Krajowej 15 street. Poland.
Kołosza, Zofia; Department of Epidemiology and Silesia Cancer Registry. Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch 44-101 Gliwice, ul. Wybrzeze Armii Krajowej 15. Poland.
Tęcza, Karolina; Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
Pamuła Piłat, Jolanta; Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
Mazur, Magdalena; Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
Nowara, Elżbieta; Clinical and Experimental Oncology Department Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch 44-101 Gliwice, Wybrzeze Armii Krajowej 15 street. Poland
2017-06-25 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.6
Medical Oncology
TP53 polymorphisms, Homozygote, Heterozygotes, Breast cancer, Clinicopathological factors
breast cancer
en
Purpose: TP53 is a tumor suppressor gene which participates in regulation of cell cycle check points, DNA repair, and apoptosis. The aim of this study was to compare TP53 germ line gene polymorphisms (c.[215G>C]) wild – type homozygotes GG with heterozygotes GC according to clinicopathological factors.Methods: We reviewed the medical records of 87 (22% TP53 gene homozygotes and 78% heterozygotes) breast cancer patients who were diagnosed and treated in COI in Gliwice. Polymorphism profile was assessed by RFLP-PCR technique.Results: The presence of lobular invasive carcinoma was observed insignificantly more often in homozygotes, especially in the group of patients at the age below 50 years (29% vs. 4%, p = 0.095). Patients being TP53 gene heterozygotes had larger tumor size (T > 2) than homozygotes (16% vs. 5%, p = 0.450). There was observed a tendency to the presence of lymph node metastases (53% vs. 34%, p = 0.182) and higher Ki67 (> 20%) (69% vs. 46%, p = 0.209) in TP53 gene homozygotes. HER2 overexpression was associated with TP53 heterozygotes, especially in the group of patients at the age above 50 years (33% vs. 8%, p = 0.144). A negative receptor status was reported more frequently in homozygotes (43% vs.21%, p = 0.340) in patients with age below 50 years. Similarly higher histological grade G3 was detected more often in homozygotes in patients at the age below 50 years (80% vs. 33%, p = 0.130).Conclusion: TP53 gene homozygotes and heterozygotes differ from each other in respect of clinicopathological factors such as: histological type, lymph node metastases, higher Ki67 (> 20%), histological grade G3, ER/PR status, tumor size (T > 2), HER2 overexpression, cancer in family history and diabetes. Patient’s age was associated with the pathological characteristics of tumor.
oai:ojs.ijcto.org:article/740
2018-06-24T14:49:11Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.6
2018-06-24T14:49:11Z
International Journal of Cancer Therapy and Oncology
Vol 6, No 1 (2018): January - December
Association between tumor response and change in EQ5D-3L quality of life among cancer patients
Garcia, Stephen Joseph; University of the Philippines- Philippine General Hospital
Uy, Charles Vincent; University of the Philippines- Philippine General Hospital
Ngelangel, Corazon; University of the Philippines- Philippine General Hospital
delos Reyes, Francisco; School of Statistics
University of the Philippines-Diliman
2018-06-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.6
Medical Oncology
Quality of Life, QOL, Tumor response, Cancer, EQ 5D 3L
Quality of Life
en
Purpose: The primary aim in cancer treatment is to provide excellent tumor response while maintaining the most acceptable quality of life. The relationship of QoL to tumor response has not yet been well discussed. This study determines the association between the change in the QoL from baseline to one (1) year follow-up and tumor response among patients enrolled in the ASEAN Cost in Oncology (ACTION) study.Methods: Pooled data from the ACTION study was reviewed. Associations between demographics, cancer type, and tumor response were analyzed.Results: Of the qualified profiles (412 / 742), breast cancer (42.2%), colorectal (21.8%), and head neck (10%) are still most common. Of these cases, 126 (30.6%) were metastatic on presentation. Demographic data showed female sex having better tumor response. More importantly, tumor response was significantly associated with improvement in QoL: complete or partial response was associated with improvement in QoL (p = .000) while progressive disease related to worse situations. The general pattern seen above was reflected in female breast cancer cases, colon and rectal cancer, and other malignant neoplasms.Conclusion: Improvement in QoL was significantly associated with better tumor response. This trend was similar for breast cancer, colorectal cancer and other malignancies. The use of universal measures of health like the EQ5D 3L may be used to quantify improvements in QoL with several limitations: 1) cultural differences should be established and 2) limitations in quantifying precise changes in QoL. The utilization of more culturally adept QoL measures may address this problem. Similarly, the use of secondary data may limit the results in this study. Prospective studies specifically addressing the objectives may improve results.
oai:ojs.ijcto.org:article/6
2014-05-31T18:23:38Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Pokharel
2014-05-31T18:23:38Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 1 (2013): September - October
Dosimetric impact of mixed-energy volumetric modulated arc therapy plans for high-risk prostate cancer
Pokharel, Shyam; Department of Medical Physics, Premier Oncology, Florida, USA.
2013-08-31 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Pokharel
Medical Physics; Radiation Oncology
Prostate Cancer, Mixed Energy Plan, VMAT, RapidArc
en
Purpose: This study investigated the dosimetric impact of mixing low and high energy treatment plans for prostate cancer treated with volumetric modulated arc therapy (VMAT) technique in the form of RapidArc.Methods: A cohort of 12 prostate cases involving proximal seminal vesicles and lymph nodes was selected for this retrospective study. For each prostate case, the single-energy plans (SEPs) and mixed-energy plans (MEPs) were generated. First, the SEPs were created using 6 mega-voltage (MV) energy for both the primary and boost plans. Second, the MEPs were created using 16 MV energy for the primary plan and 6 MV energy for the boost plan. The primary and boost MEPs used identical beam parameters and same dose optimization values as in the primary and boost SEPs for the corresponding case. The dosimetric parameters from the composite plans (SEPs and MEPs) were evaluated. Results: The dose to the target volume was slightly higher (on average <1%) in the SEPs than in the MEPs. The conformity index (CI) and homogeneity index (HI) values between the SEPs and MEPs were comparable. The dose to rectum and bladder was always higher in the SEPs (average difference up to 3.7% for the rectum and up to 8.4% for the bladder) than in the MEPs. The mean dose to femoral heads was higher by about 0.8% (on average) in the MEPs than in the SEPs. The number of monitor units and integral dose were higher in the SEPs compared to the MEPs by average differences of 9.1% and 5.5%, respectively.Conclusion: The preliminary results from this study suggest that use of mixed-energy VMAT plan for high-risk prostate cancer could potentially reduce the integral dose and minimize the dose to rectum and bladder, but for the higher femoral head dose.-----------------------------------------------Cite this article as:Pokharel S. Dosimetric impact of mixed-energy volumetric modulated arc therapy plans for high-risk prostate cancer. Int J Cancer Ther Oncol 2013;1(1):01011.DOI: http://dx.doi.org/10.14319/ijcto.0101.1 //
oai:ojs.ijcto.org:article/87
2014-05-14T17:01:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/020211
2014-05-14T17:01:15Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 2 (2014): April - June
A new calculation formula of the nuclear cross-section of therapeutic protons
Ulmer, Waldemar; Strahlentherapie Nordwürttemberg and Research Group Radiation Physics and Medical Physics,
University of Zürich, Zürich Swizzerland.
2014-04-13 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/020211
Medical Physics; Particle Therapy
Nuclear interactions of protons; Threshold energy; Bethe-Wigner resonances; Gaussian representation of resonance interactions; Tunnel effect
en
Purpose: We have previously developed for nuclear cross-sections of therapeutic protons a calculation model, which is founded on the collective model as well as a quantum mechanical many particle problem to derive the S matrix and transition probabilities. In this communication, we show that the resonances can be derived by shifted Gaussian functions, whereas the unspecific nuclear interaction compounds can be represented by an error function, which also provides the asymptotic behavior. Method: The energy shifts can be interpreted in terms of necessary domains of energy to excite typical nuclear processes. Thus the necessary formulas referring to previous calculations of nuclear cross-sections will be represented. The mass number AN determines the strong interaction range, i.e. RStrong = 1.2·10-13·AN1/3cm. The threshold energy ETh of the energy barrier is determined by the condition Estrong = ECoulomb. Results and Conclusion: A linear combination of Gaussians, which contain additional energy shifts, and an error function incorporate a possible representation of Fermi-Dirac statistics, which is applied here to nuclear excitations and reaction with release of secondary particles. The new calculation formula provides a better understanding of different types of resonances occurring in nuclear interactions with protons. The present study is mainly a continuation of published papers.1-3--------------------------------Cite this article as: Ulmer W. A new calculation formula of the nuclear cross-section of therapeutic protons. Int J Cancer Ther Oncol 2014; 2(2):020211. DOI: 10.14319/ijcto.0202.11
oai:ojs.ijcto.org:article/141
2014-12-13T14:36:25Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.4
2014-12-13T14:36:25Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Clinical use of electronic portal imaging to analyse tumor motion variation during a 3D-conformal prostate cancer radiotherapy using online target verification and implanted markers
http://www.ijcto.org/index.php/IJCTO/article/download/141/1751
Acquah, George Felix; Department of Radiation Oncology, Sweden Ghana Medical Centre,Cantonments, Accra
Gustavsson, Magnus; Department of Medical Physics, Sahlgrenska University Hospital, Gothenburg
Doudoo, Chris Osam; Department of Radiation Oncology, Sweden Ghana Medical Centre,Cantonments, Accra
Agbeve, Richard Kwabena; Department of Radiation Oncology, Sweden Ghana Medical Centre,Cantonments, Accra
Schiestl, Bernhard; Department of Therapeutic Radio Oncology, University Hospital of Innsbruck, Innsbruck
2014-09-01 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.4
Medical physics; Health sciences, Applied physics.
Gold markers; Prostate motion; Systematic and Random Errors; Portal imaging; EPID; DRR.
radiation physics; imaging; dosimetry; quality assurance; treatment planning
en
Purpose: To evaluate the daily treatment setup variation and the interfraction and intrafraction prostate motion with portal imaging and implanted fiducial markers during irradiation with a 3D conformal radiotherapy for localized prostate cancer patients.Methods: By remote verification, shifts from isocenteric positioning and inter/intra-fraction prostate motion were investigated for 34 patients treated supine with escalated dose conformal radiotherapy. To limit the effect of inter-fraction prostate motion, patients were planned and treated with an empty rectum and a comfortably full bladder. Daily pre-therapy and treatment electronic portal images were obtained for anterior and lateral treatment fields according to an on-line target localization protocol using three gold markers. From these images, random and systematic set-up errors were measured by matching corresponding patients’ gold markers on reference digitally reconstructed radiographs (DRR). Superior-inferior, anterior-posterior and lateral motions were measured from the displacement of the gold markers implanted into the prostate before planning. A planning target volume (PTV) was derived to account for the measured prostate motion and field placement deviations.Results: Analysis of 1,278 portal images to determine changes in the radiation field during the course of treatment. From the data, random isocenter positioning deviations were 2.66 mm, 2.78 mm and 2.59 mm for vertical, lateral and longitudinal movements respectively. The systematic deviations were 3.15 mm, 3.09 mm and 2.52 mm for vertical, lateral and longitudinal movements respectively. From the verification process, it was realized that 44.7%, 42.8% and 31.4% of the vertical, lateral and longitudinal prostate migrations respectively needed correction/shift.Conclusion: Random set-up errors were small using real-time isocenter placement corrections. Inter-fraction prostate motion remained the largest source of treatment error, and observed motion was greatest at the laterals. In the absence of real-time pre-treatment imaging of the prostate position, using sequential portal films of implanted gold markers, portions of the PTV is missed and surrounding tissues not spared. This research improves quality assurance by confirming the prostate position within the treatment field over the course of therapy.-----------------------------Cite this article as: Acquah GF, Gustavsson M, Doudoo CO, Agbeve RK, Schiestl B. Clinical use of electronic portal imaging to analyze tumor motion variation during a 3D-conformal prostate cancer radiotherapy using online target verification and implanted markers. Int J Cancer Ther Oncol 2014; 2(4):02044. DOI: 10.14319/ijcto.0204.4
oai:ojs.ijcto.org:article/185
2015-03-29T11:59:31Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.12
2015-03-29T11:59:31Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Extended distance non-isocentric treatment in stereotactic body radiation therapy (SBRT) for lung cancer
http://www.ijcto.org/index.php/IJCTO/article/download/185/2167
Huang, Long; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
Papiez, Lech; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
Papiez, Ewa; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
Timmerman, Robert; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
2014-12-16 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.12
Medical Physics
Lung Cancer; SBRT; Extend Distance; non-isocentric
en
Purpose: To obtain the maximum differential non-coplanar beams angle for a faster dose dropping outside Plan Target Volume (PTV) for lung cancer treated by Stereotactic body radiation therapy (SBRT), an extended distance non-isocentric (EDNI) treatment method was explored and developed.Methods: The EDNI requires delivering of the treatment beam at 120 cm or farther for sauce axial distance (SAD) instead of standard 100 cm. This change provides a more compact dose distribution around PTV and the lower toxicity to organs at risk (OAR) due to benefit of 120 cm SAD and more choice of beam and couch angle. A hand calculation formula for the translation between 100 SAD and EDNI was used to verify the treatment plan results. A phantom for end to end study based on this EDNI technique was used to compare with standard 100 SAD deliveries for SBRT. Three patients who underwent SBRT treatment were randomly chosen to demonstrate the benefits of EDNI technique. These treatment re-plans were applied to EDNI and evaluated for conformal index (CI) of PTV, R50% of PTV, 2 cm distance (D2cm) of PTV and Maximum dose (Dmax)of OARs to compare with original clinical plans.Results: All of the cases delivered by the EDNI technique satisfied dose requirements of RTOG 0263 and showed a faster dose dropping outside of PTV than standard SAD deliveries. The distance from PTV after 1.5 cm for the EDNI technique had a smaller maximum dose and much lower standard deviation for dose distribution. The EDNI applied plans for patients showed less R50% and D2cm of PTV (P≤ 0.05), also similar results for Dmax of esophagus, trachea and spinal cord.Conclusion: The EDNI method enhances the capabilities of linear accelerators as far as the increased gradient of dose drop-off outside of PTV is concerned. More angular separation between beams leads to more compact dose distributions, which allow decreasing volume of high dose exposure in SBRT treatments and better dose distribution on sensitive organs to minimize the treatment toxicity.
oai:ojs.ijcto.org:article/313
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.18
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
CBCT-based dosimetric verification and alternate planning techniques to reduce the normal tissue dose in SBRT of lung patients
Narayanasamy, Ganesh; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Feddock, Jonathan; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Gleason, John; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
McGarry, Ronald; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Molloy, Janelle; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
2015-05-07 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.18
Medical Physics
SBRT; Dose Verification; Dose Optimization; Margin Reduction; Prescription Isodose
Dosimetric Verification
en
Purpose: Confirmation of treatment delivery accuracy in stereotactic body radiotherapy (SBRT) of lung tumors suggests the possibility of treatment margin, or aperture reduction. In this investigation, the dose delivery to lung tumors using SBRT techniques was verified, and the feasibility of normal tissue sparing via aperture reduction or altered prescription isodose line was assessed. Methods: Planned and delivered doses to the gross tumor volume (GTV) and planning target volume (PTV) were compared for 10 patients using planning CT and conebeam CT image. Potential for reduction in normal tissue dose were assessed using 2 alternate treatment plans – reduced PTVs and alternate prescription techniques. Plans were assessed using conformity index, homogeneity index and the ratio of 50% / 100% isodose volumes (R50%). Results: The planned and delivered mean doses were consistent to within 4%. However, the mean dose delivered to the GTV exceeded the prescription dose (Rx) by 19% and is consistent with our planning technique of prescribing to the 80% isodose line. When reducing treatment margins and retaining a constant dose-volume constraint, block margins had to be increased which produced a constant effective field aperture outside of the GTV. Prescription to a lower isodose line using stereotactic-like planning techniques yielded the only method by which the volume of the prescription isodose could be affected, although this yielded increases in normal tissue dose due to the increased monitor units required. Conversely, conventional prescription techniques using wider field apertures were effective in reducing absolute values of normal tissue dose. Although dose conformity was similar across different prescription isodose lines, homogeneity index and R50% values were significantly different in the 60%-70% prescription isodose line plans than the 80%, 90% prescription plans.Conclusion: Traditional margin reduction techniques did not affect a reduction in the volume of normal tissue irradiated to the prescribed dose. Prescribing to low isodose lines yields reduced volumes of the prescribed dose, but at the expense of normal tissue dose.
oai:ojs.ijcto.org:article/351
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.2
2016-01-03T12:17:08Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Radiation doses and risks to neonates undergoing radiographic examinations in intensive care units in Tunisia
http://www.ijcto.org/index.php/IJCTO/article/download/351/3388
http://www.ijcto.org/index.php/IJCTO/article/download/351/3389
Bouaoun, Abir; Université de Tunis El Manar, Institut Supérieur des Technologies Médicales, LR13ES07 laboratoire de Biophysique et technologies médicales, Tunis
Ben-Omrane, Latifa; National Center of Radiation Protection, 1006, Tunis
Hammou, Azza; National Center of Radiation Protection, 1006, Tunis
2015-09-07 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.2
Medical Physics, Medical Dosimetry
Patient Dose; Diagnostic Radiology; Neonatology; DAP; Effective Dose; LDRL
en
Purpose: To assess the radiation doses to neonates from diagnostic radiography in order to derive the local diagnostic reference levels (LDRLs) for optimisation purposes.Methods: This study was carried out in the neonatal intensive care units (NICU) of two hospitals in Tunis. 134 babies, with weights ranging from 635 g to 6680 g, performed chest-abdomen X-ray examinations. Neonates were categorized into groups of birth weight. For each X-ray examination, patient data and exposure parameters were recorded. Dose area product (DAP) was measured and entrance surface dose (ESD) was estimated. Effective dose was calculated from the Monte Carlo simulation software PCXMC.Results: DAP values increased with neonatal weight and demonstrated a wide variation (5.0 - 43.0 mGy.cm2, mean 23.4 mGy.cm2) for patient weight from 600 g to 4000 g. A wide variation was also observed for ESD (14 - 93 μGy, mean 55.2 μGy). The LDRLs expressed in term of DAP were estimated to be 17.6 mGy.cm2 and 29.1 mGy.cm2 for the first and the second NICU, respectively. In terms of effective dose, the average value was about 31.6 μSv per single radiological examination. The results show the necessity to use a standardized protocol with high voltage technique combined to lower current time product (mAs) values and an adapted collimation which could lead to further reductions in the neonatal doses. Conclusion: This study presents the LDRLs and the effective doses for neonates in two NICUs and demonstrates the necessity to optimize patient protection for this category of patient.
oai:ojs.ijcto.org:article/387
2016-07-16T06:30:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.15
2016-07-16T06:30:03Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
A portable secondary dose monitoring system using scintillating fibers for proton therapy of prostate cancer: A Geant4 Monte Carlo simulation study
http://www.ijcto.org/index.php/IJCTO/article/download/387/3594
Tesfamicael, Biniam; Department of Radiation Oncology, McLaren Regional Medical Center, Flint, Michigan
Gueye, Paul; Department of Physics, Hampton University, Hampton, Virginia
Avery, Stephen; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Lyons, Donald; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Mahesh, Mahadevappa; Department of Radiology and Radiological Sciences, John Hopkins University, Baltimore, Maryland
2016-02-12 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.15
Radiation Oncology; Medical Physics; Particle Therapy
Proton Therapy, Prostate Cancer, Scintillating Fibers, Geant4, Hadrontherapy, Secondary Dose
This work was partly supported by the Department of Energy - National Security Administration under award number DE-NA0000979.
en
Purpose: The main purpose of this study was to monitor the secondary dose distribution originating from a water phantom during proton therapy of prostate cancer using scintillating fibers.Methods: The Geant4 Monte Carlo toolkit version 9.6.p02 was used to simulate a proton therapy of prostate cancer. Two cases were studied. In the first case, 8 × 8 = 64 equally spaced fibers inside three 4 × 4 × 2.54 cm3 Delrin® blocks were used to monitor the emission of secondary particles in the transverse (left and right) and distal regions relative to the beam direction. In the second case, a scintillating block with a thickness of 2.54 cm and equal vertical and longitudinal dimensions as the water phantom was used. Geometrical cuts were implemented to extract the energy deposited in each fiber and inside the scintillating block.Results: The transverse dose distributions from the detected secondary particles in both cases are symmetric and agree to within <3.6%. The energy deposited gradually increases as one moves from the peripheral row of fibers towards the center of the block (aligned with the center of the prostate) by a factor of approximately 5. The energy deposited was also observed to decrease as one goes from the frontal to distal region of the block. The ratio of the energy deposited in the prostate to the energy deposited in the middle two rows of fibers showed a linear relationship with a slope of (-3.55±2.26) × 10-5 MeV per treatment Gy delivered. The distal detectors recorded a negligible amount of energy deposited due to higher attenuation of the secondary particles by the water in that direction.Conclusion: With a good calibration and with the ability to define a good correlation between the radiation flux recorded by the external fibers and the dose delivered to the prostate, such fibers can be used for real time dose verification to the target. The system was also observed to respond to the series of Bragg Peaks used to generate the Spread Out Bragg Peak inside the water phantom. Such Bragg Peaks were detected by the fibers. The energy deposited inside the lateral blocks were also observed to decrease as one goes away from the beam nozzle due to increased attenuation.
oai:ojs.ijcto.org:article/517
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.12
2016-09-18T08:59:14Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
Quantitative expression of the eukaryotic translation initiation factor 4E (eIF4E) in egyptian acute leukemia patients and its clinical significance
Hammam, Amira Ahmed; Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni-Suef University
EL-Wakil, Mohamed Aly; Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University
Mahmoud, Sarah; Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni-Suef University
2016-08-05 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.12
Medical Oncology, Hematology; molecular biology
eIf4E, AML, ALL, RTQ-PCR.
None
en
Purpose: The eukaryotic translation initiation factor eIF4E is part of the eIF4F protein complex, which includes, in addition to eIF4E, eIF4G (a scaffolding protein) and eIF4A (an ATP-dependent RNA helicase). The eukaryotic translation initiation factor eIF4E is a potent oncogene elevated in many cancers including leukemias.Methods: In this study, the expression level of eIF4E gene was analyzed in 20 normal healthy controls and 64 patients with de novo acute leukemia (33 Acute myeloid leukemia (AML) and 31 Acute lymphoblastic leukemia (ALL)) using a real-time quantitative reverse-transcriptase polymerase chain reaction (RTQ-PCR) to investigate a possible relation, association or correlation with the clinical features at diagnosis, such as age, gender, lineage, hemoglobin (Hb), total leucocytic count (TLC), platelet count and bone marrow (BM) blast cell infiltration as well as its effect on patients̒ outcome.Results: Comparing AML and ALL patients as regards their clinical and laboratory data showed no statistical significance for TLC and hemoglobin (p-0.838 and 0.920) respectively, but was of statistically significant difference for platelets (p = 0.022) and bone marrow blasts percentage (p = 0.007). Comparison between the 2 groups as regards eIF4E level was of no statistically significant difference, p-value being (p = 0.257) but there was statistically significant difference between eIF4E expression level in AML/Control (p = 0.002), ALL/Controls (p = 0.025). Also analysis of overall survival (OS) time and disease free survival (DFS) in each group and its relation to eIF4E gene showed no statistical significance (p = 0.843 and 0.310) respectively in AML group and (p = 0.971 and no p-value for DFS in ALL as all cases remained alive except for one case while 3 cases were relapsed) in ALL group. Correlation studies showed no significant correlation between AML group and eIF4E gene level as regards age, TLC, hemoglobin and platelets (r = -0.064, p = 0.722; r = 0.062, p = 0.732; r = 0.068, p = 0.712; and r = -0.318, p = 0.071) respectively, while there was significant positive moderate correlation on comparing bone marrow blast% and eIF4E gene level (r = 0.545 and p = 0.001). There was no significant correlation between ALL group and Eif4e gene level as regards age, TLC, hemoglobin, platelets and bone marrow blasts% (r = -0.214, p = 0.248; r = 0.175, p = 0.347; r = -0.056, p = 0.766; r = -0.072, p = 0.700; and r = -0.0004, p = 0.983) respectively.Conclusion: eIF4E was found to be elevated in acute leukemia patients in relation to normal controls and its levels were more in myeloid than lymphoid leukemia and positively correlated with the blast percentage in AML thus its level may contribute to leukemogenesis. eIF4E levels and translation initiation may be an attractive target for anticancer therapeutics.
oai:ojs.ijcto.org:article/588
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.15
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: a prospective randomized study
Ibrahim, Dina; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
Kelaney, Mohamed; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
Michael, Maha; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
El-Sayed, Zeinab; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
2016-12-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.15
Differentiated thyroid carcinoma, Radioactive iodine remnant ablation, I-131 optimal dose, Randomized study.
en
Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC), some patients are ablated with radioactive iodine I-131 (RAI). We compare the success of ablation with 30 millicurie (mCi) versus 80 mCi.Methods: We randomized the patients to 30 mCi or 80 mCi RAI after surgery. T1-T3, N0-N1, M0 tumors were included (based on the AJCC 7th edition). Pre-ablation baseline serum thyroglobulin (sTg), and thyroglobulin antibody (Tg Ab) were performed. Six months post-ablation successful thyroid ablation was defined as a negative whole body scan (WBS) and undetectable sTg.Results: Out of 50 patients with DTC, 45 patients fulfilled the eligibility criteria. Total thyroidectomy was performed in 27/ 45 (60%). 26/45 (57.8%) of patients received 30 mCi while 19/45 (42.2%) patients received 80 mCi. The median age was 37 and 36.5 years in the arms 80 and 30 mCi respectively. Papillary carcinoma predominated in 42/45 (93.3%) of patients. T2 tumors predominated in 10/19 (52.6%), and 15/26 (57.7%) of the 80 and 30 mCi arms respectively. According to the American Thyroid Association (ATA) risk classification, all of the patients had low risk disease. Success of ablation was achieved in 15/19 (78.9%), and in 15/26 (57. 7%) of the arms 80 and 30 mCi respectively. No patients developed distant metastases in both arms. The patients who received 80 mCi had longer hospital isolation than the 30 mCi arm (p 0.008). 6/26 (23.1%) patients in the 30 mCi arm were isolated for 2-4 days, whereas all the 80 mCi arm patients were isolated for 3-5 days.Conclusion: Both 80 mCi and 30 mCi RAI have similar success rate in the ablation of thyroid remnant of low risk DTC patients. The low dose is associated with fewer side effects, shorter hospital admission duration, and is less expensive in low risk DTC patients.
oai:ojs.ijcto.org:article/756
2017-12-17T14:56:16Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.20
2017-12-17T14:56:16Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Investigation the impact of maximum control point on dose calculation in Eclipse treatment planning system for lung SBRT
Kingkaew, Sakda; The School of Medical Physics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok
Asavaphatiboon, Sawwanee; Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok
Apipunyasopon, Lukkana; Department of Radiological Technology and Medical Physics, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand
2017-12-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.20
Control point, Stereotactic body radiation therapy, Dynamic multileaf collimator, Intensity modulated radiation therapy.
en
Purpose: Choosing an appropriate parameter on the computerized treatment planning systems (TPSs) influences on the accuracy of dose calculation. Several dosimetric parameters have been studied to achieve a more accurate dose and qualitative plan. The purpose of this study was to determine the impact of maximum control point on the dose calculation on Eclipse TPSs for lung Stereotactic Body Radiation Therapy (SBRT) considering the plan quality, the computation time and the treatment file size.Methods: Dose distributions for the 8 lung SBRT plans with varying maximum control point of 64, 166, and 320 were calculated by Eclipse TPSs with flattening filter free (FFF) beam. The treatment dose was prescribed at 85% isodose level of 54 Gy to the planning target volume (PTV). The dosimetric impact can be evaluated from target coverage, conformity index (CI), homogeneity index (HI), and organ at risk (OAR) doses, while the computation time and the file storage space were compared with the recommended number of control point.Results: The use of 64 control points per subfields tended to increase the dose at PTV and OARs comparing with the 166 and 320 control point plans, while the HI and CI values were similar. The average increases of OARs doses including the spinal cord, heart, esophagus and total lung depended on the photon beam energy. The higher average control point (AVG) number leaded to increase the computation time and the file size for both 6X-FFF and 10X-FFF photon beams. The correlations between AVG and plan storaage space were observed in the same ratio as the computation time.Conclusion: Using the minimal number of control point, the quantitative analysis in the PTV and OARs showed no clinically significant variation in dose, therefore choosing an optimal number of fixed control points leaded to balance the plan quality, the computation time and the file size.
oai:ojs.ijcto.org:article/76
2014-05-14T17:01:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Tesfamicael
2014-05-14T17:01:15Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 2 (2014): April - June
Scintillating fiber based in-vivo dose monitoring system to the rectum in proton therapy of prostate cancer: A Geant4 Monte Carlo simulation
http://www.ijcto.org/index.php/IJCTO/article/download/76/612
Tesfamicael, Biniam Yohannes; Department of Physics, Hampton University, Hampton, Virginia
Avery, Steven; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Gueye, Paul; Department of Physics, Hampton University, Hampton, Virginia
Lyons, Don; Department of Physics, Hampton University, Hampton, Virginia
Mahesh, Mahadevappa; Deparment of Radiology and Radiological Sciences, John Hopkins University, Baltimore, Maryland
2014-03-26 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Tesfamicael
Medical Physics; Proton Therapy; Particle Therapy
Prostate Cancer; Proton therapy; Endorectal Balloon; Scintillating Fibers; Geant4 Monte Carlo; Rectal Wall; Hadron Therapy
en
Purpose: To construct a dose monitoring system based on an endorectal balloon coupled to thin scintillating fibers to study the dose to the rectum in proton therapy of prostate cancer.Method: A Geant4 Monte Carlo toolkit was used to simulate the proton therapy of prostate cancer, with an endorectal balloon and a set of scintillating fibers for immobilization and dosimetry measurements, respectively.Results: A linear response of the fibers to the dose delivered was observed to within less than 2%. Results obtained show that fibers close to the prostate recorded higher dose, with the closest fiber recording about one-third of the dose to the target. A 1/r2 (r is defined as center-to-center distance between the prostate and the fibers) decrease was observed as one goes toward the frontal and distal regions. A very low dose was recorded by the fibers beneath the balloon which is a clear indication that the overall volume of the rectal wall that is exposed to a higher dose is relatively minimized. Further analysis showed a relatively linear relationship between the dose to the target and the dose to the top fibers (total 17), with a slope of (-0.07 ± 0.07) at large number of events per degree of rotation of the modulator wheel (i.e., dose).Conclusion: Thin (1 mm × 1 mm), long (1 m) scintillating fibers were found to be ideal for real time in-vivo dose measurement to the rectum during proton therapy of prostate cancer. The linear response of the fibers to the dose delivered makes them good candidates as dosimeters. With thorough calibration and the ability to define a good correlation between the dose to the target and the dose to the fibers, such dosimeters can be used for real time dose verification to the target.-----------------------------------Cite this article as: Tesfamicael BY, Avery S, Gueye P, Lyons D, Mahesh M. Scintillating fiber based in-vivo dose monitoring system to the rectum in proton therapy of prostate cancer: A Geant4 Monte Carlo simulation. Int J Cancer Ther Oncol 2014; 2(2):02024.DOI: http://dx.doi.org/10.14319/ijcto.0202.4
oai:ojs.ijcto.org:article/145
2014-08-16T18:42:02Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.16
2014-08-16T18:42:02Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
A dosimetric analysis of the aeroformTM tissue expander in radiation therapy
Tran, Tai; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Ding, Wei; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Subramanian, Brindha; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Melven, Leon; Department of Radiation Therapy, Radiation Oncology Victoria, Epping, Australia.
Chao, Michael; Department of Oncology, Radiation Oncology Victoria, Ringwood, Australia.
Farrow, Hamish; Plastic and Reconstructive Surgery Unit, Austin Hospital, Heidelberg, Australia.
Baker, Caroline; Department of Surgery, Victorian Breast and Oncology Care, East Melbourne, Australia.
2014-08-01 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.16
Radiation Oncology
Aeroform; Tissue Expander; Metal; Radiotherapy; Contour
Breast Expander
en
Purpose: The aim of this study is to evaluate the effects of the metallic reservoir and the use of gas within the Aeroform™ tissue expander with respect to the radiation dose distribution.Methods: Dosimetric effects of using a metallic reservoir within a breast tissue expander during external beam radiotherapy were investigated. To view the internal components of the reservoir, it was removed from the tissue expander and imaged on a Varian AS500 electronic portal imager. To calculate the relative density of each component within the reservoir, an ionization chamber within solid water was used to measure the dose and compared to a simulation within the Pinnacle treatment planning system (TPS). To examine the relative dose profile along the length of the reservoir, the reservoir was exposed on EBT3 film and analyzed using SNC Patient™. In-vivo Dosimetry was performed using a RANDO® Woman phantom. Thermo-luminescent dosimeters were placed within the wax bolus enveloping the tissue expander.Results: Imaging the reservoir on the electronic portal imager revealed it consists of 3 distinct components. The densities assigned in the TPS, which resulted in calculated doses which matched the measured doses were; Section 1 = 0 g/cm3, Section 2 = 2.8 g/cm3 and Section 3 = 0.7 g/cm3. Relative dose reductions were observed due to the metallic case; Section 1 = 20%, Section 2 = 40% and Section 3 = 30%. Entrance doses ranged from 2.39 - 2.53 Gy for both the medial and lateral beams. Exit doses ranging from 1.10 - 1.71 Gy were observed in both beams. There was a significant difference in measured and calculated doses at exit locations in the beam.Conclusion: Dosimetric effects due to the metallic reservoir within the Aeroform breast tissue expander have been demonstrated and have been observed to be significant. To increase the dosimetric accuracy when contouring, individual components of the reservoir should be distinguished. Our in-vivo experiment showed that dose homogeneity was difficult due to the metallic reservoir and we recommend stringent patient dose monitoring when using this expander during radiotherapy.-----------------------------Cite this article as: Tran T, Ding W, Subramanian B, Melven L, Chao M, Farrow H, Baker C. A dosimetric analysis of the aeroformTM tissue expander in radiation therapy. Int J Cancer Ther Oncol 2014; 2(3):020316. DOI: 10.14319/ijcto.0203.16
oai:ojs.ijcto.org:article/193
2015-03-29T11:59:31Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.2
2015-03-29T11:59:31Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Cyberknife fractionated radiotherapy for adrenal metastases: Preliminary report from a multispecialty Indian cancer care center
http://www.ijcto.org/index.php/IJCTO/article/download/193/2240
http://www.ijcto.org/index.php/IJCTO/article/download/193/2501
http://www.ijcto.org/index.php/IJCTO/article/download/193/2502
Basu, Trinanjan; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Kataria, Tejinder; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Abhishek, Ashu; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Gupta, Deepak; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Goyal, Shikha; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Bisht, Shyam S; Department of Radiation Oncology, Medanta - The Medicity, Gurgaon, Haryana, India
Payaliappan, Karthick K; Department of Medical Physics, Medanta - The Medicity, Gurgaon, Haryana, India
Subhramani, Vikraman; Department of Medical Physics, Medanta - The Medicity, Gurgaon, Haryana, India
2014-11-29 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.2
Radiation Oncology; Medical Physics
Cyberknife; Adrenal Metastases; Local Control; PETCT Response; X Sight Spine Tracking
en
Purpose: Metastasis to adrenal gland from lung, breast, and kidney malignancies are quite common. Historically radiotherapy was intended for pain palliation. Recent studies with stereotactic body radiotherapy (SBRT) including Cyberknife robotic radiosurgery aiming at disease control brings about encouraging results. Here we represent the early clinical experience with Cyberknife stereotactic system from an Indian cancer care center. The main purpose of this retrospective review is to serve as a stepping stone for future prospective studies with non- invasive yet effective technique compared to surgery. Methods: We retrospectively reviewed four cases of adrenal metastases (three: lung and one: renal cell carcinoma) treated with Cyberknife SBRT. X sight spine tracking was employed for planning and treatment delivery. Patients were evaluated for local response clinically as well as with PETCT based response criteria.Results: With a median gross tumor volume of 20.5 cc and median dose per fraction of 10 Gy, two patients had complete response (CR) and two had partial response (PR) when assessed 8-12 weeks post treatment as per RECIST. There was no RTOG grade 2 or more acute adverse events and organs at risk dosage were acceptable. Till last follow up all the patients were locally controlled and alive. Conclusion: Cyberknife SBRT with its unique advantages like non- invasive, short duration outpatient treatment technique culminating in similar local control rates in comparison to surgery is an attractive option. World literature of linear accelerator based SBRT and our data with Cyberknife SBRT with small sample size and early follow up are similar in terms of local control in adrenal metastases. Future prospective data would reveal more information on the management of adrenal metastases.
oai:ojs.ijcto.org:article/255
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.8
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
Total Body Irradiation using VMAT (RapidArc): A Planning Study of a novel treatment delivery method
Chakraborty, Santam; Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala
Cheruliyil, Suja; Division of Radiation Physics, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala
Bharathan, Resmi; Division of Radiation Physics, Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala
Muttath, Geetha; Department of Radiation Oncology, Malabar Cancer Centre, Thalassery, Kerala
2015-02-26 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.8
Radiation Oncology; Medical Physics
Total Body Radiation; Volumetric Modulated Arc Therapy; RapidArc; Multiple Isocenters
Total Body Radiation
en
Purpose: To evaluate the feasibility of using volumetric modulated arc therapy (VMAT) using RapidArc to deliver total body irradiation (TBI) treatment. Methods: VMAT planning was performed a whole body computed tomography (CT) data set using Rapid Arc. The planning target volumes included entire body trimmed to 3 mm below the skin. The organs at risk included the lungs and kidneys. A dose of 12 Gy in 10 fractions was prescribed to the target volume. The VMAT-TBI technique consisted of three isocentres and three overlapping arcs: the head and neck, the chest, and the pelvis. The plans were prescribed to ensure, at a minimum, 95% planning target volume dose coverage with the prescription dose (percentage of volume receiving dose of 12 Gy was 95%) and maximum dose of 109.8%. Mean dose to lung was restricted at 8.6Gy. Results: The total body volume in the study was 15469cm3 and the PTV volume was 11322cm3. The mean dose to PTV was 104%. The homogeneity index was 0.09. Sparing of normal tissues with adequate coverage of skeletal bones was shown to be feasible with Rapid Arc. The study demonstrates that VMAT is feasible for TBI treatment. Unlike conventional TBI chest wall boost with electrons was not required. Conclusion: The technique for total body irradiation using RapidArc VMAT was found feasible and is undergoing further studies prior to clinical use.
oai:ojs.ijcto.org:article/280
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.19
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
A quantitative method to implement and to assess the single isocenter technique for breast cancer radiation therapy
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Fayolle, Sara; UniversityJoseph Fourier, Grenoble
Gabelle-Flandin1, Isabelle; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Marguet, Maud; Institute of Radiation Physics, Lausanne University Hospital, Grand-Pré 1, Lausanne
Docquiere, Nicolas; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
Giraud, Jean-Yves; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
2015-08-11 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.19
Radiation Oncology; Medical Physics, Medical Oncology
Breast Cancer; Single Isocenter; Radiotherapy
Radiation oncology
en
Purpose: We propose a process of quality assurance to validate and implement the single isocenter technique for breast cancer radiotherapy. We evaluated the dosimetric and temporal gains using the single isocenter technique compared to classic source to skin distance (SSD) technique. Methods: 6 patients of breast cancer localization were studied. For each patient 2 treatment plans were generated. In plan 1 the dose was calculated using SSD technique. In plan 2 the dose was calculated using single isocenter technique. To implement the plan 2 a dosimetric analysis including monitor units (MU), isodose curves, cumulative and differential dose volume histograms cDVH, dDVH respectively, coverage index, conformity index for planning target volume were used. The measurements using a PMMA phantom consist of measuring point dose by an ionization chamber and 2D dose distributions using 2D diodes arrays. Wilcoxon signed rank and Spearman’s tests were used to calculate p-value and correlation coefficient, respectively.Results: The single isocenter technique reduced the MU by average on -30.1 ± 13.6%, (p = 0.03). We observed an improvement with statistical significance between the two techniques for the mean dose, minimum dose and volume receiving 95% of the prescribed dose without over-dosage. The analysis for dDVH showed that the dose distribution in the target volume calculated in the single isocenter technique is more homogeneous than the SSD technique. Wilcoxon test showed that the two treatment plans had the same quality (p > 0.05). The difference between calculated and measured dose was within 2.4 ± 3.3% for absolute point dose and the percentage of points passing gamma criteria was on average 99.8 ± 0.2%. Conclusion: This method provides a quantitative evaluation and comparison of the two irradiation techniques for breast cancer and the consequences of the technical change on dose calculation.
oai:ojs.ijcto.org:article/418
2016-07-16T06:27:02Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.8
2016-07-16T06:27:02Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
Dosimetric study of RapidArc plans and conventional intensity modulated radiotherapy for prostate cancer involving seminal vesicles and pelvis lymph nodes
Rout, Birendra; Department of Radiation Physics, Indo-American Cancer Institute and Research Center, Hyderabad
Chandra Shekar, Mukka; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad
Kumar, Alok; Department of Radiation Physics, Mahavir Cancer Sansthan, Patna
Muralidhar, Kanaparthy; Department of Radiation Physics, American Oncology Institute, Hyderabad
2016-01-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.8
Medical Physics
IMRT, RapidArc, Sigma-Index, Conformity Index, Normal Tissue Integral Dose
Dosimetric of Prostate Cancer
en
Purpose: The main purpose of this study is to (1) identify the continual diversity between conventional fixed field intensity modulation radiotherapy (IMRT) and RapidArc (RA) for high-risk prostate cancer; and (2) determine potential benefits and drawbacks of using for this type of treatment.Methods: A cohort of 20 prostate cases including prostate, seminal vesicles and pelvic lymph nodes was selected for this study. The primary planning target volume (PTVP) and boost planning target volume (PTVB) were contoured. The total prescription dose was 75.6 Gy (45 Gy to PTVP and an additional 21.6 Gy to PTVB). Two plans were generated for each PTV: multiple 7-fields for IMRT and two arcs for RA.Results: A Sigma index (IMRT: 2.75 ± 0.581; RA: 2.8 ± 0.738) for PTVP and (IMRT: 2.0 ± 0.484; RA: 2.1 ± 0.464) for PTVB indicated similar dose homogeneity inside the PTV. Conformity index (IMRT: 0.96 ± 0.047; RA: 0.95 ± 0.059) for PTVP and (IMRT: 0.97 ± 0.015; RA: 0.96 ± 0.014) for PTVB was comparable for both the techniques. IMRT offered lower mean dose to organ at risks (OARs) compared to RA plans. Normal tissue integral dose in IMRT plan resulted 0.87% lower than RA plans. All the plans displayed significant increase (2.50 times for PTVP and 1.72 for PTBB) in the average number of necessary monitor units (MUs) with IMRT beam. Treatment delivery time of RA was 2 ‒ 6 minutes shorter than IMRT treatment.Conclusion: For PTV including pelvic lymph nodes, seminal vesicles and prostate, IMRT offered a greater degree of OARs sparing. For PTV including seminal vesicles and prostate, RA with two arcs provided comparable plan with IMRT. RA also improved the treatment efficiency due to smaller number of MUs required.
oai:ojs.ijcto.org:article/485
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.1
2016-09-18T08:59:14Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
DVH Analysis of Cobalt-60 treatment plans incorporating a recently developed MLC
http://www.ijcto.org/index.php/IJCTO/article/download/485/4077
Sri Krishna, Gangarapu; Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad
Akula, Roopa Rani; Department of Physics, International Cancer Centre, Bhimavaram
Anil Kumar, Ayyalasomayajula; Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad
Srinivas, Vuppu; Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad
Ayyangar, Komanduri; Department of Physics, International Cancer Centre, Bhimavaram
Reddy, Palreddy Yadagiri; Department of Physics, Osmania University, Hyderabad
2016-07-16 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.1
Medical Physics
DVH Analysis, Conformity index, Homogeneity index, Conformation number, MLC Fields, ROPS TPS
en
Purpose: The aim of this investigation was to measure the gain in DVH indices when the recently developed MLC was used for Cobalt-60 treatments.Methods: A prototype multileaf collimator (MLC) that was retrofitted to telecobalt-60 therapy machine was reported and is currently proposed for clinical trials in our institution. Ten patients’ plans that were previously planned through an ECLIPSE® treatment planning system and were treated with open beams from Cobalt-60 machine were imported into Radiation Oncology Planning System [ROPS] and the dose calculations and dose volume histogram (DVH) analysis were performed. The plans were re-planned using the Cobalt-MLC, a feature available in the ROPS planning system. The DVH analysis consisted of conformity index (CI), homogeneity index (HI) and conformation number (CN). The results of this study are presented in this paper. The analysis specifically aimed at measuring the gain in these indices when the MLC was compared with open beams.Results: DVH Comparison of ten sites using open and Cobalt MLC fields showed that the use of MLC results in reduced normal tissue dose, while maintaining the GTV dose. Lower value of CI for normal structures was observed demonstrating the sparing of critical organs when MLC was used. The index HI was studied to show the significance of hot spots outside the PTV. Hot spots were observed even with MLC beams for some cases due to less number of fields.Conclusion: It has been demonstrated through DVH analysis that the use of the recently developed MLC for Cobalt Teletherapy machine results in benefit for the treatment of patients.
oai:ojs.ijcto.org:article/550
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.11
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Guanylyl Cyclase C as a tumor marker for detection of circulating tumor cells in the peripheral blood of colorectal cancer patients
http://www.ijcto.org/index.php/IJCTO/article/download/550/4452
http://www.ijcto.org/index.php/IJCTO/article/download/550/4453
http://www.ijcto.org/index.php/IJCTO/article/download/550/4454
http://www.ijcto.org/index.php/IJCTO/article/download/550/4455
http://www.ijcto.org/index.php/IJCTO/article/download/550/4456
http://www.ijcto.org/index.php/IJCTO/article/download/550/4457
Moghbeli, Meysam; Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
Chavoshi, Somaye; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Tavallaie, Mahmud; Human Genetics Research Center, Baqiatallah University of Medical Sciences, Tehran, Iran
Dadkhah, Ezzat; School of Systems Biology, George Mason University, Manassass, VA, USA
Raeissosadati, Reza; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Farshchian, Moein; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
Towliat Kashani, Mohsen; Department of Surgery, Baqiatallah University of Medical Sciences, Tehran, Iran
Ganji, Azita; Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Jangjoo, Ali; Department of Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Bromand Noughabi, Samaneh; Department of Pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Abbaszadegan, Mohammad Reza; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
2016-12-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.11
Guanylyl cyclase C, Colorectal cancer, Peripheral blood, Tumor marker, Circulating tumor cells
en
Purpose: Guanylyl cyclase C (GCC) is one of the most frequent tumor markers to detect the circulating tumor cells (CTCs) in peripheral blood of colorectal cancer (CRC) patients. It has been proposed as a new marker for the molecular staging of CRC. The level of GCC mRNA expression in peripheral blood of CRC patients was evaluated to explore its probable correlations with the clinicopathological features.Methods: Relative quantitative expression analysis of GCC mRNA was performed on 80 blood samples (40 patients and 40 normal) using the Real-time RT-PCR.Results: GCC mRNA expression was detected in 70% of the CRC blood samples. The level of GCC mRNA expression in peripheral blood of patients was significantly higher than that in the normal cases (p = 0.031). Moreover, there was a significant correlation between the GCC copy number and advanced stages of tumor (p = 0.041). Furthermore, we have observed a significant correlation between tumor sizes and GCC copy numbers (p = 0.050).Conclusion: GCC can be a useful marker not only for detection of CTCs in CRC blood samples, but also for the molecular staging of colorectal cancer.
oai:ojs.ijcto.org:article/709
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.14
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
The efficacy of the quercetin analogue LY294002 in immortalized cancer cell lines is related to the oxygenic and metabolic status of cells
http://www.ijcto.org/index.php/IJCTO/article/download/709/4989
http://www.ijcto.org/index.php/IJCTO/article/download/709/4990
http://www.ijcto.org/index.php/IJCTO/article/download/709/4991
http://www.ijcto.org/index.php/IJCTO/article/download/709/4992
http://www.ijcto.org/index.php/IJCTO/article/download/709/4993
http://www.ijcto.org/index.php/IJCTO/article/download/709/4994
http://www.ijcto.org/index.php/IJCTO/article/download/709/4995
http://www.ijcto.org/index.php/IJCTO/article/download/709/4996
http://www.ijcto.org/index.php/IJCTO/article/download/709/4997
http://www.ijcto.org/index.php/IJCTO/article/download/709/4998
Huang, Xinyue; Oxford University
Potter, Michelle
Pilgrim, Ben; Oxford University
Ardkhean, Ruchuta; Oxford University
Kabeshov, Mikail; Oxford University
Claridge, Tim DW; Oxford University
Wiseman, Matt; NIM genetics
Morten, Karl J; Oxford University
Donohoe, Timothy J
Townley, Helen Elizabeth; Oxford University
2017-12-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.14
Oncology; Chemotherapy; Cancer Biology; cancer science and therapeutics
Apoptosis; Cancer; Hypoxia; Quercetin; Metabolism; PI3K
Cancer biology
Williams Fund; EPSRC, Christchurch College
en
Purpose: LY294002, a promising drug for chemotherapy, suppresses the activity of Phosphatidylinositol 3-Kinase (PI3K) which is pivotal to a number of processes such as proliferation, metabolism, and apoptosis. The compound has, however, been seen to have very variable efficacy in vivo.Methods: Proliferation and viability of two immortalized cells with divergent bioenergetic profiles was determined using crystal violet staining, and the 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. Oxygen consumption rates were determined using MitoXpress-Xtra probes, and lactate generation was assessed with pH-Xtra probe and BM-lactate strips. Immunoblotting was performed with phospho-Akt-Ser 473 and Akt-pan primary antibodies.Results: U87 cells were shown to have a glycolytic metabolism, whereas RD cells exhibited a more aerobic metabolism. In both lines, hypoxia was shown to increase lactate production, and LY294002 reduced lactate production. The drug decreased cell proliferation and viability under all conditions, but the effect was greatest in U87 cells under normoxic conditions.Conclusion: Metabolic analysis showed a link between a glycolytic cell status and LY294002 induced cell death. However, in both cell lines the drug was also less effective under hypoxic conditions, as would be found in a tumour in vivo. Furthermore, in the presence of LY294002 the phosphorylation status of Akt, a target of PI3K, was found to be related to both the mechanism of cell respiration, and the oxygenic status of the cells.
oai:ojs.ijcto.org:article/33
2014-03-18T16:06:50Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Wong
2014-03-18T16:06:50Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 2 (2013): November - December
Human epidermal keratinocytes death and expression of protein markers of apoptosis after ionizing radiation exposure
Wong, Sharon; Department of Medicine, National University of Singapore, Yong Loo Lin School of Medicine
Chor, Han Hor; Division of Radiation Oncology, National Cancer Centre
Moorthy, Sathiya; Department of Pathology, Singapore General Hospital
Ong, Chee Tian; Department of Pathology, Singapore General Hospital
Phan, Toan Thang; Department of Medicine, National University of Singapore, Yong Loo Lin School of Medicine
Lu, Jaide Jay; Department of Radiation Oncology, National University Cancer Institute, National University of Singapore
2013-12-02 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Wong
Radiation Oncology
Apoptosis; Fractionated radiation therapy; Immunohistochemistry; Skin
Radiation Biology, Radiation Therapy
en
Purpose: Knowledge of the pathophysiology of the irradiated skin is important to understand the tolerance and cosmetic response of the human skin to radiation. There are limited studies on the effect of radiotherapy dosage and fraction size in inducing apoptotic cell death in human skin. The expression of apoptotic biomarkers within a controlled population in different fractionation schemes has also never been studied. This study aims to investigate radiation induced apoptotic cell death in human skin cells after fractionated radiation exposure and the expression of unique biomarkers that reflect cell death or biology using multiplexed immunoassays.Methods: Breast skin biopsies were obtained from a single individual and divided into small pieces. Each piece was irradiated under different radiotherapy treatment fractionation schedules to a total dose of 50Gy. The irradiated skin tissues were analysed using Tunnel, immunohistochemistry and Western blot assays for expression of apoptotic keratinocytes and biomarkers (p53, p21, and PCNA). Haematoxylin and eosin (H&E) immunostaining was performed to study the morphological changes in the skin cells. Results: Radiation is mostly absorbed by the epidermal layers and observed to damage the epidermal keratinocytes leading to the activation of apoptotic proteins. Apoptotic proteins (p53, p21 and PCNA) were confirmed to be up-regulated in radiation exposed skin cells as compared to normal skin cells with no radiation. There is strong correlation of apoptotic protein expressions with increased radiation dosage and dose fractionation. Statistical analysis with ANOVA revealed a significant increase of PCNA and p21 expression with increased radiation dosage and dose fractionation (p < 0.05). Immunohistochemically, 14 % (range 10.71% to 17.29%) of the keratinocytes were positive for PCNA and 22.5% (range 18.28% to 27.2%) for p21 after 2Gy of irradiation. The most widespread, intense and uniform staining for PCNA and p21 was observed in skin that had received 50Gy of irradiation. The maximum expression of p53 (range 37.09% to 50.91%) was reached at 10Gy.Conclusion: Findings from this study will assist clinicians in predicting radiation induced skin toxicity with the current changes in radiation fractionation protocols.-----------------------------------Cite this article as: Wong S, Chor HH, Moothy S, Ong CT, Phan TT, Lu JJ. Human epidermal keratinocytes death and expression of protein markers of apoptosis after ionizing radiation exposure. Int J Cancer Ther Oncol 2013; 1(2):01027.DOI: http://dx.doi.org/10.14319/ijcto.0102.7
oai:ojs.ijcto.org:article/96
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Barbosa
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code
Barbosa, Nilseia Aparecida; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
da Rosa, Luiz Antonio Ribeiro; Instituto de Radioproteção e Dosimetria
de Menezes, Artur Ferreira; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
Reis, Juraci; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
Facure, Alessandro; Comissão Nacional de Energia Nuclear
Braz, Delson; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
2014-05-22 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Barbosa
Medical Physics; Brachytherapy; Monte Carlo
Eye Brachytherapy; Monte Carlo; Dose Distribution; Ruthenium-106
Nilséia Aparecida Barbosa would like to acknowledge the Brazilian Conselho Nacional de Pesquisas, CNPq, for her financial support. This research work was supported by CNPq project INCT em Metrologia das Radiações em Medicina.
en
Purpose: Melanoma at the choroid region is the most common primary cancer that affects the eye in adult patients. Concave ophthalmic applicators with 106Ru/106Rh beta sources are the more used for treatment of these eye lesions, mainly lesions with small and medium dimensions. The available treatment planning system for 106Ru applicators is based on dose distributions on a homogeneous water sphere eye model, resulting in a lack of data in the literature of dose distributions in the eye radiosensitive structures, information that may be crucial to improve the treatment planning process, aiming the maintenance of visual acuity. Methods: The Monte Carlo code MCNPX was used to calculate the dose distribution in a complete mathematical model of the human eye containing a choroid melanoma; considering the eye actual dimensions and its various component structures, due to an ophthalmic brachytherapy treatment, using 106Ru/106Rh beta-ray sources. Two possibilities were analyzed; a simple water eye and a heterogeneous eye considering all its structures. Two concave applicators, CCA and CCB manufactured by BEBIG and a complete mathematical model of the human eye were modeled using the MCNPX code. Results and Conclusion: For both eye models, namely water model and heterogeneous model, mean dose values simulated for the same eye regions are, in general, very similar, excepting for regions very distant from the applicator, where mean dose values are very low, uncertainties are higher and relative differences may reach 20.4%. For the tumor base and the eye structures closest to the applicator, such as sclera, choroid and retina, the maximum difference observed was 4%, presenting the heterogeneous model higher mean dose values. For the other eye regions, the higher doses were obtained when the homogeneous water eye model is taken into consideration. Mean dose distributions determined for the homogeneous water eye model are similar to those obtained for the heterogeneous eye model, indicating that the homogeneous water eye model is a reasonable one. The determined isodose curves give a good visualization of dose distributions inside the eye structures, pointing out their most exposed volume....................................................Cite this article as:Barbosa NA, da Rosa LAR, de Menezes AF, Reis JP, Facure A, Braz D. Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code. Int J Cancer Ther Oncol 2014; 2(3):02038. DOI: 10.14319/ijcto.0203.8
oai:ojs.ijcto.org:article/172
2014-12-13T14:36:25Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.15
2014-12-13T14:36:25Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Commissioning and quality assurances of the Intrabeam Intra-Operative radiotherapy unit
Muralidhar, KR; Department of Radiation Physics, American Oncology Institute Nallagandla, Lingampally, Hyderabad, India
Rout, Birendra Kumar; Department of Radiation Physics, Indo-American Cancer Institute, Hyderabad, India
Mallikarjuna, Adavala; Department of Radiation Physics, Indo-American Cancer Institute, Hyderabad, India
Poornima, A; Department of Radiation Physics, Indo-American Cancer Institute, Hyderabad, India
Murthy, P Narayana; Department of Radiation Physics, Nagarjuna University, Guntur, India
2014-10-20 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.15
Medical Physics
IORT; Intrabeam; X-Ray Source; Isotropy; Photo Diode Array
en
Purpose: The authors report comprehensive commissioning and quality assurance (QA) procedures for Intrabeam, Intra-Operative radiotherapy (IORT) unit. The Intrabeam system miniature X-ray source is a 50 kV and 40 µA unit. Methods: The authors’ tests include measurements of output, beam deflection, isotropy, kVp and mAs measurements, quality index, isodose, reproducibility, linearity, depth dose verification, and 3D dose distribution. IC ionization chamber and the UNIDOSE dosimeter were used for the output commissioning. Probe adjuster/ionization chamber holder (PAICH) was used to check the mechanical straightness of the probe. For radiation tests, NACP parallel plate chamber, Standard Imaging electrometer, 30 × 30 × 30 cm3 IAEA water phantom, solid water slabs, EDR-2 Films with RIT software, and ionization based survey meters were used. Unfors Xi platinum edition kVp meter was used to measure the kVp and mAs. Results: In mechanical QA test, X-Beam position (-0.09 mm), Y-Beam position (0.01 mm), and radial position (0.11 mm) errors were within the tolerance level. Isotropy test with PDA, survey meter, ion chamber, and film measurements also produced results within the specifications. Output measurements with PAICH and external chamber measurements were matched. Beam quality, linearity, and reproducibility values were ascertained at 50KV and 40 µA and found to be within limits. Isodose, 3D dose distribution, transverse, and horizontal profiles showed the good isotropy of the source. Conclusion: The authors’ methodology provides comprehensive commissioning and calibration procedures for the Intrabeam system.
oai:ojs.ijcto.org:article/222
2015-03-29T11:59:33Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.17
2015-03-29T11:59:33Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Evaluation of surface dose outside the treatment area for five breast cancer irradiation modalities using thermo-luminescent dosimeters
http://www.ijcto.org/index.php/IJCTO/article/download/222/2405
http://www.ijcto.org/index.php/IJCTO/article/download/222/2406
http://www.ijcto.org/index.php/IJCTO/article/download/222/2407
Khanal, Suraj Prasad; Department of Physics, Medical Physics Program, Florida Atlantic University, Boca Raton, Florida
Ouhib, Zoubir; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, Florida
Benda, Rashmi K; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, Florida
Leventouri, Theodora; Department of Physics, Medical Physics Program, Florida Atlantic University, Boca Raton, Florida
2015-01-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.17
Medical Physics; Radiation Oncology; Medical Oncology
TLDs; Absorbed Dose; Deterministic Effect; Boost; Induced Cancer
Medical Physics; Breast Cancer
en
Purpose: To measure and compare the surface dose outside the treatment area at six different points of interest (POIs) for five different breast cancer radiation treatment modalities by using thermo-luminescent dosimeters (TLDs). This experiment will evaluate the magnitude of the dose due to scatter and leakage radiation at different areas outside the target on a patient that could potentially lead, in the long term, to radiation induced secondary malignancies.Methods: TLD-100 were calibrated according to the University of Wisconsin Radiation Calibration Laboratory protocol and then used for dose measurements at selected POIs namely sternum, lower abdomen, contralateral breast, thyroid, shoulder, and eye. Twenty five breast cancer patients and the following modalities were included in this study: Strut-adjusted volume implant (SAVI), mammosite multi-lumen (ML), Accuboost, electron boost and photon boost. The surface doses in all patients were measured in a single fraction. The delivered target doses were normalized to 200 cGy. Finally, breast quadrant analysis was performed.Results: The maximum average dose for each POI was as follows: Sternum 6.51 cGy (SD 2.93), lower abdomen 4.50 cGy (SD 2.63), contralateral breast 8.52 cGy (SD 3.86), thyroid 5.50 cGy (SD 2.75), shoulder 5.58 cGy (SD 2.77), and eye 2.65 cGy (SD 0.68). The highest POI dose of 15.84 cGy was found in contralateral breast.Conclusion: The measured surface dose at each POI varies with the modality of treatment. The surface doses show a strong correlation to the tumor bed location in the breast quadrant. The SAVI, electron boost, and photon boost modalities had delivered smaller surface dose at POIs than the Accuboost and Mammosite ML modalities. While the measured doses fall within the low range, its significance in producing second malignancies would require a large cohort of patients and a longer follow up.
oai:ojs.ijcto.org:article/320
2015-08-15T11:54:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.21
2015-08-15T11:54:27Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
Co-expression of CXCR4 and CD133 in gastric neoplastic tissue and their correlation with clinicopathological factors and prognosis in gastric cancer
http://www.ijcto.org/index.php/IJCTO/article/download/320/3170
Poddar, Snigdha; Department of Zoology, Unit of Biochemistry, School of Life Science, University of Madras,
Maraimalai Campus, Guindy, Chennai, Tamil Nadu
D’Cruze, Lawrence; Department of Pathology, Sri Ramachandra Medical College, Porur, Chennai, Tamil Nadu
Halagowder, Devaraj; Department of Zoology, Unit of Biochemistry, School of Life Science, University of Madras,
Maraimalai Campus, Guindy, Chennai, Tamil Nadu
2015-06-19 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.21
Clinical Oncology
Cancer Stem Cell; Gastric Cancer; CXCR4; CD133; Immunohistochemical Study; Co-immunolocalisation; RT-PCR
en
Purpose: Worldwide Gastric carcinoma considered as the second most common cause of cancer related death. Cancer stem cell plays significant role in prognosis and invasion of gastric cancer. CXCR4 is a chemokine receptor and plays an important role in self renewal, differentiation potential, and cell adhesion of cancer stem cell (CSC). On the other hand CD133 is a cell surface glycoprotein and could serve as a prognostic indicator for tumor re-growth, malignant progression, and patient survival. The aim of this study was to establish the expression pattern of CXCR4 and CD133 in gastric cancer tissues; and their correlation with clinicopathological factors like age and gender of patients, position, size and depth of tumor, lymphatic invasion and node metastasis.Methods: Expression of CXCR4 and CD133 proteins were assessed by immunohistochemical and immunofluorescence staining of paraffin–embedded tissues, and followed by RT-PCR in 90 tumors (observed group) and 30 normal gastric samples. The clinical pathological data was statistically analyzed by chi-square methods. Results: The positive rate of CXCR4 and CD133 expression in the observed group was 94.44 (85/90) and 95.55 (86/90) respectively. The expression of CXCR4 and CD133 were correlated with age and gender of patients, and position, size, & depth of the tumor, lymphatic invasion and node metastasis (p < 0.05). While CXCR4 was positive, CD133 had a positive rate of 92.22% but the positive rate was 2.22% when CXCR4 expression was negative (χ2 = 58.657; p < 0.001). Conclusion: Overall this data suggests that increased expression of CXCR4 and CD133 might be attributed with disease progression and malignant transformation of gastric epithelium cells. A significant correlation was found in between CXCR4 and CD133 expression and their co-expression may play significant role in invasiveness of gastric cancer.
oai:ojs.ijcto.org:article/377
2016-07-16T10:58:36Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.11
2016-07-16T10:58:36Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Statistical methods to evaluate the correlation between measured and calculated dose using quality assurance method in IMRT
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical physics,
Grenoble University Hospital, France.
Desgranges, Charline; Department of Radiation Oncology and Medical physics, University Hospital of Grenoble, France.
Balosso, Jacques; Department of Radiation Oncology and Medical physics, University Hospital of Grenoble, France.
Université Grenoble-Alpes, Grenoble, France.
2015-11-27 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.11
Radiation Oncology; Medical Physics, Medical Oncology
IMRT, Quality Assurance, Statistical Method
Medical Physics;Radiation Oncology
en
Purpose: the objective of this study is to validate a procedure based on a statistical method to assess the agreement and the correlation between measured and calculated dose in the process of quality assurance (QA) for Intensity-Modulated Radiation Therapy (IMRT).Patients and methods: 10 patients including 56 fields for head and neck cancer treatment were analyzed. For each patient, one treatment plan was generated using Eclipse TPS®. To compare the calculated dose with measured dose a CT-scan of solid water slabs (30 × 30 × 15 cm3) was used. The measurements were done for absolute dose by a pinpoint ionization chamber and 2D dose distributions using electronic portal imaging device dosimetry. Six criteria levels were applied for each case (3%, 3 mm), (4%, 3 mm), (5%, 3 mm), (4%, 4 mm), (5%, 4 mm) and (5%, 5 mm). The normality of the data and the variance homogeneity were tested using Shapiro-Wilks test and Levene’s test, respectively. Wilcoxon signed-rank paired test was used to calculate p-value. Bland-Altman method was used to calculate the limit of agreement between calculated and measured doses and to draw a scatter plot. The correlation between calculated and measured doses was assessed using Spearman’s rank test.Results: The statistical tests indicate that the data do not fulfill normal distribution, p < 0.001 and had a homogenous variance, p = 0.85. The upper and lower limit of agreements for absolute dose measurements were 6.44% and -6.40%, respectively. Wilcoxon test indicated a significance difference between calculated and measured dose with ionization chamber, p = 0.01. Spearman’s test indicated a strong correlation between calculated and absolute measured dose, ρ = 0.99. Therefore, there is a lack of correlation between dose difference for absolute dose measurements and gamma passing rates for 2D dose measurements.Conclusion: the statistical tests showed that the common acceptance criteria’s using gamma evaluation are not able to predict the dose difference for a global treatment plan or per beam. The current QA method is limited to protect the patient. The described method provides an overall analysis for dosimetric data issued from calculation and measurement and it can be quickly integrated in QA system for IMRT.
oai:ojs.ijcto.org:article/514
2016-07-16T06:10:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.5
2016-07-16T06:10:15Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 2 (2016): April - June
Serum vascular cell adhesion molecule-1 (VCAM1) level is elevated in colorectal cancer regardless of the tumor stage
Ciftci, Rumeysa; Bakirkoy Dr Sadi Konuk Education and Research Hospital, Medical Oncology Department, Istanbul,
Tambas, Makbule; Istanbul University, Institute of Oncology, Radiation Oncology Department,
Istanbul
Kilic, Leyla; Istanbul University, Institute of Oncology, Medical Oncology Department,
Istanbul
Tilgen Yasasever, Ceren; Istanbul University, Institute of Oncology, Basic Oncology Department,
Istanbul
Gurdal, Necla; Istanbul University, Institute of Oncology, Radiation Oncology Department,
Istanbul
Serilmez, Murat; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Celebi, Koray; Istanbul University, Institute of Oncology, Medical Oncology Department,
Istanbul
Pilanci, Kezban Nur; Haseki Education and Research Hospital, Medical Oncology Department,
Istanbul
Duranyildiz, Derya; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Yasasever, Vildan; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Vatansever, Sezai; Istanbul University, Institute of Oncology, Medical Oncology Department ,
Istanbul
Aykan, Nuri Faruk; Istanbul University, Institute of Oncology, Medical Oncology Department ,
Istanbul
2016-05-23 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.5
Medical Oncology
Colorectal Cancer, Serum VCAM1, Survival
None
en
Purpose: Vascular cell adhesion molecule-1 (VCAM1) is a transmembrane glycoprotein, which is expressed on endothelium and plays role in inflammation. It is over-expressed on colorectal cancer (CRC) cells and plays role in metastasis development and angiogenesis. We aimed to compare serum VCAM1 levels of CRC patients with heathy controls and evaluate its relationship with clinicopathological parameters, treatment response and overall survival (OS).Methods: The study enrolled 111 patients with histopathologically confirmed CRC followed-up in our clinic and 30 sex- and age-matched healthy controls. Pre-treatment serum VCAM1 levels were determined by the solid-phase sandwich ELISA method.Results: Metastatic disease was present in 57 patients. Forty percent of 40 metastatic patients receiving systemic therapy had partial or complete response. The median serum VCAM1 level was significantly higher in CRC patients than controls (p<0.001). In addition, serum VCAM1 level was significantly higher in diabetic CRC patients than those without diabetes (p = 0.03). There was no significant relationship between VCAM1 and other clinicopathological parameters including stage and response to systemic therapy. The median follow-up period was 12 (±8.2) months. Twenty patients were dead at the time of analysis. The presence of metastasis (p < 0.001) and elevated CEA level (p < 0.001) were factors affecting OS significantly. However, serum VCAM1 did not have a significant impact on OS (p = 0.55).Conclusion: Serum VCAM1 level is significantly elevated in CRC patients regardless of the tumor stage. However, it has no prognostic or predictive role for response to systemic therapy.
oai:ojs.ijcto.org:article/540
2017-02-12T15:24:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.1
2017-02-12T15:24:26Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Role of Interleukin-18 in Thyroid tumorigenesis
Kobawala, Toral; Division of Molecular Endocrinology,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
Ahmedabad-380 016,
India
Trivedi, Trupti; Division of Molecular Endocrinology,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
Ahmedabad-380 016,
India
Gajjar, Kinjal; Division of Molecular Endocrinology,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
Ahmedabad-380 016,
India
Patel, Girish; Division of Molecular Endocrinology,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
Ahmedabad-380 016,
India
Ghosh, Nandita; Division of Molecular Endocrinology,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
Ahmedabad-380 016,
India
2016-12-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.1
IL-18, Thyroid tumorigenesis, Papillary thyroid cancer, Immuno- histochemistry, ELISA
This study was financially supported by Gujarat Cancer Society (GCS) and was approved by the GCRI/GCS ethics committee.
en
Purpose: Although the significance of Interleukin-18 (IL-18) has been studied in pathogenesis of different cancers including, ovarian, gastric, breast, lung carcinoma and melanoma, its role in thyroid cancer- the most common endocrine malignancy has not yet been looked at extensively. Hence, this study intended to examine the role of IL-18 in thyroid tumorigenesis.Methods: Sixty seven patients with benign thyroid diseases and 106 thyroid cancer patients (including 83 papillary, 6 follicular, 9 medullary and 8 anaplastic thyroid carcinoma patients) were enrolled in the study. To accomplish the aim, the circulating levels of IL-18 were estimated by enzyme linked immunosorbent assay (ELISA) from all patients and compared with controls. Further, protein expression of IL-18 was determined from the primary tumors of the patients using immunohistochemistry.Results: It was observed that the circulating levels of IL-18 were significantly higher in all patients: benign thyroid diseases (p = 0.006), papillary (p < 0.001), follicular (p = 0.023), medullary (p = 0.002) and anaplastic thyroid cancer (p < 0.001) than the controls. In addition to this, IL-18 could well discriminate papillary (AUC = 0.627, p =0.008) and anaplastic thyroid carcinoma patients (AUC = 0.777, p = 0.011) from patients with benign thyroid diseases. However, the difference between tumoral protein expression of IL-18 in patients with benign thyroid diseases and thyroid carcinoma was not significant. The Kaplan - Meier survival analysis revealed that neither the circulating nor the tumoral protein expression of IL-18 was the significant predictor of disease free survival (DFS) or overall survival (OS) in papillary thyroid cancer patients.Conclusion: Though not a significant prognosticator, circulating IL-18 may be useful as a differentiating factor in thyroid tumorigenesis and the increase in serum IL-18 levels may be provoked in response to the tumor. Thus, including IL-18 along with the current treatment practice may have a significant role in better management of the disease. However, further exploration of this interleukin is required in a larger series of patients with longer follow up period.
oai:ojs.ijcto.org:article/663
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.12
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Multileaf-collimator daily quality assurance of Vero4DRT system: our one-year experience
Miura, Hideharu; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
Ozawa, Shuichi; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
Tsuda, Shintaro; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
Yamada, Kiyoshi; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
Nagata, Yasushi; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
2017-08-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.12
Medical Physics
Multileaf-collimator daily quality assurance of Vero4DRT system: Our one-year experience
en
Purpose: We assessed the daily quality assurance (QA) of multi-leaf collimator (MLC) using the Vero4DRT system. Methods: As part of daily MLC QA, the irradiation field was set to 100 × 150 mm2 with a gantry angle of 0 º. Only the leaf positioning error values only were displayed. We developed an in-house program to easily acquire these values using an open source optical character recognition engine. This test was implemented between 24 August 2015 and 23 August 2016. Results: The maximum leaf positioning error was 0.40 mm in both banks. In addition, the maximum deviation was 0.10 mm in both banks. The average and standard deviation for left and right banks were 0.19 mm ± 0.11 mm and 0.15 mm ± 0.09 mm, respectively. In our one-year measurement, the leaf positioning error was less than 0.50 mm. Therefore, if the leaf position error for daily MLC QA exceeded 0.50 mm, then an external intervention is required.Conclusion: The daily MLC QA of our one-year evaluation of the Vero4DRT system demonstrates an excellent leaf accuracy and reproducibility, thereby giving confidence in the quality of the treatment.
oai:ojs.ijcto.org:article/785
2018-06-24T14:49:11Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.7
2018-06-24T14:49:11Z
International Journal of Cancer Therapy and Oncology
Vol 6, No 1 (2018): January - December
IL-2 and IL-12 in thyroid cancer: Clinical implication
Kobawala, Toral; Research Assistant,
Tumor Biology Lab-2,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
NCH Compound, Asarwa,
Ahmedabad-380 016,
India
Gajjar, Kinjal; Junior Research Assistant,
Tumor Biology Lab-2,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
NCH Compound, Asarwa,
Ahmedabad-380 016,
India
Trivedi, Trupti; Senior Scientific Officer,
Clinical Carcinogenesis Lab-3,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
NCH Compound, Asarwa,
Ahmedabad-380 016,
India
Patel, Girish; Retired Senior Scientific Officer,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
NCH Compound, Asarwa,
Ahmedabad-380 016,
India
Ghosh, Nandita; Assistant Professor and In-charge,
Tumor Biology Lab-2,
Department of Cancer Biology,
The Gujarat Cancer & Research Institute (GCRI),
NCH Compound, Asarwa,
Ahmedabad-380 016,
India
2018-06-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.7
Cancer Biology
IL-2, IL-12, Thyroid tumorigenesis, Papillary thyroid cancer, Immunohistochemistry, ELISA
-
en
Purpose: The roles of IL-2 and IL-12, in different malignancies have been looked for since years. But very few studies have elucidated their role in thyroid tumorigenesis. Hence, present study sought to explore their utility in thyroid cancer, mainly the papillary thyroid cancer (PTC).Methods: A total of 67 patients with benign thyroid diseases, 106 with thyroid cancer and 67 healthy individuals were included in the study. Circulating levels of IL-2 and IL-12 were estimated by ELISA from all patients and controls. Protein expression of both interleukins was determined using immunohistochemistry. The results were statistically analysed using SPSS software.Results: Serum IL-12 exhibited good discriminatory efficacy between patients with benign thyroid diseases and healthy individuals. IL-2 and IL-12 levels could efficiently differentiate PTC and anaplastic thyroid cancer (ATC) patients from healthy individuals. Additionally, IL-12 showed good discriminating efficacy between PTC and benign thyroid disease patients and IL-2 well discriminated ATC patients from benign thyroid diseases. IL-2 was significantly higher in patients having unilateral tumors (P=0.006) while, IL-12 was significantly higher in patients with smaller tumor size (P=0.036) and early stage disease (P=0.008). The cytokine protein expressions in benign thyroid tissues and carcinoma did not differ significantly. IL-12 expression was significantly higher in male patients (P=0.042) and unilateral tumors (P=0.031).Kaplan-Meier survival analysis revealed that nuclear IL-2 expression was able to predict disease free survival and overall survival (OS) in subgroup of PTC patients having multifocal tumors and only OS in patients having bilateral tumors. Moreover, higher IL-12 immunoreactivity was a significant predictor of shorter OS in PTC patients treated with surgery alone.Conclusion: Serologic determination of IL-2 and IL-12 may help in validating indeterminate FNAC results and disclose diagnostic difference between benign and malignant thyroid diseases. However, a large cohort study is mandatory to establish a defined cut off for such discrimination.
oai:ojs.ijcto.org:article/5
2014-03-16T11:28:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Vasdev
2014-03-16T11:28:14Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 1 (2013): September - October
Urological management (medical and surgical) of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation
Vasdev, Nikhil; Hertfordshire and South Bedfordshire Urological Robotic Cancer Centre, Lister Hospital, UK.
Davidson, Angela; Departmentof Urology, Freeman Hospital, Newcastle upon Tyne, UK
Harkensee, Christian; Supra-regional Children’s Bone Marrow Transplant Unit (CBMTU), Newcastle General Hospital, Newcastle upon Tyne, UK
Slatter, Mary; Supra-regional Children’s Bone Marrow Transplant Unit (CBMTU), Newcastle General Hospital, Newcastle upon Tyne, UK
Gennery, Andrew; Supra-regional Children’s Bone Marrow Transplant Unit (CBMTU), Newcastle General Hospital, Newcastle upon Tyne, UK
Willetts, Ian; Department of Paediatric Urology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Thorpe, Andrew; Departmentof Urology, Freeman Hospital, Newcastle upon Tyne, UK
2013-09-08 10:07:36
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Vasdev
Haemorrhagic Cystitis, Haemopoitic Stem Cell Transplant, Urological Management, Patient Outcome
en
Aim: Haemorrhagic cystitis (HC) is uncommon and in its severe form potentially life threatening complication of Haematopoietic stem cell transplantation (HSCT) in children. We present our single centre experience in the urological management of this clinically challenging condition. Patients and Methods: Fourteen patients were diagnosed with BK-Virus HC in our centre. The mean age at diagnosis was 8.8 years (range, 3.2-18.4 years). The mean number of days post-BMT until onset of HC was 20.8 (range, 1 – 51). While all patients tested urine positive for BKV at the clinical onset of HC, only four patients had viral quantification, with viral loads ranging from 97,000 to >1 billion/ml. 8 patients had clinical HC. Ten patients experienced acute GVHD (grade I: 6 patients, grade II: 3 patients, grade 4: 1 patient).Results: Four patients received medical management for their HC. Treatments included hyperhydration, MESNA, blood and platelet transfusion, premarin and oxybutynin (Table 6). Two patients received both medical and surgical management which included cystoscopy with clot evacuation, bladder irrigation and supra-pubic catheter insertion. One patient received exclusive surgical management. Seven patients were treated conservatively. Conclusion: There is limited available evidence for other potential therapeutic strategies highlighting the need for more research into the pathophysiology of HSCT-associated HC. Commonly used interventions with possible clinical benefit (e.g. cidofovir, ciprofloxacin) still require to be evaluated in multi-centre, high-quality studies. Potential future preventative and therapeutic options, such as modulation of conditioning, immunosuppression and engraftment, new antiviral and anti-inflammatory and less nephrotoxic agents need to be assessed.---------------------------Cite this article as:Vasdev N, Davidson A, Harkensee C, Slatter M, Gennery A, Willetts I, Thorpe A.Urological management (medical and surgical) of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation. Int J Cancer Ther Oncol 2013;1(1):01013. DOI:http://dx.doi.org/10.14319/ijcto.0101.3
oai:ojs.ijcto.org:article/94
2014-08-16T18:42:02Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.3
2014-08-16T18:42:02Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
A 3D quantitative evaluation for assessing the changes of treatment planning system and irradiation techniques in radiotherapy
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
Giraud, Jean Yves; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
2014-05-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.3
Irradiation therapy, Medical physics
Gamma Index; Dose Distributions; Gamma Voxels Histograms; Gamma Maps
Irradiation therapy
en
Purpose: This work proposes and compares two 3D global evaluation methods for assessing the alteration of calculated dose distributions when treatment planning system algorithms or irradiation techniques is modified in radiation therapy. Methods: The global analysis is based on gamma index (γ) proposed by Low et al.1 and Chi (χ) index proposed by Bakai et al.2. The γ and χ values are signed in order to identify the over and under estimating dosage. The 3D maps, the cumulative Gamma Voxels Histograms (GVHs) and Chi Voxels Histograms (CVHs) were generated using two software. The γ and χ criteria were set to 3 mm for the distance to agreement and 3% for dose. Pearson's Chi-squared test was applied to assess the statistically significance between GVHs and CVHs. We illustrated this method for the change of dose calculation algorithms for lung cancer, and the change of irradiation techniques for breast cancer. For each patient, 2 treatment plans were generated. For the example of change of dose calculation algorithms, a plan 1 was calculated using Pencil Beam Convolution (PBC) algorithm and a plan 2 was calculated using Modified Batho method (PBC-MB). For the example of change of irradiation technique, a plan 1 was calculated using Source Skin Distance SSD technique and a plan 2 was calculated using a single isocenter technique. Results: The 3D analysis based on γ and χ indexes showed a significant effect on the dosimetric representation in the lung cancer when we change the PBC algorithm to PBC-MB method. The comparison between the two irradiation techniques showed that the single isocenter technique produces a better dose distribution for the treatment of breast cancer. Pearson's Chi-squared test showed that there was no statistically significance between GVHs and CVHs generated by γ and χ indexes, (p > 0.05). The global analysis using 3D for γ and χ indexes confirmed the results obtained from dosimetric analysis. Conclusion: The methods proposed in this study provide useful tools for radiotherapy to compare two dose distributions obtained using different algorithms or different irradiation techniques. The χ-index was (~190) times faster than γ-index. The χ-index is thus a valuable and more convenient method for 3D global analysis compared with γ-index.------------------------Cite this article as: Chaikh A, Giraud JY, Balosso J. A 3D quantitative evaluation for assessing the changes of treatment planning system and irradiation techniques in radiotherapy. Int J Cancer Ther Oncol 2014; 2(3):02033. DOI: 10.14319/ijcto.0203.3
oai:ojs.ijcto.org:article/156
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.6
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Dosimetric study of RapidArc plans with flattened beam (FB) and flattening filter-free (FFF) beam for localized prostate cancer based on physical indices
Rout, Birendra Kumar; Department of Radiation Physics,American Oncology Institute, Hyderabad,India.
Department of Physics,Jawaharlal Nehru Technological University(JNTU), Hyderabad, India.
Muralidhar, Kanaparthy R; Department of Radiation Physics,American Oncology Institute, Hyderabad, India.
Ali, Mirza; Department of Radiation Physics,American Oncology Institute, Hyderabad,India.
Shekar, Mukka C; Department of Physics, Jawaharlal Nehru Technological University(JNTU), Hyderabad, India.
Kumar, Alok; Radiation Physics, Mahavir Cancer Sansthan, Patna, India
2014-09-05 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.6
Radiation Physics
Flattening Filter-Free; Flattened Beam; Sigma-Index; Conformity Index; Normal Tissue Integral Dose; Rapid Arc
NIL
en
Purpose: To identify the continual diversity between flattening photon beam (FB) and Flattening Filter Free (FFF) photon beams for localized prostate cancer; and to determine potential benefits and drawbacks of using unflattened beam for this type of treatment.Methods: Eight prostate cases including seminal vesicles selected for this study. The primary planning target volume (PTVP) and boost planning target volume (PTVB) were contoured. The total prescription dose was 78 Gy (56 Gy to PTVP and an additional 22 Gy to PTVB). For all cases, treatment plans using 6MV with FB and FFF beams with identical dose-volume constraints, arc angles and number of arcs were developed. The dose volume histograms for both techniques were compared for primary target volume and critical structures.Results: A low Sigma index (FFF: 1.65 + 0.361; FB: 1.725 + 0.39) indicating improved dose homogeneity in FFF beam. Conformity index (FFF: 0.994 + 0.01; FB: 0.993 + 0.01) is comparable for both techniques. Minimal difference of Organ at risk mean dose was observed. Normal tissue integral dose in FB plan resulted 1.5% lower than FFF plan. All the plans displayed significant increase (1.18 times for PTVP and 1.11 for PTBB) in the average number of necessary MU with FFF beam.Conclusion: Diversity between FB and FFF beam plans were found. FFF beam accelerator has been utilized to develop clinically acceptable Rapid Arc treatment plans for prostate cancer with 6 MV.---------------------------------Cite this article as: Rout BK, Muralidhar KR, Ali M, Shekar MC, Kumar A. Dosimetric study of RapidArc plans with flattened beam (FB) and flattening filter-free (FFF) beam for localized prostate cancer based on physical indices. Int J Cancer Ther Oncol 2014; 2(4):02046. DOI: 10.14319/ijcto.0204.6
oai:ojs.ijcto.org:article/203
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.10
2015-03-29T11:59:32Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Consistency analysis for the performance of planar detector systems used in advanced radiotherapy
http://www.ijcto.org/index.php/IJCTO/article/download/203/2566
Jassal, Kanan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Sarkar, Biplab; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Munshi, Anusheel; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Roy, Shilpi; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Paul, Sayan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Mohanti, Bidhu Kalayan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Ganesh, Tharmar; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon
Chougule, Arun; Department of Radiological Physics, SMS Medical College and Hospital, Jaipur, India
Sachdev, Kanupriya; Department of Physics, Malaviya National Institute of Technology, Jaipur, India
2014-12-18 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.10
Medical Physics
a-Si EPID Dosimetry; γ – Analysis; Statistical Process Control; Capability Index
en
Purpose: To evaluate the performance linked to the consistency of a-Si EPID and ion-chamber array detectors for dose verification in advanced radiotherapy.Methods: Planar measurements were made for 250 patients using an array of ion chamber and a-Si EPID. For pre-treatment verification, the plans were generated on the phantom for re-calculation of doses. The γ-evaluation method with the criteria: dose-difference (DD) ≤ 3% and distance-to-agreement (DTA) ≤ 3 mm was used for the comparison of measurements. Also, the central axis (CAX) doses were measured using 0.125cc ion chamber and were compared with the central chamber of array and central pixel correlated dose value from EPID image. Two types of statistical approaches were applied for the analysis. Conventional statistics used analysis of variance (ANOVA) and unpaired t-test to evaluate the performance of the detectors. And statistical process control (SPC) was utilized to study the statistical variation for the measured data. Control charts (CC) based on an average , standard deviation ( ) and exponentially weighted moving averages (EWMA) were prepared. The capability index (Cpm) was determined as an indicator for the performance consistency of the two systems.Results: Array and EPID measurements had the average gamma pass rates as 99.9% ± 0.15% and 98.9% ± 1.06% respectively. For the point doses, the 0.125cc chamber results were within 2.1% ± 0.5% of the central chamber of the array. Similarly, CAX doses from EPID and chamber matched within 1.5% ± 0.3%. The control charts showed that both the detectors were performing optimally and all the data points were within ± 5%. EWMA charts revealed that both the detectors had a slow drift along the mean of the processes but was found well within ± 3%. Further, higher Cpm values for EPID demonstrate its higher efficiency for radiotherapy techniques.Conclusion: The performances of both the detectors were seen to be of high quality irrespective of the radiotherapy technique. Higher Cpm values for EPID indicate its higher efficiency than array.
oai:ojs.ijcto.org:article/297
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.20
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
Impact of lymphoceles on organ at risk doses in patients undergoing adjuvant pelvic radiation for carcinoma cervix
http://www.ijcto.org/index.php/IJCTO/article/download/297/3001
Hotwani, Chandani; Department Radiation Oncology and Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Mumbai
Chopra, Supriya; Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai
Moirangthem, Nara; Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai
Mohanty, Sarthak; Department Radiation Oncology and Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Mumbai
Paul, Siji; Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai
Engineer, Reena; Department Radiation Oncology and Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Mumbai
Mahantshetty, Umesh; Department Radiation Oncology and Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Mumbai
Shrivastava, Shyam; Department Radiation Oncology and Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Mumbai
2015-05-30 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.20
Radiation Oncology; Gynecology;IMRT
Lymphoceles; IMRT; Cervix
Cervical Cancer
Department of Atomic Energy Clinical Trials Centre
en
Purpose: Lymphoceles form part of target volume during adjuvant radiation for cervical cancer. The impact of lymphocele on doses to adjacent organs at risk (OAR) has not been studied. The present study was designed to investigate the same. Methods: From January 2011- December 2013 all patients were evaluated for presence of postoperative lymphocele. Planned target volume (PTV) was generated with and without lymphocele volume. Intensity modulated radiation therapy (IMRT) plans were generated and dose to OARs was determined. The impact of lymphocele volume on OAR dose was determined by Spearman rank test and Wilcoxon sign rank sum test was performed to determine the impact of lymphocele on OAR dose. Results: A total of 11/93 patients had postoperative lymphoceles. Of these 63% were located in internal iliac region. The median lymphocele volume at simulation was 42.8 cc (range 6.4-105cc) and remained almost stable at 44 cc (range 3-100 cc) at fifth week of radiation. Negative correlation was observed between mean lymphocele volume and dose to bladder, rectum and bowel bag. Presence of lymphocele led to reduction in V30 and V40 of bladder (84 cc vs 77 cc, p = 0.004; 68 cc vs 63 cc; p = 0.01) and rectum (87 cc vs 80 cc, p = 0.0001; 73.5 cc vs 65 cc, p = 0.01) and V15 of bowel bag (843 cc vs 804 cc; p = 0.01). Conclusion: Presence of lymphoceles displaced OARs leading to reduction in high dose volumes of rectum and bladder.
oai:ojs.ijcto.org:article/346
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.4
2016-01-03T12:17:08Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy
http://www.ijcto.org/index.php/IJCTO/article/download/346/3286
Kim, Hyun-Jun; Department of Obstetrics and Gynecology, Konkuk University College of Medicine, Chungju
Kim, Kyoung Ha; Department of Internal Medicine, Soonchunghyang University College of Medicine, Seoul
Kim, Seung Tae; Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul
Park, Se Hoon; Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul
2015-09-20 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.4
Medical Oncology, Gastroenterology
Gastric Cancer; Chemotherapy; Young Age
en
Purpose: Despite conflicting data regarding survival after curative surgery, little is known about the prognosis of metastatic gastric cancer (MGC) in young adults. The current study was performed to determine whether younger age is an independent prognostic factor among MGC patients receiving first-line chemotherapy and to evaluate how age relates to other known prognostic parameters. Methods: The records of 1843 MGC patients who were consecutively treated with first-line combination chemotherapy at Samsung Medical Center (Seoul, Korea) between 2000 and 2007, including 570 patients aged 45 years or younger, were retrieved from a prospective cancer chemotherapy database.Results: In the younger group, there were significantly more bone metastases, ascites, poor performance status, low albumin, elevated alkaline phosphatase, and resections that were non-curative than in the older patients. Progression-free survival (PFS) and overall survival (OS) was shorter in younger patients (PFS, 4.2 months; OS, 7.1 months) than in older ones (PFS, 5.1 months; OS, 8.4 months). Nonetheless, younger age did not show an independent association with PFS or OS. Stratified analyses showed that younger age was related with poor outcome in the subgroups of good performance status and no bone metastasis. Conclusion: When matched for other prognostic factors, the prognosis of younger MGC patients receiving first-line combination chemotherapy does not differ from that of older patients. The poor survival of younger patients may be attributed to the association with other adverse prognostic factors.
oai:ojs.ijcto.org:article/454
2016-07-16T06:30:54Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.14
2016-07-16T06:30:54Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
Preliminary experience of fractionated stereotactic radiosurgery with extend system of Gamma Knife
Bisht, Raj; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Kale, Shashank; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Nathanasabapathi, Gopishankar; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Kumar, Pratik; Department of Medical Physics (BRAIRCH), All India Institute of Medical Sciences, New Delhi
Singh, Manmohan; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Agarwal, Deepak; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Thulkar, Sanjay; Department of Radiodiagnosis (BRAIRCH), All India Institute of Medical Sciences, New Delhi
Garg, Ajay; Department of Neuroradiology, All India Institute of Medical Sciences, New Delhi
Julka, Pramod; Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi
Rath, Gaura; Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi
Sharma, Bhawani; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
2016-02-16 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.14
Medical Physics
Gamma Knife, Stereotactic Radiosurgery, Positional Accuracy
Fractionated Radiosurgery
Research section of "All India institute of Medical Sciences" New Delhi, India
en
Purpose: The purpose of this study is to present multisession stereotactic radiosurgery with initial experience using custom made extend system (ES) of Gamma Knife.Methods: The ES is comprised of a carbon fiber frame also called extend frame, vacuum head rest cushion, patient surveillance unit and a configurable front piece with dental impression tray. The extend frame is a rigid connection between patient's head and patient positioning system (PPS) of Gamma Knife. A dental impression of patient was created and attached to the frontal piece of extend system. The treatment setup involves positioning the patient within the extend frame using patient specific headrest cushion and front piece. The reference patient’s head position was recorded through measurements of repositioning check tool (RCT) apertures using a high precision digital probe before computed tomography (CT) scan. The RCT measurements taken before treatment were compared with recorded reference position to ensure appropriate patient treatment position. Volumetric magnetic resonance (MR) scan was co-registered with stereotactic CT scan on Leksell Gamma plan. Fused MR to CT images on Gamma Plan was utilized to delineate regions of interest and prepare a precise treatment plan. The presented study includes positional reproducibility check and dosimetric evaluation of ten patients treated with ES.Results: Forty-three fractions on ten patients with prescribed treatment format were delivered successfully. An average tumor volume of 11.26 cm3 (range, 340 mm3 to 59.12 cm3) was treated with ES. The mean tumor coverage of 91.91% (range, 90% to 95%) was able to achieve at 50% prescription isodose without compromising adjacent normal structure radiation dose tolerances. The mean inter-fraction positional variation of 0.69 mm influences an inherent strength of immobilization technique. Follow-up of seven patients at a median interval of 16 months (range, 9 months to 26 months) showed evidence of 100% radiographic control with improved clinical results.Conclusion: Conjugative clinical outcome shows the efficacy of fractionation in various clinical indications.
oai:ojs.ijcto.org:article/518
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.13
2016-09-18T08:59:14Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
Involved-site radiation therapy by volumetric modulated arc therapy versus 3D- conformal radiotherapy for treatment of stages I and II supra-diaphragmatic Hodgkin’s lymphoma
http://www.ijcto.org/index.php/IJCTO/article/download/518/4398
http://www.ijcto.org/index.php/IJCTO/article/download/518/4399
http://www.ijcto.org/index.php/IJCTO/article/download/518/4648
Daoud, Mohamed A; Department of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura
Aboualnaga, Engy A; Department of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura
Mahfouz, Mohamed A; Department of Radiation Oncology, King Abdullah Medical City, Jeddah
Elkhaiate, Samah; Department of Pediatric Oncology, King Faisal Specialist hospital, Jeddah
Habash, Ahmed S; Department of Radiation Oncology, King Abdullah Medical City, Jeddah
2016-08-07 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.13
Radiation oncology; Medical Physics
Hodgkin's lymphoma, Supradiaphragmatic, Radiation Therapy Involved site
clinical research
en
Purpose: Based on the observation that recurrences of Hodgkin's lymphoma (HL) typically occur in sites of initial nodal involvement the need to concise radiotherapy to only involved nodes that was termed as involved nodal radiotherapy (INRT) or of involved site lymph nodes, involved-site radiation therapy (ISRT) is starting to be widely accepted to use in early stage HL. We aimed in our study to compare between volumetric modulated arc therapy (VMAT) and 3D-conformal radiotherapy (3D-CRT) in radiation of early stage supra-diaphragmatic HL.Methods: The clinical and dosimetric data of 34 patients affected with stages I and II supra-diaphragmatic HL, treated between January 2011 and September 2015 with combined modalities therapy in a single institution were analyzed. Patients received 2-8 cycles of combination chemotherapy ABVD (Adriamycin, Bleomycin, Vinblastine & Dacarbazine) on days 1 and 15 repeated every 28 days. The clinical target volume (CTV) was contoured based on the pre-chemotherapy CT and PET-CT scans. Modification of the CTV was done according to post-chemotherapy anatomical changes. The radiation dose given was 30 Gy/15 fractions.Results: After a median follow up period of 30 months, the progression free survival (PFS) and overall survival (OS) in both groups were 100%. Oropharengeal mucositis was the commonest toxicity in both groups. There was no statistically significant deference between the acute radiation toxicities in both groups. The Dmean valuefor lung was higher in 3D-CRT than VMAT (12.0 ± 6.1 Gy vs. 9.9 Gy ± 8.6 Gy). For the breasts volume, the V5Gy was slightly higher for 3D-CRT compared with VMAT at, 7.6% and 6.5% respectively. For the heart, V5Gy and V10Gy valueswere higher for the RA than for 3D-CRT accounting for (51.9 ± 28.9%) and (41.0 ± 24.6%) versus (40.0 ± 25.9% and 30.7 ± 22.5%) respectively. Thyroid gland mean dose was lower for VMAT (21.8 ± 7.7 Gy) than for 3D-CRT (26.8 Gy ± 4.1 Gy) but did not reach statistically significant value (P = 0.06).Conclusion: Involved-site VMAT technique is safe and effective in term of providing excellent local control and survival following ABVD-based chemotherapy.
oai:ojs.ijcto.org:article/595
2017-02-12T15:24:28Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.12
2017-02-12T15:24:28Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Anti-tumor effects of interferon-beta cell therapy in murine model of melanoma
http://www.ijcto.org/index.php/IJCTO/article/download/595/4726
http://www.ijcto.org/index.php/IJCTO/article/download/595/4727
Nakamura, Masaki; Department of Microbiology, Kitasato University School of Allied Health Sciences
Kagawa, Lisa; Department of Microbiology, Kitasato University School of Allied Health Sciences
Nakada, Norihiro; Department of Pathology, Kitasato University School of Medicine
Satoh, Masashi; Department of Immunology, Kitasato University School of Medicine
Maehana, Shotaro; Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences
Kojima, Fumiaki; Department of Pharmacology, Kitasato University School of Allied Health Sciences
Amano, Hideki; Department of Pharmacology, Kitasato University School of Medicine
Murakumo, Yoshiki; Department of Pathology, Kitasato University School of Medicine
Iwabuchi, Kazuya; Department of Immunology, Kitasato University School of Medicine
Majima, Masataka; Department of Pharmacology, Kitasato University School of Medicine
Kitasato, Hidero; Department of Microbiology, Kitasato University School of Allied Health Sciences
2016-12-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.12
Cancer Biology; Gene Therapy; Cell Therapy
Cell therapy, Interferon-beta, Melanoma
en
Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment of cancers. However, the efficacy of recombinant IFN-β is limited because of its short half-life and side effects. To overcome these problems, we focused on the efficacy of cell-based therapy (cell therapy) using IFN-β-producing cells in the treatment of melanoma.Methods: IFN-β-producing therapeutic cells were constructed by gene transduction using retrovirus vector. Anti-tumor effects of the cell therapy were investigated by a murine melanoma model.Results: IFN-β cell therapy significantly suppressed the proliferation of B16 melanoma in vitro and the growth of B16-derived tumor in vivo, accompanied with the activation of natural killer (NK) cells. IFN-β cell therapy did not show any systemic side-effects concerning hepatic dysfunction and bone marrow suppression.Conclusion: IFN-β cell therapy could be a candidate as a novel cancer treatment.
oai:ojs.ijcto.org:article/839
2017-12-17T14:56:44Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.23
2017-12-17T14:56:44Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Area-level factors associated with spatial variation of prostate cancer incidence for black men
Dagne, Getachew; University of South Florida
Odedina, Folakemi
Aime, Nickyjeanna
Young, Mary Ellen
2017-12-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.23
Biostatistics; prostate cancer
Bayesian inference, Health disparity, Prostate cancer, Poisson model
en
Purpose: Black men are disproportionately affected by prostate cancer (CaP) compared to any other racial/ethnic groups within the United States. Identifying CaP hotspots along with associated local area-level risk factors is crucial to tackling the significant burden of CaP and the disparity seen in Black men. The objective of this study was to determine the scope of geographical variation in CaP incidences and to assess the degree to which this variation is associated with county-level risk and protective factors.Methods: The study population was Black men diagnosed with prostate cancer between 2006-2010 in Florida. County-level CaP incidence rates were computed as the ratios of the numbers of new CaP cases diagnosed between 2006 and 2010 to the corresponding 2000 US census population of Black men 20 and over years old data (US Census 2000). Other county-level environmental and health care factors were also obtained. A random effects Poisson model and Geographical Information System (GIS) were used to map and assess the spatial patterns of CaP incidences in 67 Florida counties. These statistical techniques involved a Bayesian approach for estimating the underlying county-specific CaP risk since the data are very sparse.Results: The findings showed that an increasing CaP incidence of Black Men in Florida was significantly associated with an increasing unemployment rate ( 2 with 95% CI: (.0025, .2703), does not include zero suggesting significance) and with increasing number of physicians per capita after controlling for other county characteristics. There was a negative association between poverty and CaP incidence. Regarding spatial distribution of CaP incidence, we observed that there are clustering and hotspots of high CaP incidence rates in Palm Beach county in South Florida, and Alachua and Marion counties in north Florida.Conclusion: Our findings showed that indicators of socioeconomic status and accessibility of health care services such as poverty, unemployment and health care providers are important variables that explain spatial variation of prostate cancer incidence rates of Black Men. Better understanding of such risk factors and identifying specific counties with a disproportionate burden of CaP disease may help formulate targeted interventions and resource allocation by state and local public officials
oai:ojs.ijcto.org:article/56
2014-05-14T17:01:16Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Gao
2014-05-14T17:01:16Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 2 (2014): April - June
Monte Carlo study of secondary electron production from gold nanoparticle in proton beam irradiation
http://www.ijcto.org/index.php/IJCTO/article/download/56/487
http://www.ijcto.org/index.php/IJCTO/article/download/56/581
Gao, Jeff; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Zheng, Yuanshui; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
2014-03-27 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Gao
Medical Physics; Particle Therapy
Gold nanoparticle; Secondary electron production; Proton
en
Purpose: In this study, we examined some characteristics of secondary electrons produced by gold nanoparticle (NP) during proton beam irradiation.Method: By using the Geant4 Monte Carlo simulation toolkit, we simulated the NP at the range from radius (r) of 17.5 nm, 25 nm, 35 nm to r = 50 nm. The proton beam energies used were 20MeV, 50MeV, and 100MeV. Findings on secondary electron production and their average kinetic energy are presented in this paper. Results: Firstly, for NP with a finite size, the secondary electron production increase with decreasing incident proton beam energy and secondary buildup existed outside NP. Secondly, the average kinetic energy of secondary electrons produced by a gold NP increased with incident proton beam energy. Thirdly, the larger the NP size, the more the secondary electron production.Conclusion: Collectively, our results suggest that apart from biological uptake efficiency, we should take the secondary electron production effect into account when considering the potential use of NPs in proton beam irradiation.-----------------------------------------------Cite this article as: Gao J, Zheng Y. Monte Carlo study of secondary electron production from gold nanoparticle in proton beam irradiation. Int J Cancer Ther Oncol 2014; 2(2):02025.DOI: http://dx.doi.org/10.14319/ijcto.0202.5
oai:ojs.ijcto.org:article/147
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.17
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery?
Shang, Charles; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kasper, Michael E; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kathriarachchi, Vindu; Department of Physics, Florida Atlantic University, Boca Raton, FL, USA.
Benda, Rashmi K; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kleinman, Joseph H; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Cole, Jeremy; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Williams, Timothy R; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
2014-08-06 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.17
Radiation Oncology; Clinic
Lung SBRT, FDG-PET, Local Control
Lung Cancer
en
Purpose: Although [18F] FDG-positron emission tomography (PET) provides vital information in diagnosing lung malignancies, the inherent uncertainties of standard uptake value (SUV) compromises its confidence. People have attempted to reduce this uncertainty by comparing the normal tissues, such as liver and spleen. However, those common reference structures may be inappropriate in some cases when pathological conditions exist. Hence, using alternative reference structures becomes valuable in such practice. The purpose of this study is to explore an alternative reference-correction method to reduce the inherent variation of SUV in the tumor or irradiated region. Methods: 106 analyzable FDG-PET scans from 49 cases who received lung SBRT for non-small cell lung cancer were retrospectively analyzed. The follow-up time ranges from 14.5 weeks to 113.2 weeks. The maximal SUV (SUVmax) was measured within the lung lesion or its corresponding region in post-SBRT. SUVmax was then corrected (or divided) by a reference SUV, or the mean SUV of the adjacent aorta, and results in the new SUVcmax. Results: SUVcmax of the positive group are significant higher than that of locally controlled cases (5.82 ± 3.10 vs. 1.45 ± 0.55, p = 0.026), while inconsequential differences were identified between the groups (p = 0.086). Respectively 85.2% and 96.3% of locally controlled cases post SBRT showed decreased values in the latter PET using SUVmax and SUVcmax. PET taken 24 weeks or sooner post-SBRT yielded higher uncertainties.Conclusion: Comparing with the conventional SUVmax, the alternative regional background-corrected SUV indicator, SUVcmax of PTV suggests a stronger correlation between low (<2.5 - 3.0) values and the local tumor control post lung SBRT for NSCLC. However, FDG-PET images taken earlier than 24 weeks post-SBRT presents larger variations in SUV of the irradiated region due to underlying radiation induced inflammatory changes, and is not recommended for assessing local tumor control after lung SBRT......................................................Cite this article as: Shang CY, Kasper ME, Kathriarachchi V, Benda RK, Kleinman JH, Cole J, Williams TR. Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery? Int J Cancer Ther Oncol 2014; 2(4):020317.DOI: 10.14319/ijcto.0203.17
oai:ojs.ijcto.org:article/210
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.18
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Evaluation of the generalized gamma as a tool for treatment planning optimization
http://www.ijcto.org/index.php/IJCTO/article/download/210/2311
Petrou, Emmanouil I; Laboratory of Medical Physics, Medical School, University of Patras, Patras, Greece
Narayanasamy, Ganesh; Divison of Medical Physics, Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, TX, USA
Lavdas, Eleftherios; Department of Medical Radiological Technologists, Technological Education Institute of Athens, Greece
Stathakis, Sotirios; Division of Medical Physics, Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, TX, USA
Papanikolaou, Nikos; Division of Medical Physics, Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, TX, USA
Lind, Bengt K; Division of Medical Radiation Physics, Karolinska Institutet and Stockholm University, Stockholm, Sweden
Mavroidis, Panayiotis; Division of Medical Physics, Department of Radiation Oncology, Cancer Therapy and Research Center, University of Texas Health Sciences Center San Antonio, San Antonio TX, USA
2014-12-01 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.18
Radiation Oncology; Medical Physics
Prostate Cancer; Radiobiological Treatment Planning; Generalized Gamma; TCP; NTCP
en
Purpose: The aim of that work is to study the theoretical behavior and merits of the Generalized Gamma (generalized dose response gradient) as well as to investigate the usefulness of this concept in practical radiobiological treatment planning.Methods: In this study, the treatment planning system RayStation 1.9 (Raysearch Laboratories AB, Stockholm, Sweden) was used. Furthermore, radiobiological models that provide the tumor control probability (TCP), normal tissue complication probability (NTCP), complication-free tumor control probability (P+) and the Generalized Gamma were employed. The Generalized Gammas of TCP and NTCP, respectively were calculated for given heterogeneous dose distributions to different organs in order to verify the TCP and NTCP computations of the treatment planning system. In this process, a treatment plan was created, where the target and the organs at risk were included in the same ROI in order to check the validity of the system regarding the objective function P+ and the Generalized Gamma. Subsequently, six additional treatment plans were created with the target organ and the organs at risk placed in the same or different ROIs. In these plans, the mean dose was increased in order to investigate the behavior of dose change on tissue response and on Generalized Gamma before and after the change in dose. By theoretically calculating these quantities, the agreement of different theoretical expressions compared to the values that the treatment planning system provides could be evaluated. Finally, the relative error between the real and approximate response values using the Poisson and the Probit models, for the case of having a target organ consisting of two compartments in a parallel architecture and with the same number of clonogens could be investigated and quantified. Results: The computations of the RayStation regarding the values of the Generalized Gamma and the objective function (P+) were verified by using an independent software. Furthermore, it was proved that after a small change in dose, the organ that is being affected most is the organ with the highest Generalized Gamma. Apart from that, the validity of the theoretical expressions that describe the change in response and the associated Generalized Gamma was verified but only for the case of small change in dose. Especially for the case of 50% TCP and NTCP, the theoretical values (ΔPapprox.) and those calculated by the RayStation show close agreement, which proves the high importance of the D50 parameter in specifying clinical response levels. Finally, the presented findings show that the behavior of ΔPapprox. looks sensible because, for both of the models that were used (Poisson and Probit), it significantly approaches the real ΔP around the region of 37% and 50% response. The present study managed to evaluate the mathematical expression of Generalized Gamma for the case of non-uniform dose delivery and the accuracy of the RayStation to calculate its values for different organs. Conclusion: A very important finding of this work is the establishment of the usefulness and clinical relevance of Generalized Gamma. That is because it gives the planner the opportunity to precisely determine which organ will be affected most after a small increase in dose and as a result an optimal treatment plan regarding tumor control and normal tissue complications can be found.
oai:ojs.ijcto.org:article/274
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.9
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
The effect of halofuginone on radiation-induced cardiovascular injury
http://www.ijcto.org/index.php/IJCTO/article/download/274/2874
http://www.ijcto.org/index.php/IJCTO/article/download/274/3041
http://www.ijcto.org/index.php/IJCTO/article/download/274/3042
http://www.ijcto.org/index.php/IJCTO/article/download/274/3043
http://www.ijcto.org/index.php/IJCTO/article/download/274/3044
http://www.ijcto.org/index.php/IJCTO/article/download/274/3045
http://www.ijcto.org/index.php/IJCTO/article/download/274/3046
http://www.ijcto.org/index.php/IJCTO/article/download/274/3047
http://www.ijcto.org/index.php/IJCTO/article/download/274/3048
Yavas, Cagdas; Department of Radiation Oncology, Konya Training and Research Hospital, Konya
Calik, Mustafa; Department of Thoracic Surgery, Konya Training and Research Hospital, Konya
Yavas, Guler; Department Radiation Oncology, Selcuk University, Faculty of Medicine, Konya
Toy, Hatice; Department Radiation Oncology, Selcuk University, Faculty of Medicine, Konya
Esme, Hidir; Department of Thoracic Surgery, Konya Training and Research Hospital, Konya
Calik, Goknil; Department of Emergency Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya
Sargon, Mustafa; Department of Anatomy, Hacettepe University, Faculty of Medicine, Ankara
2015-02-26 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.9
Halofuginone; Cardiovascular Toxicity; Radiotherapy; Rat
en
Purpose: The main purpose of this study was to evaluate the effects of Halofuginone on radiation-induced cardiovascular injury in a rat model. Methods: Sixty Wistar-Albino rats were divided into six groups (the control group, radiotherapy (RT) only group Irradiation (IR), 2.5 and 5 μg Halofuginone groups (Hal (2.5)/C and Hal (5.0)/C), and RT plus 2.5 and 5 μg Halofuginone groups (Hal (2.5)/IR and Hal (5.0)/IR). Rats were exposed to a single dose of 12 Gy irradiation generated by a linear accelerator. Halofuginone was applied intraperitoneally with daily doses. At the 6th and 16th weeks of RT, 5 rats from each group sacrificed and; heart and thoracic aorta tissues removed for both light microscopic and electron microscopic examinations. Results: Light microscopic examinations revealed that the endocardial thickness of all study groups was significantly different at 6th and 16th week of RT (p < 0.001 for both). Pair-wise comparisons showed that the differences were significant in IR- Hal (2.5)/IR (p < 0.001); IR-Hal (5.0)/IR (p < 0.001); and Hal (2.5)/IR-Hal (5.0)/IR (p = 0.001) at 16th week of RT. There were significant differences within the study groups regarding to the thoracic aorta fibrosis scores only at 16th week of RT (p = 0.002). Electron microscopic examinations demonstrated that there were significant differences between all the groups with respect to heart mitochondria scores at both 6th week and 16th weeks of RT (p < 0.001 for both). The differences between Hal (2.5)/IR and Hal (5.0)/IR with respect to the heart mitochondria scores were significant only at 16th week of RT (p = 0.001). Conclusion: These data demonstrated that Halofuginone may improve radiation-induced cardiovascular injury. The most prominent improvement was observed in higher dose of Halofuginone group after long term follow-up.
oai:ojs.ijcto.org:article/361
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.20
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
Role of laparoscopic surgery in cancer of stomach: Our early experience
http://www.ijcto.org/index.php/IJCTO/article/download/361/3363
Chrungoo, Rajinder; Department of Surgery, ASCOMS Jammu, Jammu And Kashmir (J&K)
Mala, Tariq; Department of Surgery, ASCOMS Jammu, Jammu And Kashmir (J&K)
Gupta, Rahul; Department of Surgery, Government Medical College, Jammu
Kachroo, Shadi; Department of Surgery, Government Medical College, Jammu
Chrungoo, Inakshi; Department of Medicine & Surgery, Government Medical College, Jammu
Malla, Shahid; Department of Medicine & Surgery, Government Medical College, Jammu
2015-08-11 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.20
Surgery
Diagnostic Laparoscopy; Laparoscopic Gastrojejunostomy; Laparoscopic Gastrectomy; Unresectable Tumors; Palliation; Laparoscopic Biopsy
none
en
Purpose: To study the clinical outcome and scope of laparoscopic management in patients of cancer stomach. Methods: This is a prospective study of our first 25 patients of cancer stomach managed laparoscopically. Following procedures were undertaken: 1) Gastric resection in resectable cases; 2) Palliative bypass; 3) Tumor/ nodal/ peritoneal/ any other/ biopsy in cases of unresectable tumors. Results: Growth was resectable in 10 (40%) patients, and unresectable in 15 (60%) patients. Diagnostic laparoscopy had sensitivity of 100%, while other modalities of investigation were not totally useful in 1/3 to ½ of cases. Laparoscopic gastrojejunostomy was done in 5 (20%) patients, laparoscopy assisted distal partial gastrectomy was performed in 8 (32%) patients while totally laparoscopic gastrectomy was possible in 1 (4%) patient. Long term follow up was observed. Conclusion: In cancer stomach laparoscopy is a safe, effective, and cost effective means of directing appropriate therapy especially in patients requiring diagnostic, staging and palliative procedures.
oai:ojs.ijcto.org:article/420
2016-07-16T06:29:18Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.9
2016-07-16T06:29:18Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
Cone beam computed tomography: An accurate imaging technique in comparison with orthogonal portal imaging in intensity-modulated radiotherapy for prostate cancer
Gurjar, Om Prakash; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Mutneja, Abhinav; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Bagdare, Priyusha; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Goyal, Harsh; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Batra, Manika; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Bhandari, Virendra; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Gupta, Krishna Lal; Roentgen-SAIMS Radiation Oncology Centre, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh
Mishra, Surendra Prasad; Department of Radiotherapy, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow
2016-02-03 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.9
Medical Physics, Radiation Oncology
Cone Beam Computed Tomography, Organ Motion, Orthogonal Portal Imaging, Prostate Cancer
CBCT and OPI
en
Purpose: Various factors cause geometric uncertainties during prostate radiotherapy, including interfractional and intrafractional patient motions, organ motion, and daily setup errors. This may lead to increased normal tissue complications when a high dose to the prostate is administered. More-accurate treatment delivery is possible with daily imaging and localization of the prostate. This study aims to measure the shift of the prostate by using kilovoltage (kV) cone beam computed tomography (CBCT) after position verification by kV orthogonal portal imaging (OPI).Methods: Position verification in 10 patients with prostate cancer was performed by using OPI followed by CBCT before treatment delivery in 25 sessions per patient. In each session, OPI was performed by using an on-board imaging (OBI) system and pelvic bone-to-pelvic bone matching was performed. After applying the noted shift by using OPI, CBCT was performed by using the OBI system and prostate-to-prostate matching was performed. The isocenter shifts along all three translational directions in both techniques were combined into a three-dimensional (3-D) iso-displacement vector (IDV).Results: The mean (SD) IDV (in centimeters) calculated during the 250 imaging sessions was 0.931 (0.598, median 0.825) for OPI and 0.515 (336, median 0.43) for CBCT, p-value was less than 0.0001 which shows extremely statistical significant difference.Conclusion: Even after bone-to-bone matching by using OPI, a significant shift in prostate was observed on CBCT. This study concludes that imaging with CBCT provides a more accurate prostate localization than the OPI technique. Hence, CBCT should be chosen as the preferred imaging technique.
oai:ojs.ijcto.org:article/522
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.5
2016-09-18T08:59:14Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
Can neck irradiation be an alternative to neck dissection in early stage carcinoma oral tongue operated for primary alone? Experience from a single institute
Ghoshal, Sushmita; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Bansal, Anshuma; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Panda, Naresh Kumar; Department of Otolaryngology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Bakshi, Jaimanti; Department of Otolaryngology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
2016-07-16 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.5
Radiation Oncology
Carcinoma oral tongue, disease free survival, early stage, nodal dissection, neck irradiation
Head and Neck
nil
en
Purpose: To study pattern of failure, locoregional control rates (LCR) and disease free survival (DFS) in post-operative patients of carcinoma oral tongue, and to study the impact of nodal dissection on DFS in stage I and II patients.Methods: 102 patients of carcinoma oral tongue treated between January 2009 and December 2013 were analyzed. All patients were operated for primary disease, but neck dissection was done in 78 (76.5%) patients only. However, radiation to primary site along with neck region was received by all patients. Pattern of failure, LCR and DFS were estimated.Results: At median follow up of 12 months, 10.8% patients failed locally, 10.8% in nodal region, 2.9% both at local and nodal site, and 5.9% patients failed distally. 2 year LCR and DFS was 71.2%, 90.9%, 79.5%, 0% and 55.2%, 64.4%, 57.8%, 0% in stage I, II, III, IV respectively. 2 year DFS in stage I patients, who underwent nodal dissection and post-operative radiation (14 patients) was 64.3% and in whom only neck irradiation was done (15 patients), it was 45.8%, however difference was not significant (p = 0.5). But in stage II patients, 33 patients who underwent nodal dissection and post-operative radiation, 2 year DFS was 85.4% and it was 21.4% in 7 patients who underwent neck radiation only, and difference showed trend towards significance (p = 0.05). 2 or more positive lymph nodes post dissection was the only poor prognostic factor that correlated with DFS (p = 0.02)Conclusion: While in stage I, neck irradiation alone can be a possible alternative to neck dissection and post-operative radiation; for stage II, neck dissection is mandatory.
oai:ojs.ijcto.org:article/558
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.13
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Role of preoperative 18-FDG- PET/CT in early-stage breast cancer upstaging and modification of treatment
http://www.ijcto.org/index.php/IJCTO/article/download/558/4512
Tewari, Anshu; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
Sundaram, Shanmuga Palaniswamy; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
Subramanyam, Padma; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
2016-12-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.13
Nuclear medicine
Breast cancer, Initial staging, PET/CT, Upstaging, Treatment modification
PET/CT
NA
en
Purpose: The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer.Methods: A total of 72 consecutive patients (age: range 24-78 years, mean 51 years), with newly diagnosed operable breast cancer (Infiltrating Ductal carcinoma: Lobular carcinoma: Others - 49:15:8) with tumor size 10-65 mm were examined preoperatively. All patients underwent conventional assessment imaging modalities like mammography, breast/axillary ultrasound and PET/CT.Results: PET/CT identified a primary tumor in all but two patients. PET/CT solely detected unsuspected distant metastases (bones, lung, brain etc) in 9 patients and new primary cancers (endometrium and lung) in another two patients, as well as 11 cases of extra-axillary lymph node involvement. In 6 patients, extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 9% (6/70) and ultimately a modification of planned treatment in 12% (9/70) of patients. PET/CT evaluation led 5 patients of stage II A to stage IV, 3 patients of stage II B to stage IV and 1 patient to Stage IIIB which further modified treatment plan from an adjuvant to a metastatic approach.Conclusion: PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative 18F fluorodeoxyglucose PET/CT has a substantial impact on initial staging and on clinical management in patients with early-stage breast cancer.
oai:ojs.ijcto.org:article/603
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.25
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Evaluation of Eclipse 3D plans using an independent treatment planning system
http://www.ijcto.org/index.php/IJCTO/article/download/603/4770
http://www.ijcto.org/index.php/IJCTO/article/download/603/4771
http://www.ijcto.org/index.php/IJCTO/article/download/603/4773
http://www.ijcto.org/index.php/IJCTO/article/download/603/4774
http://www.ijcto.org/index.php/IJCTO/article/download/603/4775
http://www.ijcto.org/index.php/IJCTO/article/download/603/4776
http://www.ijcto.org/index.php/IJCTO/article/download/603/4777
http://www.ijcto.org/index.php/IJCTO/article/download/603/4778
http://www.ijcto.org/index.php/IJCTO/article/download/603/4779
http://www.ijcto.org/index.php/IJCTO/article/download/603/4780
Ayyalasomayajula, Anil kumar; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
Ayyangar, Komanduri; Department of Medical physics, University of Nebraska Medical Center, Omaha, NE
Vuppu, Srinivas; Medical Physics, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad,
Roopa Rani, Akula; Medical Physics, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad,
Lakshmi Narayana, Paladugu venkata; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
Rao, Angalakuduru Durga Prasada; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
2017-12-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.25
Radiation Oncology
Quality Assurance, 3D Treatment Planning, DVH analysis, Eclipse TPS, ROPS TPS
This work was sponsored by a grant from the Atomic Energy Regulatory Board, Mumbai, India.
en
Purpose: The goal of the current investigation was to compare complex 3D conformal plans generated on Eclipse™ treatment planning system (TPS) with independent dose calculations from radiation oncology planning system (ROPS™) TPS used as a secondary quality assurance check.Methods: Fifteen cancer patients that were treated with complex conformal treatment plans with cobalt and linac beams, using Eclipse TPS, were selected for this study. The structure sets, treatment beam data and prescription information were exported from the Eclipse TPS using DICOM-RT export. Using custom software, these data were imported into ROPS TPS. Independent dose calculation on the ROPS planning system using Clarkson summation algorithm was done. The dose volume histograms (DVH) from both planning systems were extracted and analyzed using custom software. Dose assessment was accomplished by defining criteria based on gross tumor volume (GTV) dose coverage, dose homogeneity and mean dose. For organs at risk (OAR) other than GTV, the main dose parameters were, mean dose and percentage of volume receiving 95% of prescription dose.Results: For the GTV, all 15 cases met the criteria set for the mean dose and dose homogeneity index. However, breast cases were found to have deviation in the percentage volume receiving the 95% of prescription dose.Conclusion: Using the criteria set for plan acceptance, all the 15 clinical cases were evaluated. Except for breast tangent plans, all plans passed all the criteria set. The large deviation for breast tangent plans was attributed to differences in dose calculation algorithms.
oai:ojs.ijcto.org:article/28
2014-04-12T11:23:45Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Fawzy
2014-04-12T11:23:45Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 1 (2014): January - March
Hepatoblastoma survival and the prognostic role of cancer stem cell markers
http://www.ijcto.org/index.php/IJCTO/article/download/28/194
http://www.ijcto.org/index.php/IJCTO/article/download/28/195
http://www.ijcto.org/index.php/IJCTO/article/download/28/196
http://www.ijcto.org/index.php/IJCTO/article/download/28/197
http://www.ijcto.org/index.php/IJCTO/article/download/28/198
http://www.ijcto.org/index.php/IJCTO/article/download/28/250
Fawzy, Mohamed; National Cancer Institute, Cairo, Egypt
Bahnassy, Abeer; National Cancer Institute (NCI), Cairo University, Egypt
El-Wakil, Mohamed; Faculty of Medicine Beni-Suef University, Egypt
Abdel-Sayed, Ahmed; National Cancer Institute (NCI), Cairo University, Egypt
2013-12-15 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Fawzy
Pediatric Oncology
Hepatoblastoma; Survival; CSCs; Prognosis
Liver Tumers
none
en
Purpose: Hepatoblastoma (HB) is an embryonal tumor of the liver that occurs in infants and young children. Complete surgical resection and cisplatin-containing chemotherapy are crucial for cure in HB. Cancer stem cells (CSCs) constitute a newly identified subpopulation, which may differentiate into heterogeneous progenies of malignant cells. The aim of this study was to assess the survival outcome and the prognostic value of CSCs markers (CD133, CD90 and CD44) in a cohort of HB patients from Egypt.Methods: Disease status of 43 HB patients was evaluated at the main checkpoints of therapy and during follow-up. Treatment included surgical tumor resection and systemic chemotherapy (cisplatin, 5-fluorouracil, doxorubicin, and vincristine). Protein and RNA expressions of CD44, CD 90 and CD 133 were assessed by immunohistochemistry and quantitative PCR. Results: The OS for all patients was 58.2 at 4 years. Patients with localized disease stages (I&II) had a better OS than those with advanced stages (III&IV) (81.9% versus 30%, p<0.001). Total surgical resection was superior to incomplete/no resection (83.8% versus 25.2 %; p<0.001). The OS was significantly correlated with tumor response (p<0.001) and each of CD44, CD 90, CD 133 expression (p<0.001) whereas reduced DFS was associated with CD44 and CD133 expression (p<0.001).Conclusion: Localized disease is associated with higher OS than more advanced stages III and IV. Complete surgical resection facilitated with systemic preoperative chemotherapy in initially irresectable cases can improve survival in HB while CSC markers (CD133, 44, and 90) can predict survival and response to treatment in HB patients.-------------------------------------------------------------Cite this article as:Fawzy M, Bahnassy A, El-Wakil M, Abdel-Sayed A. Hepatoblastoma survival and the prognostic role of cancer stem cell markers. Int J Cancer Ther Oncol 2014; 2(1):02011.DOI: http://dx.doi.org/10.14319/ijcto.0201.1
oai:ojs.ijcto.org:article/88
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.4
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Response to chemotherapy and association with three tumour markers in breast cancer patients in Ghana
http://www.ijcto.org/index.php/IJCTO/article/download/88/825
http://www.ijcto.org/index.php/IJCTO/article/download/88/826
http://www.ijcto.org/index.php/IJCTO/article/download/88/827
http://www.ijcto.org/index.php/IJCTO/article/download/88/1603
Frempong, Emmanuel Amankwaa; Department of Molecular Medicine, School of Medical Sciences-Kwame Nkrumah, University of Science and Technology, Kumasi, Ghana.
Yeboah, Francis Agyemang; Department of Molecular Medicine, School of Medical Sciences-Kwame Nkrumah, University of Science and Technology, Kumasi, Ghana.
Nguah, Samuel Blay; Department of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Afriyie, Osei Owusu; Department of Pathology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
2014-06-07 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.4
Cancer Biology
Tumor Markers; Chemotherapy Response; Estrogen Receptors; HER/2neu; Progesterone Receptors
Cancer Biology
en
Purpose: Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2/neu) expression in breast cancer patients predict response to chemotherapy though recorded extent vary. This retrospective study aimed to investigate the relationship between ER, PR and HER2/neu expression and response of breast cancer to chemotherapy at a tertiary hospital in Ghana. Methods: Records of all breast cancer cases seen from 2009 through 2011 were reviewed. Their receptor status, first line treatment [4 cycles of Adriamycin (60mg/m2) + Cyclophosphamide (600mg/m2)], second line treatment [Capecitabine (1g/m2) + Paclitaxel (170mg/m2)] and clinical response were extracted.Results: Complete remission after first and second line treatments were observed in 36 (38.3%, 95% CI: 28.5 to 48.9) and 34 (58.6%, 95% CI: .44.9 to 71.4) respectively. After both first and second line treatment 70 (74.5%, 95% CI: 64.4 - 82.9) had gone into remission. Prevalence of ER, PR, HER2/neu and Triple negative breast cancer (TNBC) were 34.0% (95% CI: 24.6 to 44.5), 20.2% (95% CI: 12.6 to 29.7), 8.5% (95% CI: 3.7 to 16.1) and 59.6% (95%CI: 48.9 to 69.6) respectively. ER and PR positivity were independently associated with complete remission after first line treatment while TNBC was associated with non-remission. Conversely ER was independently associated with non-remission after second line treatment while TNBC was associated with complete remission. Conclusion: ER and TNBC status are significant predictors of complete remission and non-remission respectively after chemotherapy for breast cancer patient in Ghana.................................................................Cite this article as:Amankwaa-Frempong E, Yeboah FA, Nguah SB, Afriyie OO. Response to chemotherapy and association with three tumour markers in breast cancer patients in Ghana. Int J Cancer Ther Oncol 2014; 2(3):02034. DOI: 10.14319/ijcto.0203.4
oai:ojs.ijcto.org:article/183
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.16
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Pretreatment quality assurance of volumetric modulated arc therapy on patient CT scan using indirect 3D dosimetry system
Thirumalai Swamy, Shanmugam; Department of Radiation Oncology, Yashoda Hospitals, Hyderabad, India
Anuradha, Chandrasekaran; School of Advanced Sciences, VIT University, Vellore, India
Kathirvel, Murugesan; Department of Radiation Oncology, Yashoda Hospitals, Hyderabad, India
Arun, Gandhi; Department of Radiation Oncology, Yashoda Hospitals, Hyderabad, India
Subramanian, Shanmuga; Department of Radiation Oncology, Yashoda Hospitals, Hyderabad, India
2014-10-22 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.16
Medical Physics
COMPASS; VMAT; 3D Gamma; Pretreatment QA
en
Purpose: Aim of this study is to clinically implement the COMPASS 3D dosimetry system for pretreatment quality assurance of volumetric modulated arc therapy (VMAT-RapidArc) treatment plans. Methods: For this study, 10 head and neck (H&N) and 10 pelvis VMAT plans dose response from Linac was measured using COMPASS system along with MatriXXEvolution and 3D dose was reconstructed in the patient computed tomography (CT) scan. Dose volume histograms and 3D gamma were used to evaluate the difference between the measured and calculated values. In order to validate the COMPASS system, dose response for open fields were acquired for both homogeneous and inhomogeneous phantoms. Results: The average dose difference between Eclipse treatment planning system (TPS) calculated and COMPASS measured (homogenous medium) in normalization region, inner region, penumbra region and buildup region was less than ±2%. In inhomogeneous phantom, there was a maximum difference of -3.17% in lung, whereas the difference other densities was within ±2%. The systematic increase in the average 3D gamma between the TPS calculated and COMPASS measured for VMAT plans with known dose errors and multi-leaf collimator (MLC) offset errors shows that COMPASS system was sensitive enough to find clinical significant errors. The 3D dose parameters (D95, D1, and average dose) of all H&N and pelvis patients were well within the clinically acceptable tolerance level of ±5%. The average 3D gammas for planning target volumes (PTV) and organ at risks (OAR) of the patients were less than 0.6. Conclusion: The results from this study show that COMPASS along with MatriXXEvolution can be effectively used for pretreatment verification of VMAT plans in the patient anatomy.
oai:ojs.ijcto.org:article/227
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.1
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
Advantage of using deep inspiration breath hold with active breathing control and image-guided radiation therapy for patients treated with lung cancers
http://www.ijcto.org/index.php/IJCTO/article/download/227/2933
Muralidhar, KR; Department of Radiation Physics, American Oncology Institute, Hyderabad
Sha, Rajib Lochan; Radiological Safety Division, Atomic Energy Regulatory Board, Mumbai- 94
Rout, Birendra Kumar; Department of Medical Physics, Aditya Birla Hospital
Narayana Murthy, P; Department of Physics, Nagarjuna University, Guntur
2015-01-22 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.1
Radiation Oncology
Active breath control; mDIBH; Lung tumors
Management of Moving organs
none
en
Purpose: The aim of this study was to evaluate the irradiated volume and doses to the target, heart, left lung, right lung and spinal cord, the number of segments and treatment time by using moderated deep inspiration breath hold (mDIBH) with active breathing control (ABC) and image-guided radiotherapy (IGRT) for patients treated with lung cancers.Methods: The suitability of this technique for lung patient treated with ABC was investigated and the solutions to achieve better treatments were discussed. Eleven lung cancer patients (3 left-sided and 8 right sided lesions) with stages I-III underwent standard free breath (FB) and ABC computed tomography (CT) scans in the treatment supine position. This can be achieved by applying respiratory manoeuvres, such as mDIBH, during which the threshold volume utilized is defined as 75-80% of the maximum aspiratory capacity. Five to seven, 6-MV photon beams with optimized gantry angles were designed according to the tumor location to conform to the PTV while sparing as much heart, spinal cord, and contra lateral lung as possible. For eleven patients, treatment planning using mDIBH CT data with intensity modulated radiation therapy (IMRT) was then reoptimized on the free breathing data set for comparison. The studied parameters of the plans for each patient were evaluated based on the average of the minimum, mean, and maximum difference in dose, the range of difference, and the p-value using two-tailed paired t test assuming equal variance.Results: The average volume of the planning target volume (PTV) in 11 patients increased to 1.32% in ABC compared to FB. The average volume of heart in 11 patients decreased to 2.9% in ABC compared to free breathing IMRT. In the case of lungs, the volume increased to 27.5% and 25.85% for left and right lungs, respectively. The range of mean difference in dose to the PTV in 11 patients was -54 cGy to 230 cGy with ABC technique when compared with free breathing. The range of mean dose difference of heart in 11 patients observed were -88 cGy to 66 cGy (p < 0.0410) between ABC and FB. The range of maximum dose difference to the spinal cord in 11 patients were -1592 cGy to 190 cGy (p < 0.041) with ABC technique when compared with FB IMRT. Monitor units (MUs) were -22.9% less in ABC compared to FB. Segments were more in ABC compared to FB for about 16.39% on an average. The average of minimum, mean and maximum difference in dose to the right lung and left lung were less in ABC compared with FB.Conclusion: In most of the cases, IGRT with ABC significantly reduces the mean dose to heart, right lung, left lung, and spinal cord compared with FB. Discrepancy observed in few cases made the statistical data inconsistent. Depending on anatomy and arbitrary phase of the breathing cycle, the results may vary and for better outcome of the results optimum treatment procedures need to follow.
oai:ojs.ijcto.org:article/352
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.11
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
Estimation of transition doses for human glioblastoma, neuroblastoma and prostate cell lines using the linear-quadratic formalism
http://www.ijcto.org/index.php/IJCTO/article/download/352/3343
Akudugu, John; Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Cape Town
Serafin, Antonio; Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Cape Town
2015-07-02 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.11
Radiation Oncology; Medical Dosimetry
Transition Dose; Linear-Quadratic Model; Stereotactic Radiotherapy
Radiobiology
South African National Research Foundation
en
Purpose: The introduction of stereotactic radiotherapy has raised concerns regarding the use of the linear-quadratic (LQ) model for predicting radiation response for large fractional doses. To partly address this issue, a transition dose D* below which the LQ model retains its predictive strength has been proposed. Estimates of D* which depends on the a, β, and D0 parameters are much lower than fractional doses typically encountered in stereotactic radiotherapy. D0, often referred to as the final slope of the cell survival curve, is thought to be constant. In vitro cell survival curves generally extend over the first few logs of cell killing, where D0-values derived from the multi-target formalism may be overestimated and can lead to low transition doses. Methods: D0-values were calculated from first principles for each decade of cell killing, using experimentally-determined a and β parameters for 17 human glioblastoma, neuroblastoma, and prostate cell lines, and corresponding transition doses were derived.Results: D0 was found to decrease exponentially with cell killing. Using D0-values at cell surviving fractions of the order of 10-10 yielded transition doses ~3-fold higher than those obtained from D0-values obtained from conventional approaches. D* was found to increase from 7.84 ± 0.56, 8.91 ± 1.20, and 6.55 ± 0.91 Gy to 26.84 ± 2.83, 23.95 ± 2.03, and 22.49 ± 2.31 Gy for the glioblastoma, neuroblastoma, and prostate cell lines, respectively. Conclusion: These findings suggest that the linear-quadratic formalism might be valid for estimating the effect of stereotactic radiotherapy with fractional doses in excess of 20 Gy.
oai:ojs.ijcto.org:article/472
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.14
2016-01-03T12:17:08Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Investigating dosimetric effect of rotational setup errors in IMPT planning of synchronous bilateral lung cancer
Rana, Suresh; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Zhang, Yongbin; Department of Medical Physics, Scripps Proton Therapy Center, San Diego, California
Larson, Gary; Department of Radiation Oncology, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Vargas, Carlos; Radiation Oncology, Proton Collaborative Group (PCG), Warrenville, Illinois
Dunn, Megan; Radiation Oncology, Proton Collaborative Group (PCG), Warrenville, Illinois
Zheng, Yuanshui; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
2015-12-01 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.14
Medical Physics
Proton Therapy; Rotational Setup Error; IMPT; Bilateral Lung Cancer
en
Purpose: The purpose of this study is to evaluate the dosimetric effect of rotational setup errors on the synchronous bi-lateral lung cancer plans generated by the intensity modulated proton therapy (IMPT) technique.Methods: The original IMPT plans were generated in for the left planning target volume (PTV) and right PTV of the left lung and right lung, respectively. Each plan was generated using two beams (lateral and posterior-anterior) with an isocenter placed at the center of the corresponding PTV. The IMPT plans were optimized for a total dose of 74 Gy[RBE] prescribed to each PTV with 2 Gy(RBE) per fraction. Original plans were recalculated by introducing simulated rotational errors. For each PTV, 18 rotational plans (±1⁰, ±2⁰, and ±3⁰) for each of the yaw, roll, and pitch rotations were generated. Results: Rotational errors caused the reduction in the clinical target volume (CTV) and PTV coverage in new rotational IMPT plans when compared to the original IMPT lung plans. The CTV D99 was reduced by up to 13.3%, 9.1%, and 5.9% for the yaw (+3⁰), roll (-3⁰), and pitch (+3⁰), respectively. The PTV D95 was reduced by up to 8.7%, 7.3%, and 4.6% for the yaw (+3⁰), roll (-3⁰), and pitch (+3⁰), respectively. The PTV V100 showed the highest deviation with a reduction of dose coverage by up to 40.1%, 31.8%, and 33.9% for the yaw (-3⁰), roll (-3⁰), and pitch (+3⁰) respectively. Conclusion: The rotational setup errors with magnitude of ≥2⁰ can produce a significant loss of dose coverage to the target volume in the IMPT of a synchronous bi-lateral lung cancer. The yaw had the most severe impact on the dosimetric results when compared to other two rotational errors (roll and pitch).
oai:ojs.ijcto.org:article/466
2016-07-16T06:06:21Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.7
2016-07-16T06:06:21Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 2 (2016): April - June
Anticancer role of antidiabetic drug Metformin in ovarian cancer cells
Patel, Seema; Department of Biochemistry, All India Institute of Medical sciences (AIIMS), New Delhi
Singh, Neeta; Department of Biochemistry, All India Institute of Medical sciences (AIIMS), New Delhi
Kumar, Lalit; Department of Oncology, All India Institute of Medical sciences (AIIMS), New Delhi
2016-05-29 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.7
Metformin, Ovarian Cancer, Apoptosis, p53
en
Purpose: Epithelial ovarian cancer is the most common ovarian cancer and has life threatening implications. Despite the progress in surgical and therapeutic strategies, resistance to chemotherapy is still a major concern. Chemotherapeutic agents cause cytotoxicity, primarily by the induction of apoptosis. The status of p53 is a key factor in determining the efficacy of apoptotic signaling. p53 is the most commonly mutated tumor suppressor gene in ovarian cancer. Metformin (an antidiabetic drug) has shown putative effects in many solid tumors. Hence we aimed to study the role of metformin in p53 mutated cancer cells.Methods: SKOV3 and OAW42 ovarian cancer cell line were used. The cancer cells were treated with metformin. MTT, Flow cytometry and Western blotting were used to characterize the effects of the different treatments.Results: Metformin treatment leads to cell cycle arrest in the G0/G1, S and G2/M phase of the cell cycle in SKOV3 and OAW42 respectively. Moreover, there was upregulation of Bax and downregulation of Bcl-2 protein and increased apoptosis in SKOV3 and OAW42 ovarian cancer cells.Conclusion: These findings support the potential of metformin to be used as chemoadjuvant and reflects its ability to sensitize cancer cells to apoptosis independent of p53 status.
oai:ojs.ijcto.org:article/547
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.4
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
A dosimetric dnalysis of flattening-filter-free mode linear accelerator-based stereotactic body radiation therapy and HDR brachytherapy for prostate cancer
http://www.ijcto.org/index.php/IJCTO/article/download/547/4441
http://www.ijcto.org/index.php/IJCTO/article/download/547/4442
Wong, Andrew Thomas; Department of Veterans Affairs, New York Harbor Healthcare
Telivala, Tejas
Worth, Matthew
Schwartz, David
Schreiber, David
2016-12-26 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.4
Radiation Oncology; Medical Dosimetry
Prostate cancer, High-dose rate brachytherapy, Stereotactic body radiation therapy, Dosimetry, Flattening filter-free
en
Purpose: Prior studies have reported that linear accelerator (LINAC)-based stereotactic body radiation therapy (SBRT) plans for prostate cancer are unable to achieve comparable intraprostatic doses to high-dose-rate brachytherapy (HDR). However, the utilization of flattening-filter-free (FFF) beams provides superior dose distributions compared with flattened beams. The purpose of this study was to test the feasibility of achieving the high intraprostatic doses observed in HDR by utilizing LINAC - based SBRT with FFF beams.Methods: We randomly selected 10 patients with localized prostate cancer previously treated at our institution in 2013. FFF-mode LINAC-based SBRT and simulated HDR (using virtual HDR catheters) plans were generated for each patient. The planning target volume (PTV) V100, V125, V150 and V200 values were compared between the two plans using the two-sided paired samples t-test.Results: Regarding the PTV coverage, the mean V100 was slightly higher for SBRT at 96.47% compared with 94.68% for HDR (p = 0.003). The V125 (61.69% versus 66.51%, p = 0.004) and V200 (15.06% versus 19.66%, p < 0.001) were slightly lower for SBRT. There were no significant differences in V150 between the two plans (47.59% versus 49.8%, p = 0.375). Rectal and bladder dosimetry were also comparable between the two modalities, though the rectal maximum dose was lower in the SBRT plan (99.6% versus 103.66%, p = 0.006) and the dose to 15cc of bladder was lower in the HDR plan (96.34% versus 78.18%, p = 0.005).Conclusion: Utilization of FFF mode LINAC-based SBRT allows for achievable dosimetry that is very similar to high dose rate brachytherapy. Further studies are warranted regarding the safety and efficacy of this modality.
oai:ojs.ijcto.org:article/635
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.8
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Preferred treatment position between supine and prone for pelvic radiation therapy; quantification of the intrafractional body motion component by 3D surface imaging system
Zhao, Hui; Department of Radiation Oncology, University of Utah, Salt Lake City
Sarkar, Vikren; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Huang, Long; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Wang, Brian; Department of Radiation Oncology, University of Louisville, Louisville, USA
Rassiah-Szegedi, Prema; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Huang, Y. Jessica; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Szegedi, Martin; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Gonzalez, Victor; University of Arizona Cancer Center, Tucson, Arizona, USA
Salter, Bill; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
2017-08-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.8
AlignRT, Intrafractional motion, Supine, Prone
en
Purpose: We investigated the preferred treatment position between supine and prone during pelvic radiation treatment using real time tracking data from AlignRT. Our findings will provide valuable information regarding the role of intrafractional body motion in answering the question of prone versus supine position for pelvis radiation. Methods: Ten patients receiving pelvic radiation were enrolled in this study. For each patient, two simulation helical CT scans were performed, one in supine and one in prone position. Body surface contours were automatically generated and then exported to the AlignRT system as reference images. AlignRT continuous patient body motion tracking (1.5 to 2 minutes) was performed for both positions for each patient once per week for five weeks. The equivalent patient body motion along three principle directions was calculated from the six degree of freedom real time patient displacements data. The maximum and the standard deviation (STD) of equivalent patient body motion were calculated, so as the average of maximum and STD of equivalent patient motion over five fractions. These were then compared between supine and prone orientations. Results: A correlation was observed between the intrafractional body motion and large BMI. For overweight/obese patients, the intrafractional body motion was smaller for the supine position in both vertical and longitudinal directions. For normal range BMI patients, we observed no clear advantage for either supine or prone position in both vertical and longitudinal directions. In lateral direction, the intrafractional motion did not have statistically difference between two positions. Conclusion: Our study shows that the amount of intrafractional body motion between supine and prone orientation is correlated with patient BMI. Overweight/obese patients experienced significantly less overall body motion in supine orientation. The preferred treatment position for normal BMI patients was seen to be individually variable.
oai:ojs.ijcto.org:article/802
2018-06-24T14:49:11Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.8
2018-06-24T14:49:11Z
International Journal of Cancer Therapy and Oncology
Vol 6, No 1 (2018): January - December
5-FU resistant colorectal cancer cells possess improved invasiveness and βIII-tubulin expression
Akalovich, Sviatlana; The Republic Research & Production Center for Transfusiology and Medical Biotechnologies, Dolginovsky tract 160, Minsk, Belarus 220053.
Portyanko, Anna; N.N. Alexandrov National Cancer Centre of Belarus.Lesnoy 2, Minsk District, Belarus 223040.
Pundik, Anastasia; The Republic Research & Production Center for Transfusiology and Medical Biotechnologies, Dolginovsky tract 160, Minsk, Belarus 220053
Mezheyeuski, Artur; Karolinska Institutet, Stockholm, Sweden SE-171 76.
Doroshenko, Tatyana Mikhailovna; N.N. Alexandrov National Cancer Centre of Belarus.Lesnoy 2, Minsk District, Belarus 223040.
2018-06-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.8
Medical Oncology; cancer biology
Colorectal cancer, 5-Fluorouracil, Chemoresistance, III-tubulin, Invasiveness
This study was funded by by the Ministry of Health of Republic of Belarus (grant №1.2.42) and International Scientific and Technology Center (ISTC №B-1636).
en
Purpose: Elevated bIII-tubulin levels are associated with resistance to a broad spectrum of drugs in different carcinomas and are associated with poor prognosis of different epithelial cancers. 5-Fluorouracil (5-FU) is a widely used standard drug in chemotherapeutic regimens for colorectal cancer treatment, although the resistance to 5-FU is a major obstacle to successful therapy. The aim of the study was to compare the invasive and adhesion properties and the expression levels of bIII-tubulin in a 5-Fluorouracil (5-FU)-resistant colorectal cancer (CRC) cell line HCT116 and parental cells.Methods: The 5-FU-resistant cell line was established by continuous stepwise selection with increasing concentrations of 5-FU. Cell viability and properties were evaluated using MTT, adhesion and transwell invasion assays respectively. The expression of bIII-tubulin was revealed by immunoblot and immunofluorescence.Results: The derivative line is 25-fold resistant to 5-FU and characterized by altered cell morphology, twice as many cells of the 5-FU-resistant line fail to adhere than is the case for the parental cell line and were characterized by enhanced invasiveness, accompanied by increased bIII-tubulin expression. In addition, we found that loss of bIII-tubulin expression was correlated with loss of 5-FU resistance.Conclusion: Our results indicate that even though 5-FU does not target microtubules, there appears to be a correlation between bIII-tubulin expression and resistance to 5-FU and that this is particularly important with regard to invasiveness. These findings indicate a possible contribution of bIII-tubulin to 5-FU resistance in vivo.
oai:ojs.ijcto.org:article/7
2013-11-03T16:25:16Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Oyewale
2013-11-03T16:25:16Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 1 (2013): September - October
Dose prediction accuracy of collapsed cone convolution superposition algorithm in a multi-layer inhomogenous phantom
http://www.ijcto.org/index.php/IJCTO/article/download/7/21
http://www.ijcto.org/index.php/IJCTO/article/download/7/22
Oyewale, Stephen; Cancer Centers of Southwest Oklahoma
2013-09-18 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Oyewale
Medical Physics; Radiation Oncology
Collapsed Cone Convolution Superposition, Heterogeneity Correction, PDD, Pinnacle
en
Purpose: Dose prediction accuracy of dose calculation algorithms is important in external beam radiation therapy. This study investigated the effect of air gaps on depth dose calculations computed by collapsed cone convolution superposition (CCCS) algorithm. Methods: A computed tomography (CT) scan of inhomogenous phantom (30 × 30 × 30 cm3) containing rectangular solid-water blocks and two 5 cm air gaps was used for central axis dose calculations computed by CCCS in Pinnacle treatment planning system. Depth dose measurements were taken using a cylindrical ionization chamber for identical beam parameters and monitor units as in the depth dose computations. The calculated and the measured percent depth dose (PDDs) were then compared. The data presented in this study included 6 MV photon beam and field sizes of 3 × 3 cm2, 5 × 5 cm2, 10 × 10 cm2, and 15 × 15 cm2.Results: The results of CCCS were within ±1.4% in the first water medium. However, upon traversing the first air gap and re-entering the water medium, in comparison to the measurements, the CCCS under-predicted the dose, with difference ranged from -1.6% to -3.3% for 3 × 3 cm2, from -2.4% to -4.2% for 5 × 5 cm2, from -2.4% to -6.7% for 10 × 10 cm2, and from -1.6% to -6.3% for 15 × 15 cm2. After the second air gap, the CCCS continued to under-predict the dose, and the difference ranged from -3.2% to -3.9% for 3× 3cm2, from -2.4% to -5.6% for 5 × 5 cm2, from -2.3% to -6.0% for 10 × 10 cm2, and from -1.5% to -5.6% for 15 × 15 cm2. Conclusion: The CCCS under-predicted the dose in water medium after the photon beam traversed the air gap. Special attention must be given during the patient set-up since large air gap between the patient body and immobilization devices may lead to unacceptable dose prediction errors.----------------------------------------------Cite this article as:Oyewale S. Dose prediction accuracy of collapsed cone convolution superposition algorithm in a multi-layer inhomogenous phantom. Int J Cancer Ther Oncol 2013; 1(1):01016.DOI: http://dx.doi.org/10.14319/ijcto.0101.6
oai:ojs.ijcto.org:article/86
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Mukherjee
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Clinical trends and outcomes of male breast cancer: Experience of a tertiary oncology centre in India
Mukherjee, Anindya; Department of Radiation Oncology, Medical College, Kolkata
Saha, Aramita; Department of Medical Oncology, Apollo Gleneagles Cancer Hospital
Chattopadhyay, Subrata; Department of Radiation Oncology, Medical College, Kolkata
Sur, Prabir Kumar; Department of Radiotherapy, Hemalata Cancer Institute, Bhubaneswar,
2014-05-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Mukherjee
Oncology
Male Breast Cancer; Rare; Advanced Stage; Poor Outcome
Breast Cancer
en
Purpose: Because of its rarity in any oncology centre, the clinical trends of male breast cancer specific to its geographical distribution have remained relatively unexplored. This study was done to analyze the clinico-pathological data, treatment given and survival patterns of male breast cancer patients visiting our tertiary medical centre and compare our results with available literature. Methods: All male breast cancer patients registered at our clinic from 2003 to 2009 were included. Frequency distribution analysis of the demographic and clinico-pathological data and treatment variables was done. Treatment outcome was examined from Kaplan-Meir survival estimates. Results: Thirty-three male breast cancer patients were encountered. The median age of presentation was sixty years. Mostly (87.9%) they presented with lump in breast or axilla and were clinically staged to be ‘3’ (57.6%).Obesity and alcohol were the commonest risk factors identified. Modified radical mastectomy was the commonest (69.6%) definitive therapy rendered with (only for clinically staged 3 patients) or without neo-adjuvant chemotherapy. Infiltrating ductal carcinoma was identified in most cases. Twenty-two patients received adjuvant chemotherapy and twenty-four received adjuvant radiotherapy. Eighteen (54.5%) patients were hormone-receptor positive and received tamoxifen. The median Overall survival (OS) and Progression-free survival (PFS) came out to be 14.3 months (standard error, SE of 1.185; 95% confidence interval, CI 12-16.6) and 15.7 (SE 5.35, 95% CI 5.2-26.19) months respectively.Conclusion: Male breast cancers usually carry a poor prognosis due to presentation at later stages. Most of our results correlate with previous literature. Multi-centric prospective studies are required to validate the etiological factors and prognostic determinants of survival.-----------------------------Cite this article as: Mukherjee A, Saha A, Chattopadhyay S, Sur P. Clinical trends and outcomes of Male Breast Cancer: experience of a tertiary oncology centre in India. Int J Cancer Ther Oncol 2014; 2(3):02035. DOI: 10.14319/ijcto.0203.5
oai:ojs.ijcto.org:article/157
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.9
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Quality control test for electronic portal imaging device using QC-3 phantom with PIPSpro
Rout, Birendra Kumar; Department of Radiation Physics, Aditya Birla Memorial Hospital, Pune, India
Department of Physics, Jawaharlal Nehru Technological University, Hyderabad, India
Shekar, Mukka Chandra; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad, India
Kumar, Alok; Department of Radiation Physics, Mahavir Cancer Sansthan, Patna, India
Ramesh, Kondapalli Kesava Durga; Department of Radiation Oncology, Navodaya Cancer Institute & Research Center, Bhopal, India
2014-09-29 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.9
Medical Physics
EPID; QC-3 Phantom; PIPSpro; Spatial Resolution; CNR; Noise
Radiation Physics
NIL
en
Purpose:A Quality control (QC) test suitable for routinely daily use has been established for electronic portal imaging device (EPID) using PIPSpro software version 4.4 (Standard Imaging, Middleton, WI). It provides an objective and quantitative test for tolerable image quality on the basis of the high contrast spatial resolution, the contrast-to-noise ratio (CNR) and noise.Methods: The test uses a QC-3 phantom consisting of five sets of high contrast rectangular bar patterns with spatial frequeinces of 0.10, 0.20, 0.25, 0.43 and 0.75 lp/mm using 6MV and 15MV photon energy for accquiring high quality images. A “base line” value for the relative square wave modulation transfer function (RMTF), CNR and Noise data was obtained during a one week calibration period and one month test period.Results: Subsequent measurements shows significant deviations from baseline values, resulting in warning messages “potential problems in system performance”. The QC test uses high contrast spatial resolution and CNR for the system with acceptable performance. Conclusion: The method provides an automatic, objective, and sensitive measure of the system's imaging performance. This is a useful implementation during acceptance testing, commissioning, and routine quality control.
oai:ojs.ijcto.org:article/211
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.13
2015-03-29T11:59:32Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Impact of different IMRT techniques to improve conformity and normal tissue sparing in upper esophageal cancer
http://www.ijcto.org/index.php/IJCTO/article/download/211/2324
http://www.ijcto.org/index.php/IJCTO/article/download/211/2374
Amin, Amin E; Department of Radiotherapy and Nuclear Medicine, El-Demerdash Hospital, Faculty of Medicine, Ain Shams University, Cairo
Kelaney, Mohamed; Department of Radiotherapy and Nuclear Medicine, El-Demerdash Hospital, Faculty of Medicine, Ain Shams University, Cairo
Elshamndy, Samah K; Department of Radiotherapy and Nuclear Medicine, Faculty of Medicine, Suhag University, Suhag
W. Guirguis, Osiris; Department of Biophysics, Faculty of Science, Cairo University, Giza
2014-12-18 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.13
Medical Physics
Intensity Modulated Radiotherapy; Esophageal Cancer; Local Optimization; Planning Target Volume; Organ at Risks
en
Purpose: Intensity modulated radiotherapy (IMRT) for cervical esophageal cancer is challenging. Although IMRT techniques using inverse planning algorithms are facilitating the treatment planning process, the irradiation dose to the normal tissues can be a critical issue. This study was performed to investigate the effect of beam numbers and their directions and local optimization on: (1) dose conformity and homogeneity to the planning target volume (PTV) and (2) dose to the organ at risks (OARs).Methods: Four upper esophageal cancer cases were randomly selected for this treatment planning study. Eight IMRT plans were generated for each case with the same dose-volume constraints but with different beam numbers and arrangements. Local optimization using regular structures drawn automatically around the PTV with margins from 0.5-1.5 cm was performed. IMRT plans were evaluated with respect to isodose distributions, dose-volume histograms (DVHs) parameters, homogeneity index (HI), and conformity index (CI). The statistical comparison between the types of plans was done using the One Way ANOVA test.Results: The results showed that IMRT using three or five beams was not sufficient to obtain good dose optimization. The seven field plans showed the best coverage for the PTV with tolerable doses for the OARs, and the beam orientation was very critical. Increasing beams (Bs) number from 7 to 13 did not show significant differences in the PTV coverage, while the mean lung dose was increased. The PTV coverage were 95.1, 95.1, 98.1, 97.3, 97.3, 97.3, 97.0, and 97.0% for 3Bs, 5Bs, 7Bs, 9Bs, 13Bs, 7Bs(30), 7Bs(60) (beam angles were changed from 0o to 30o and 60o), and 7Bs(R) (seven IMRT plans with ring), respectively. The mean heart dose did not exceed 0.36 Gy with p < 0.05. For lung doses, the best plan was the one with 9Bs which reduced lung volume doses V20Gy (%) and V30Gy (%), and reduced mean lung dose from 5.4 to 4.5 Gy with p < 0.05 for 7Bs(R) plans. IMRT improved the homogeneity indices (p > 0.05), yet conformity was better with 9Bs and 7Bs(R) IMRT plans with p < 0.05.Conclusion: Seven equispaced coplanar intensity-modulated beams with an addition of a ring structure can produce desirable dose distributions to the PTV. Moreover, dose-volume of exposed normal lung can be reduced with 9Bs and 7Bs(R) IMRT plans.
oai:ojs.ijcto.org:article/314
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.19
2015-08-15T11:54:26Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
Anticancer effects of monocarbonyl analogs of curcumin: oxidative stress, nuclear translocation and modulation of AP-1 and NF-κB
http://www.ijcto.org/index.php/IJCTO/article/download/314/3134
http://www.ijcto.org/index.php/IJCTO/article/download/314/3135
Adams, Brian; Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia
Herold, Marike; Department of Chemistry, Emory University, Atlanta, Georgia
Ferstl, Eva; Department of Chemistry, Emory University, Atlanta, Georgia
Choi, Jungwhan; Department of Chemistry, Emory University, Atlanta, Georgia
Zhu, Shijun; Department of Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia
Bogdanov, Vladimir; Division of Hematology/Oncology, Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
El-Rayes, Bassel; Department of Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia
Sun, Aiming; Department of Chemistry, Emory University, Atlanta, Georgia
Liotta, Dennis; Department of Chemistry, Emory University, Atlanta, Georgia
Snyder, James; Department of Chemistry, Emory University, Atlanta, Georgia
Shoji, Mamoru; Department of Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia
2015-05-30 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.19
Curcumin Analogs; EF24; UBS109; Pancreatic, Breast and Prostate Cancers; Oxidative Stress; Nuclear Translocation; NF-κB; AP-1
en
Purpose: In order to elucidate anticancer effects of monocarbonyl analogs of curcumin (MACs), we have undertaken the present study to obtain information regarding drug targets by using a microarray approach, and to study the cellular localization of EF24 and the activity of two key transcription factors, AP-1 and NF-κB, involved in complex cellular responses of cell survival and death. Methods: Cytotoxic activity of various drugs was evaluated using a Neutral Red Dye assay. Cellular localization of biotinylated EF24 (active) and reduced EF24 (inactive) was determined using light and confocal microscopy. Measurement of transcription factor binding was carried out using Transfactor ELISA kits (BD Clontech, Palo Alto, CA). Gene microarray processing was performed at Expression Analysis, Inc (Durham, NC) using Affymetrix Human U133A Gene Chips.Results: In this study, we demonstrated that EF24 and UBS109 exhibit much more potent cytotoxic activity against pancreatic cancer than the current standard chemotherapeutic agent gemcitabine. EF24, rapidly localizes to the cell nucleus. The compound modulates the DNA binding activity of NF-κB and AP-1 in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. Immunohistochemical studies utilizing biotinylated-EF24 and chemically-reduced EF24 show that the unsaturated compound and biotinylated EF24, but not reduced EF24, translocates to the nucleus within 30 minutes after the addition of drug. Through a gene microarray study, EF24 is shown to affect genes directly involved in cytoprotection, tumor growth, angiogenesis, metastasis and apoptosis. Conclusion: EF24 and UBS109 warrant further investigation for development of pancreatic cancer therapy. The dualistic modulations of gene expression may be a manifestation of the cell responses for survival against oxidative stress by EF24. However, the cytotoxic action of EF24 ultimately prevails to kill the cells.
oai:ojs.ijcto.org:article/401
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.5
2016-01-03T12:17:08Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 4 (2015): October - December
Possible involvement of tyrosine kinase inhibitors on the expression of CXCR4 in chronic myeloid leukemia
http://www.ijcto.org/index.php/IJCTO/article/download/401/3677
http://www.ijcto.org/index.php/IJCTO/article/download/401/3678
Fujita, Thiago; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Vitiello, Glauco; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Amarante, Marla Karine; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Oliveira, Carlos; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Hirata, Bruna; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Oda, Julie; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
Turkowski, Luis; Hematologist at Londrina Cancer Hospital, Londrina/PR
Watanabe, Maria; Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina
2015-09-21 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.5
Oncology
Chronic Myeloid Leukemia; Tyrosine Kinase Inhibitors; CXCL12; CXCR4
Therapy
We acknowledge the volunteers who made this study possible. This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq, the Fundação Araucária and the Coordenadoria de Pós-Graduação, Londrina State University - PR
en
Purpose: Chronic myeloid leukemia (CML) treatment has improved significantly in the last decade with the introduction of tyrosine kinase inhibitors (TKIs), which target BCR/ABL oncoprotein. However, a large proportion of patients develop resistance to this treatment protocol, with frequent relapse cases. CXCR4 up-regulation in leukemic cells induced by TKIs has been reported as a mechanism of chemoresistance by promoting migration of these cells to bone marrow, where they receive pro-survival signals and persist as quiescent cells. In the present study, we investigated the possible influence of treatment on the expression of CXCR4 and CXCL12 in peripheral blood cells of CML patients. Methods: Relative expressions (RE) were calculated from mRNA obtained from leukocytes of 21 patients in chronic phase, under treatment, and 54 healthy individuals, used as controls.Results: CXCR4 expression was increased in CML patients compared to controls (RE: 1.931; p = 0.006). In CML patients, CXCR4 and CXCL12 expressions were correlated (r = 0.631; p = 0.002), and no differences in the expression of these genes were observed among different treatment protocols. However, CXCR4 expression was positively correlated with imatinib treatment period duration of treatment (r = 0.56; p = 0.02). Conclusion: This data has pointed peripheral blood CXCR4 expression as a possible marker for treatment monitoring, which may be useful to predict which patients would be benefit from newly developed treatments targeting CXCR4 and BCR/ABL concomitantly.
oai:ojs.ijcto.org:article/446
2016-07-16T06:07:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.1
2016-07-16T06:07:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 2 (2016): April - June
Commissioning and quality control of a dedicated wide bore 3T MRI simulator for radiotherapy planning
Xing, Aitang; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Holloway, Lois; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Arumugam, Sankar; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Walker, Amy; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Rai, Robba; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Juresic, Ewa; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Cassapi, Lynette; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Goozee, Gary; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Liney, Gary; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
2016-03-03 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.1
Medical Physics; Radiation Oncology
MRI in Radiotherapy, Wide-Bore 3T MRI Scanner, Radiotherapy Planning, Quality Control
en
Purpose: The purpose of this paper is to describe a practical approach to commissioning and quality assurance (QA) of a dedicated wide-bore 3 Tesla (3T) magnetic resonance imaging (MRI) scanner for radiotherapy planning.Methods: A comprehensive commissioning protocol focusing on radiotherapy (RT) specific requirements was developed and performed. RT specific tests included: uniformity characteristics of radio-frequency (RF) coil, couch top attenuation, geometric distortion, laser and couch movement and an end-to-end radiotherapy treatment planning test. General tests for overall system performance and safety measurements were also performed.Results: The use of pre-scan based intensity correction increased the uniformity from 61.7% to 97% (body flexible coil), from 50% to 90% (large flexible coil) and from 51% to 98% (small flexible coil). RT flat top couch decreased signal-to-noise ratio (SNR) by an average of 42%. The mean and maximum geometric distortion was found to be 1.25 mm and 4.08 mm for three dimensional (3D) corrected image acquisition, 2.07 mm and 7.88 mm for two dimensional (2D) corrected image acquisition over 500 mm × 375 mm × 252 mm field of view (FOV). The accuracy of the laser and couch movement was less than ±1 mm. The standard deviation of registration parameters for the end-to-end test was less than 0.41 mm. An on-going QA program was developed to monitor the system’s performance.Conclusion: A number of RT specific tests have been described for commissioning and subsequent performance monitoring of a dedicated MRI simulator (MRI-Sim). These tests have been important in establishing and maintaining its operation for RT planning.
oai:ojs.ijcto.org:article/510
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.11
2016-09-18T08:59:14Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
Concurrent versus sequential chemoradiotherapy for locally advanced resectable hypopharyngeal carcinoma
EL-Hadaad, Hend Ahmed; Department of Clinical Oncology & Nuclear Medicine, Mansoura University Hospital, Faculty of Medicine, Mansoura
Wahba, Hanan Ahmed; Department of Clinical Oncology & Nuclear Medicine, Mansoura University Hospital, Faculty of Medicine, Mansoura
2016-09-05 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.11
Radiation oncology
Hypopharyngeal Carcinoma, Chemotherapy, Radiotherapy, Sequential Chemoradiotherapy
en
Purpose: Both concurrent and sequential chemoradiotherapy have been reported to be good alternatives to total laryngectomy in patients with locally advanced hypopharyngeal cancer. We retrospectively reviewed the results of concurrent vs sequential chemoradiotherapy in two institutions for treatment of locally advanced resectable hypopharyngeal cancer in an effort to optimize future laryngeal preservation treatment.Methods: Seventy-two patients with locally advanced resectable hypopharyngeal squamous cell carcinoma were reviewed. Arm I included 38 patients treated by concurrent chemoradiotherapy (CCRT) while arm II included 34 patients received sequential chemoradiotherapy. In arm I patients received CCRT of cisplatin 100 mg/m2 d1, 22 of radiotherapy at dose of 65 Gy/1.8 - 2 Gy/f, 5 days/week. Patients in arm II received 2 cycles of induction chemotherapy consisted of 5 - fluorouracil 1000 mg/m2 on d1 - 4 on 24 h continuous infusion plus cisplatin 100 mg/m2 d1; cycle was repeated every 3 weeks followed by radiotherapy as in arm I.Results: Demographic data were balanced in both arms. The median age was 50 and 48 years in arm I and II respectively. There was male predominance in both arms. Most of the patients were of ECOGPS of 1and of stage III. No recorded deaths due to treatment toxicities .But as expected CCRT was associated with higher toxicity. In order of frequency; mucositis, anemia were higher in arm I. Significantly higher response rate was observed in arm I (p = 0.04).Three-year survival rates were 74% in arm I and 67.9% in arm II with no significant difference (p = 0.074) but 3 - year PFS rate was significantly higher in arm I (52.6% vs. 47%) (p = 0.03). Laryngeal - preservation rate was 78% in arm I vs. 56% in arm II with significant difference.Conclusion: There was higher benefit of concurrent chemo-radiotherapy over sequential chemoradiotherapy. However, larger number of patients and prospective randomized trials are needed to confirm our findings. New strategies that improve organ preservation with less toxicity are needed.
oai:ojs.ijcto.org:article/641
2017-12-17T14:56:14Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.1
2017-12-17T14:56:14Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Is targeting glycolysis with 2-deoxyglucose a viable therapeutic approach to bladder cancer?
http://www.ijcto.org/index.php/IJCTO/article/download/641/4859
Valera, Vladimir; New York Medical College
Ferretti, Mark; New York Medical College
Prabharasuth, Derek; New York Medical College
Chaimowitz, Matthew; New York Medical College
Choudhury, Muhammad; New York Medical College
Phillips, John; New York Medical College
Konno, Sensuke; New York Medical College
2017-02-12 14:25:15
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.1
Bladder Cancer Research
2-deoxyglucose, Anticancer, Chemosensitization, Glycolysis, Bladder cancer
Bladder cancer
N/A
en
Purpose: Although several therapeutic options for bladder cancer are available, the poor efficacy and palpable side effects are a major concern. Establishing a more effective intervention is urgently demanded. Glycolysis is considered a strategic target and has been often investigated in various cancers. Particularly, 2-deoxyglucose (2DG), a glycolysis inhibitor, has been intensely studied and shown to be encouraging and promising. Accordingly, we investigated how targeting glycolysis with 2DG would be effective on bladder cancer cells.Methods: Bladder cancer 5637 cells were employed and cell viability was determined by MTT assay. To explore the anticancer mechanism of 2DG linked to glycolysis, two glycolytic parameters of hexokinase (HK) activity and ATP synthesis, metabolic signaling pathways, and induction of apoptosis were examined. Whether 2DG may potentiate several chemotherapeutic drugs being clinically used was also assessed for its possible chemosensitizing effect.Results: A dose-dependent study of 2DG showed a 23-80% reduction in cell viability. HK activity and cellular ATP level were decreased by ~46% and ~56% with 2DG, respectively, indicating the glycolysis inhibition. AMP-activated protein kinase was activated while protein kinase B was inactivated and also mammalian target of rapamycin was inhibited with 2DG. These modulations would lead to the growth cessation and the cell viability reduction. In fact, the down-regulation of anti-apoptotic bcl-2 and the up-regulation of pro-apoptotic Bax in 2DG-treated cells indicated induction of apoptosis. Moreover, chemotherapeutic drugs with poor cytotoxic activity were selectively sensitized with 2DG, resulting in a significantly improved cell viability reduction.Conclusion: 2DG has anticancer activity on bladder cancer cells and its anticancer mechanism involves the glycolysis inhibition, the modulations of certain signaling pathways, and induction of apoptosis. Additionally, 2DG has a chemosensitizing effect when combined with drugs. Thus, targeting glycolysis with 2DG appears to be an alternative, viable therapeutic approach to bladder cancer.
oai:ojs.ijcto.org:article/829
2018-06-24T14:49:10Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.1
2018-06-24T14:49:10Z
International Journal of Cancer Therapy and Oncology
Vol 6, No 1 (2018): January - December
A single center study of cancer patients with chronic kidney disease
http://www.ijcto.org/index.php/IJCTO/article/download/829/5121
Mirza, Abu-Sayeef; University of South Florida
Mushtaq, Sarah
Reddy, Revati
Mousa, Mina
Kongpakpaisarn, Kullatham
Bohra, Chandrashekar
Verma, Sean
Mhaskar, Rahul
Baz, Rachid
Bassil, Claude
2018-06-24 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.1
Medical Oncology; Nephrology; Epidemiology
oncology, chemotherapy, chronic kidney disease, epidemiology
Onconephrology
en
Purpose: It is clinically understood that chronic kidney disease (CKD) and cancer are interrelated. Yet, few studies measure how renal outcomes vary according to common malignancies and common therapeutic agents. We report the incidence and the nature of CKD among cancer patients from a single institution.Methods: A retrospective chart review of cancer patients managed in the onconephrology clinic at the Moffitt Cancer Center from 05/01/2015 to 07/31/2016 was conducted. Patients with kidney injury were included in this study. Renal function was recorded at three-month follow-up intervals for 15-month duration.Results: Out of the total 88 patients with median age of 68 years, 63 patients (~ 72%) were diagnosed with chronic kidney disease (CKD), whereas the remaining had acute kidney injury. Kidney cancer and multiple myeloma represented the single malignancies with the largest proportion of CKD with 12 patients each (~14% each). Patients with kidney cancer had a mean creatinine of (2.35, 1.74 SD) mg/dl compared to patients without kidney cancer with creatinine (1.97, 1.07 SD) mg/dl. Abdominal cancers represented the highest frequency category of malignancies in this sample (n = 38), and about 32 (84%) of these patients had CKD. About 80% of patients with genitourinary cancers (n = 27) had CKD. In terms of prescribed chemotherapeutic agents, patients treated with tyrosine kinase inhibitors had a lower average estimated glomerular filtration rate (28.37, 9.86 SD) mL/min/1.73 m2 compared to other chemotherapeutic agents, though this was weakly significant (p-value = 0.07). Similar renal outcomes per malignancy and chemotherapy are reported.Conclusion: This group of patients demonstrated the frequency of chronic kidney disease differs depending on the type of malignancy or chemotherapy. A multidisciplinary approach involving oncologists and nephrologists should be adopted to prevent further renal damage from cancer and its therapies.
oai:ojs.ijcto.org:article/82
2014-05-14T17:01:16Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Jassal
2014-05-14T17:01:16Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 2 (2014): April - June
Validation of an integrated patient positioning system: Exactrac and iViewGT on Synergy Platform
http://www.ijcto.org/index.php/IJCTO/article/download/82/797
Jassal, Kanan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Department of Radiological Physics, SMS Medical College and Hospital, Jaipur.
Munshi, Anusheel; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Sarkar, Biplab; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Paul, Sayan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Sharma, Aman; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Mohanti, Bidhu Kalyan; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Ganesh, T; Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, India.
Chougule, Arun; Department of Radiological Physics, SMS Medical College and Hospital, Jaipur, India.
Sachdev, Kanupriya; Department of Physics, Malviya National Institute of Technology, Jaipur, India.
2014-04-09 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Jassal
Medical Physics
image guided radiotherapy, patient set-up, Exactrac, quality assurance
en
Purpose: Evaluation of the newly integrated system for its validation and designing a quality assurance frame work to assess its geometrical, radiological and mechanical accuracy.Methods: Isocentric accuracy of two independent imaging modalities, kV based ExacTrac and MV based iViewGT was evaluated using Winston-Lutz test. A pelvic humanoid phantom was used for the radiological end-to-end test for its clinical utilization. Image quality for the systems was evaluated using Las Vegas Phantom and ETR-1 plate. The kV system was also assessed for kVp accuracy, kVp - dose linearity, mAs-dose linearity and timer linearity and its accuracy. The system was tested for total filtration and output consistency. Tests for uniformity and noise measurement of kVp accuracy and its reproducibility, linearity test between applied kVp and the x-ray dose, linearity Test between applied mAs and the x-ray dose were also done. Results: Winston-Lutz test gave the isocentric deviation of 0.058 ± 0.015 mm with the average lateral deviation as 0.028 ± 0.021 mm, average longitudinal deviation as 0.032 ± 0.015 mm and average vertical deviation as 0.030 ± 0.016 mm. With the phantom test, the minimum measured displacement of Exactrac positioning was 0.2 ± 0.3 mm, 0.0 ± 0.2 mm and 0.1 ± 0.3 mm in longitudinal, lateral and vertical directions respectively. In image quality test, visible smallest visible hole size seen by both Exactrac and EPID imaging system was 5 mm and can resolve 1.5 lp/mm or better. The image uniformity was found to be 132.9 ± 3.06 pixels for MV images and 139 ± 4.41 pixels for kV images with the associated noise of ≤1% both for 120 kV-20 mAs and 4 MV beam energy of ExacTrac and iViewGT respectively. The uniformity and noise test, measured pixel intensity values for various points on MV and kV images separately were found to agree within ± 1% with respect to the central axis pixel value. The kVp accuracy and its reproducibility were tested for kV imager only. The deviation of kVp was found to be than ± 1% and its precision was seen to be even lesser than ± 0.1%. Linearity test between applied kVp and the x-ray dose and applied mAs and x-ray dose were tested only for the ExacTrac. Both the coefficient of linearity for kVp as well as mAs was found to be < 0.1. Conclusion: It is feasible to install ExacTrac imaging system with an Elekta linear accelerator. Both the imaging systems were found to be compatible in terms of image quality test and isocentric accuracy and can be used for the patient imaging in the same Linear accelerator.-----------------------------Cite this article as: Jassal K, Munshi A, Sarkar B, Paul S, Sharma A, Mohanti BK, Ganesh T, Chougule A, Sachdev K. Validation of an integrated patient positioning system: Exactrac and iViewGT on Synergy Platform. Int J Cancer Ther Oncol 2014; 2(2):020212. DOI: 10.14319/ijcto.0202.12
oai:ojs.ijcto.org:article/133
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.18
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Dosimetric comparison of 3DCRT versus IMRT in whole breast irradiation of early stage breast cancer
Ashraf, Mudasir; Department of Radiological Physics and Bio-Engineering, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India.
Janardhan, Nandigam; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Bhavani, Perumal; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Shivakumar, Radhakrishana; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Ibrahim, Syed; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Reddy, Palreddy; Department of Physics, Osmania University, Hyderabad, India.
Surrendharen, Jagdessan; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Sarangnathan, Balakrishna; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Johnson, Ben; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Madhuri, Bhagavathula; Department of Radiotherapy, Omega Hospitals, A Unit of Hyderabad Institute of Oncology, Banjara Hills, Hyderabad, India.
Dar, Rayees; Biostatistics Division, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India.
2014-08-06 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.18
Whole Breast Irradiation; Planning Tumor Volume; Organs at Risk; Conformity Index; Heterogeneity Index; Breast Conservative Surgery
Omega Hospitals, Hyderabad India,
en
Purpose: The counseling regarding the treatment option is an important objective in the management of early stages breast cancer. In this study, we attempt to compare and analyze the dosimetric aspects of 3DRT over IMRT in the whole breast radiotherapy.Methods and Materials: Both right and left sided computed tomography simulations of 14 women with early stage breast cancer were used for our retrospective study to compare the 3DCRT and IMRT. The dose prescribed was 50 Gy in 25 fractions to the whole breast PTV. The PTV was defined by adding unequal margins to the directional safety margin status of each lumpectomy cavity (i.e., medial, lateral, superior, inferior and deep margins measured from the tumor front after the examination of the surgical specimen: 2, 1.5, and 1 cm for resection margins < 1 cm, 1-2 cm, and > 2cm, respectively). And than modified so that it was no longer closer than 3mm to the skin surface and was no deep than the lung –chest interface. The prescribed dose delivered in 5 fractions per week schedule. Treatment plans were compared for target minimum dose, maximum dose, mean dose, conformity index, heterogeneity index and doses to organs at risk were compared and analysed.Results: The target coverage was achieved with 90% prescription to the 95% of the PTV. Conformity to the PTV was significantly higher with 3DCRT technique than IMRT. 3DCRT technique seems better in sparing critical organs parameters like lung V20 and Mean, heart, V25, Maximum, both lungs V20, Mean and Dose to the Normal Healthy tissue.Conclusion: We conclude from our study that treatment technique selection for whole Breast irradiation is an important factor in sparing the adjacent normal structures and in determining the associated risk. 3DCRT produces better conformity and heterogeneity indices of the target volume, also reduces dose to OARs the 3DCRT reduces the risk of radiation induced heart diseases.......................................................Cite this article as:Ashraf M, Janardhan N, Bhavani P, Shivakumar R, Ibrahim S, Reddy PY, Surrendharen J, Sarangnathan B, Johnson B, Madhuri B, Dar RA. Dosimetric comparison of 3DCRT versus IMRT in whole breast irradiation of early stage breast cancer. Int J Cancer Ther Oncol 2014; 2(3):020318. DOI: 10.14319/ijcto.0203.18
oai:ojs.ijcto.org:article/202
2014-12-13T14:36:25Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.20
2014-12-13T14:36:25Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Rate of EGFR mutation in patients with pulmonary adenocarcinoma
http://www.ijcto.org/index.php/IJCTO/article/download/202/2274
Shuaib, Waqas; Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA
Kousar, Aisha; University Medical and Dental College, Faisalabad, Pakistan
Bejori, Nosheen Anwar; Department of Medicine, Ayub Medical College, Abbottabad, Pakistan
Saeed, Asim; Department of Medicine, Rush University Medical Center, Chicago, USA
Valdes, Emilio; Jairo D. Libreros Clinic, Tampa, Florida, USA
Ahmad, Moeed; Department of Medicine, Queens Hospital Center, Jamaica, New York, USA
Khawaja, Saleem; Dow University of Health Sciences, Dow Medical College, Karachi, Pakistan
Baloch, Tariq; Karachi Institute of Radiotherapy and Nuclear Medicine, Karachi, Pakistan
2014-12-03 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.20
Medical Oncology
Adenocarcinoma; EGFR; Mutation; Lung Cancer
en
Purpose: Contemporary literature on lung adenocarcinoma has demonstrated a genetic difference of the epidermal growth factor receptor (EGFR) pathway conferring to ethnicity, such as higher frequency of activated EGFR mutations in East Asian population. This information is missing in some developing countries, and we intend to address this gap in the literature. Methods: We examined the rate of EGFR mutations among Pakistani patients with adenocarcinoma of the lung. Fine-needle aspiration samples were gathered from 73 patients. Polymerase chain reaction was performed on extracted DNA for mutational analysis of EGFR exons 19 and 21. Results: EGFR mutations were discovered in 18 of 73 (24.6%) patients. We did not find any significant difference in EGFR mutation rate with regard to patient's age, sex, smoking history, clinical stage of lung cancer, subtypes of adenocarcinoma, and tumor differentiation. Conclusion: Our investigation shows that the EGFR mutation rate in our patient population with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and was lower than the East Asian population.
oai:ojs.ijcto.org:article/260
2015-08-15T11:54:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.13
2015-08-15T11:54:27Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 2 (2015): April - June
A comparative study on patient specific absolute dosimetry using slab phantom, acrylic body phantom and goat head phantom
Gurjar, Om Prakash; Department of Physics, Mewar University, Chittorgarh
Mishra, Surendra Prasad; Department of Physics, Mewar University, Chittorgarh
2015-04-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.13
Radiation Oncology; Medical Physics; Medical Dosimetry
Acrylic Body Phantom; Goat Head Phantom; Patient Specific Absolute Dosimetry
Medical Physics
None
en
Purpose: To compare the results of patient specific absolute dosimetry using slab phantom, acrylic body phantom and goat head phantom. Methods: Fifteen intensity modulated radiotherapy (IMRT) plans already planned on treatment planning system (TPS) for head-and-neck cancer patients were exported on all three kinds of phantoms viz. slab phantom, acrylic body phantom and goat head phantom, and dose was calculated using anisotropic analytic algorithm (AAA). All the gantry angles were set to zero in case of slab phantom while set to as it is in actual plan in case of other two phantoms. All the plans were delivered by linear accelerator (LA) and dose for each plan was measured by 0.13 cc ion chamber. The percentage (%) variations between planned and measured doses were calculated and analyzed. Results: The mean % variations between planned and measured doses of all IMRT quality assurance (QA) plans were as 0.65 (Standard deviation (SD): 0.38) with confidence limit (CL) 1.39, 1.16 (SD: 0.61) with CL 2.36 and 2.40 (SD: 0.86) with CL 4.09 for slab phantom, acrylic head phantom and goat head phantom respectively. Conclusion: Higher dose variations found in case of real tissue phantom compare to results in case of slab and acrylic body phantoms. The algorithm AAA does not calculate doses in heterogeneous medium as accurate as it calculates in homogeneous medium. Therefore the patient specific absolute dosimetry should be done using heterogeneous phantom mimicking density wise as well as design wise to the actual human body.
oai:ojs.ijcto.org:article/308
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.23
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
Dosimetric analysis of intensity modulated radiotherapy (IMRT) and three dimensional conformal radiotherapy (3DCRT) for treatment of non-small cell lung cancer: A comparative study
http://www.ijcto.org/index.php/IJCTO/article/download/308/3104
Bagdare, Priyusha; Department of Medical Physics, Roentgen-SAIMS Radiation Oncology Centre, SAIMS, Indore
Gurjar, Om Prakash; Department of Medical Physics, Roentgen-SAIMS Radiation Oncology Centre, SAIMS, Indore
Shrivastav, Garima; Department of Radiotherapy, Roentgen-SAIMS Radiation Oncology Centre, SAIMS, Indore
Bhandari, Virendra; Department of Radiotherapy, Roentgen-SAIMS Radiation Oncology Centre, SAIMS, Indore
Gupta, Krishna Lal; Department of Radiotherapy, Roentgen-SAIMS Radiation Oncology Centre, SAIMS, Indore
2015-08-20 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.23
Medical Physics
Intensity Modulated Radiotherapy; Non-Small Cell Lung Cancer; Three Dimensional Conformal Radiotherapy
IMRT and 3DCRT
N/A
en
Purpose: The purpose of this study is to analyze and compare the dosimetric parameters of three dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) in selected non-small cell lung cancer (NSCLC) cases. Methods: Ten patients with inoperable NSCLC were selected for this study. The 3DCRT and IMRT plans were generated for all patients following Radiation Therapy Oncology Group (RTOG) guidelines. Generated plans were then compared on the basis of planning target volume (PTV) coverage, dose delivered to organs at risk, homogeneity index (HI), and conformity index (CI) for the prescribed dose (PD) of 50 Gy in 25 fractions.Results: The mean D95 and D99 (dose to the 95% and 99% volume) for the PTV were found better in the 3DCRT plans compared to the ones in the IMRT plans. On an average, the volume receiving 20 Gy (V20) of contralateral lung was 2.91% and 3.03% in the 3DCRT and IMRT plans, respectively. The Dmean of contralateral lung was 3.17 Gy (3DCRT) versus 4.2 Gy (IMRT), whereas the Dmean of ipsilateral lung was 12.69 Gy (3DCRT) and 13.82 Gy (IMRT). The V20 of ipsilateral lung was found to be slightly lower in the 3DCRT (25.67%) when compared to the IMRT (30.50%). The dose to the heart was comparable in the 3DCRT and IMRT plans (mean dose: 4.42 Gy versus 4.48 Gy; D33: 3.77 Gy versus and 4.02 Gy). For the spinal cord, the Dmax was found to be lower in the 3DCRT plans (18.40 Gy) when compared to the IMRT plans (25.49 Gy). The HI was 1.08 versus 1.41 in the 3DCRT and IMRT plans, respectively. The CI was identical (1.67) in both sets of plans.Conclusion: Based on the results of this study, the PTV coverage was found to be slightly better in the 3DCRT plans when compared to the one in the IMRT plans. On average, the dose to the organs at risk were found to be comparable.
oai:ojs.ijcto.org:article/440
2016-07-16T06:26:07Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.10
2016-07-16T06:26:07Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
Estimation of local confidence limit for 6 MV photon beam IMRT system using AAPM TG 119 test protocol
http://www.ijcto.org/index.php/IJCTO/article/download/440/3912
Kadam, Avinash; Department of Radiation Oncology, SevenHills Hospital, Mumbai
Sharma, Sunil; Radiological Physics and Advisory Division, Bhabha Atomic Research Centre, Mumbai
2016-02-03 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.10
Radiation Oncology
Confidence Limit, TG119, IMRT, Dosimetry
Medical Physics
en
Purpose: The aim of this study was to estimate local confidence limit for 6 MV photon beam based intensity modulated radiation therapy (IMRT) using TG119 test protocol.Methods: The American Association of Physicists in Medicine (AAPM) Task Group 119 (TG119) prescribed a protocol to evaluate overall accuracy of IMRT system rather than independent uncertainty in dose calculation, dose delivery and measurement system. Two preliminary and five clinical test cases were created based on dose prescriptions and planning objectives given by TG119 report. Verification plans were created in a planning slab phantom, 2D Matrix dosimetry system (I’MatriXX) with multicube phantom and aS-1000 electronic portal imaging device (EPID). Radiation absorbed doses to high dose points in the planning target volume (PTV) region and low dose points in avoidance structures were measured using CC13 ionization chamber having sensitive volume of 0.13 cm3. The measured and planned doses were normalized with respect to their prescription doses and intercompared. The gamma analysis was carried out for both I’MatriXX and EPID, adopting the acceptance criteria of 3% DD (dose difference) and 3 mm DTA (distance to agreement) with 10% threshold dose.Results: For the point dose measurements with ion chamber, the average dose difference ratio in high dose low gradient PTV region was -0.0133 ± 0.012 corresponding to a confidence limit of 0.037. The average dose difference in low dose region (avoidance structure) was -0.00004 ± 0.010 corresponding to a confidence limit of 0.021. The average percentage of points passing the gamma criteria of 3% DD and 3 mm DTA for composite planar dose distribution measured by I’MatriXX was 99.47 ± 0.43 which corresponds to a confidence limit of 1.38 (i.e. 98.62% passing). Similarly, the average percentage of points passing the gamma criteria of 3% DD and 3 mm DTA for per-field dose distribution measured by EPID was 98.00 ± 2.49 which corresponds to a confidence limit of 6.87.Conclusion: Our results were well within action level given by AAPM TG119 report through multi-institutional study providing us adequate confidence in delivering IMRT treatment.
oai:ojs.ijcto.org:article/463
2016-09-18T08:59:13Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.6
2016-09-18T08:59:13Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 3 (2016): July - September
Analytic derivation of central axis percent depth dose calculations in transition zones with loss of electronic equilibrium
http://www.ijcto.org/index.php/IJCTO/article/download/463/3975
http://www.ijcto.org/index.php/IJCTO/article/download/463/3976
http://www.ijcto.org/index.php/IJCTO/article/download/463/4350
http://www.ijcto.org/index.php/IJCTO/article/download/463/4351
http://www.ijcto.org/index.php/IJCTO/article/download/463/4352
http://www.ijcto.org/index.php/IJCTO/article/download/463/4387
http://www.ijcto.org/index.php/IJCTO/article/download/463/4388
http://www.ijcto.org/index.php/IJCTO/article/download/463/4389
http://www.ijcto.org/index.php/IJCTO/article/download/463/4542
Pacyniak, John M; Fort Belvoir Community Hospital
Radiation Oncology Dept.
Fort Belvoir, VA. 22060
2016-07-16 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.6
Radiation oncology; Medical Physics
Monte Carlo, Electronic Disequilibrium, Heterogeneity
Radiation Oncology Physics
en
Purpose: The study of megavoltage photon dose distribution behind and near small areas of low and high density material is best understood with Monte Carlo (MC) dose calculation or direct measurements which may not be always be possible. This is especially true for air-tissue area where the replacement of soft tissue scattering material by air results in the loss of electronic equilibrium and changes in the lateral spread of the beam as well. Monte Carlo calculations are the standards to correctly evaluate in homogeneities in transition zones. If one could develop a model with sufficient accuracy to obtain similar results, this would be very helpful clinically.Methods: To this end, we have developed an exponential model and derive an explicit expression that accounts for the under dosage. The model is an extension of a much earlier work done with electrons and photons. Our analytic model is based on the experience of the underlying physics assuming exponential attenuation of photons in matter.Results: It differs from a similar work by solving the problem correctly and introducing parameters that can be traced to direct measurements without the need of extensive statistical data analysis. It combines the generation of free electrons through ionization and their attenuation to a simple differential equation for the central axis depth dose. It involves two parameters, which can be obtained from 1) direct beam measurements, 2) primary photon attenuation coefficients from physics tables and 3) iteration techniques.Conclusion: The simplicity of the model allows us to extend our derivation to situations such as transitions zones of different densities in areas such as head and neck and lung. A clinical example is illustrated to demonstrate the problems encountered in treating cancer of the larynx.
oai:ojs.ijcto.org:article/554
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.16
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Dose-to-medium vs. dose-to-water: Dosimetric evaluation of head and neck VMAT cases using Monaco treatment planning system
Gopal, Saravana Kumar; CIMS Hospitals Pvt. Ltd, Ahmedabad- 380060
Department of Physics, Siksha ‘O’ Anusandhan University, Bhubaneswar- 751 030
Dash, Purendra Chandra; Department of Physics, Siksha ‘O’ Anusandhan University, Bhubaneswar- 751 030
2016-12-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.16
Medical Physics; Radiation Oncology
Monte Carlo based calculation, Dose-to-water, Dose-to-medium, Radiotherapy, Treatment planning system
en
Purpose: In this paper, we evaluate the dosimetric differences between absorbed dose to water and absorbed dose to medium in Monte Carlo (MC)-based calculations used for radiation therapy treatment plans.Methods: Thirty-four treated Head and Neck simultaneously integrated boost cases were analyzed retrospectively. All of them were planned by Monaco treatment planning system (TPS), calculated and reviewed on absorbed dose to medium (Dm) calculations and treated in Elekta Versa HD LINAC. Absorbed dose to medium Dm was converted to absorbed dose to water Dw in Monaco treatment planning system using the procedure based on stopping power ratios and the Bragg-Gray cavity theory. Dosimetric parameters were then compared and analyzed with respect to absorbed dose to medium (Dm) calculations for multiple planning target volumes (PTVs) and critical organs such as brainstem, spinal cord, left and right lens, left and right parotids, larynx, left and right middle ear and lips.Results: It was found that mean and minimum Dw (i.e. Dw mean and Dw min) of organs at risk did not differ much (hardly differing by 0.8-2%) with respect to those of the absorbed dose to medium. However maximum Dw (i.e. Dw max) in case of lips, left and right middle ear were found to differ more than 4% with respect to Dm max. For serial organs brainstem and spinal cord, maximum dose Dw max were found to vary around 1% and 2%, respectively, with respect to absorbed dose to medium dose calculation. In case of PTVs, the mean percentages variation of Dw min and Dw mean were found to be less than 1 %, although the variation of maximum Dw was found to be high around 5-7% with respect to that of Dm.Conclusion: The comparative analysis of dosimetric parameters in the present study shows that the selection of either Dm or Dw in Monaco planning system is less likely to produce any significant clinical effect in tumor control and to the damage of organs at risk.
oai:ojs.ijcto.org:article/592
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.3
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Exploring the role of “Glycerine plus Honey” in delaying chemoradiation induced oral mucositis in head and neck cancers
Bansal, Anshuma; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Ghoshal, Sushmita; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Yadav, Birender Kumar; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
Bahl, Amit; Department of Radiation Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
2017-12-15 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.3
Radiation Oncology
Mucositis, Glycerine, Honey, Head and neck cancer, Chemoradiation
Head and Neck
NIL
en
Purpose: The purpose of this study was to assess the efficacy of adding “Glycerine plus Honey” to standard management protocol, in terms of time to delay in oral mucositis ≥ grade 2.Methods: Hundred patients of oral cavity and oropharangeal cancers, planned for concurrent chemoradiation (Dose: 60–66 Gy/30-33 fractions) were randomized 1:1 to receive either home-made remedy made of “Glycerine plus Honey” added to the standard management protocol to prevent mucositis versus standard treatment alone. CTCAE v 4 (Common toxicity criteria for adverse events) was used for assessing oral mucositis scores weekly. Chi square test was used to compare mucositis scores, weight loss, opioid use, ryles tube feeding, and unplanned treatment breaks in each cohort. Independent T-test was used to compare means to assess the effect of treatment in delaying mucositis ≥ grade 2.Results: Significantly higher number of patients developed grade ≥ 2 mucositis in control arm [n = 43 (86%)] compared to study arm [n = 30 (60%)] (p = 0.003). CTCAE scores favored Glycerine plus honey at week 4, and on last day of radiotherapy. Whereas, time to first occurrence of oral mucositis grade ≥ 2 was 23.17 (± 1.01) days for study arm [radiation dose 31.67 Gy (± 1.44)], it was 20.65 (± 0.8) days for control arm [radiation dose 28.14 Gy (± 1.16)] (p = 0.05). Study patients had lesser weight loss (2.76 kg) than control subjects (3.9 kg) with p = 0.008. There were significantly higher number of patients in control arm who required opioid analgesia, ryles tube insertion and had unplanned treatment breaks, compared to study arm.Conclusion: Glycerine plus honey demonstrated superiority in delaying oral mucositis, and the combination is safe and well tolerable.
oai:ojs.ijcto.org:article/53
2014-04-12T11:23:45Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Chaikh
2014-04-12T11:23:45Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 1 (2014): January - March
A method to quantify and assess the dosimetric and clinical impact resulting from the heterogeneity correction in radiotherapy for lung cancer
http://www.ijcto.org/index.php/IJCTO/article/download/53/548
http://www.ijcto.org/index.php/IJCTO/article/download/53/550
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Giraud, Jean-Yves; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
2014-01-30 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Chaikh
Radiation Oncology; Medical Physics; Medical Dosimetry
Heterogeneity Correction; Pencil Beam Convolution; Modified Batho Method
en
Purpose: The aim of this study was to propose a method to quantify and assess the differences in dose computations using heterogeneity correction algorithms for the planning target volumes and organs at risk.Methods: Six patients with lung cancer treated with 3-dimensional conformal radiation therapy were included and analysed. Dose calculations were performed using the pencil beam convolution (PBC) algorithm without heterogeneity correction and the Modified Batho method (PBC-MB) with heterogeneity correction. For each patient, 3 treatment plans were generated using exactly the same beam configuration. In plan 1, the dose was calculated using the PBC algorithm. In plan 2, the dose was calculated using the PBC-MB. In plan 3, the dose was calculated using the PBC-MB method but with the same number of monitor units obtained from plan 1. To evaluate the treatment plans computed by the PBC and PBC-MB, the monitor units, dose at the isocenter, spatial isodose distribution, dose volume histograms, conformity index, homogeneity index, planning target volumes conformity index, and geometrical index were compared. A statistical analysis was carried out using Wilcoxon signed rank test. Results: The PBC-MB method in plan 2 produced a lower number of monitor units than in plan 1 using PBC algorithm (p < 0.001). Dosimetric parameters derived from the dose volume histograms were higher for the planning target volumes and organs at risks using PBC-MB method for plans 2 and 3 when compared to plan 1. There was no significant difference for all the quality indices between plan 1 and plan 2, (p > 0.05), but a significant difference for the geometric index between plans 2 and 3 (p = 0.002) was observed.Conclusion: The risks related to the modification from the homogeneity plan to the heterogeneity plan were the reduction of delivered dose in monitor units for the planning target volumes and the increment of the dose to the organs at risk. We suggest the adaption in the dose prescriptions when switching the dose calculation algorithm from the PBC to PBC-MB.------------------------------------------------------Cite this article as: Chaikh A, Giraud J, Balosso J. A method to quantify and assess the dosimetric and clinical impact resulting from the heterogeneity correction in radiotherapy for lung cancer. Int J Cancer Ther Oncol 2014; 2(1):020110.DOI: http://dx.doi.org/10.14319/ijcto.0201.10
oai:ojs.ijcto.org:article/148
2014-08-16T18:42:02Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0203.12
2014-08-16T18:42:02Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Radiobiological investigations at tumor cell lines by exploiting aspects of chronological dose administration
Ulmer, Waldemar; Department of Radiation Physics and Medical Physics, Radio-Oncology North-Wuerttemberg, University of Zurich, Switzerland.
2014-06-09 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0203.12
Medical Physics; Radiobiology
31P-NMR Spectroscopy; Biorhythms; Tumor Spheroids; Radiobiology
en
Purpose: Using 31P-NMR spectroscopy the chronological behavior of the ATP-metabolism of the tumor spheroids C3H-MA, 9L-Gliome and the mono-layer L1210 has been analyzed via increase and decrease of the β-peak. The goal of this study is to elaborate an optimal fractionation scheme with regard to the irradiation of tumor spheroids and possibly to human tumors. Methods: The NMR-spectroscopy has been carried out by the FID technique (free induction decay), and the intensity of the β-peak provides a measure of the survival fraction S after radiation exposure with 30 kV X-rays. The linear-quadratic model has to be generalized in order to be valid for irradiation beyond the shoulder. Results and Conclusion: All three cell lines show characteristic periods, and a homeostatic control cannot be recognized. Essential components of these periods are circadian (i.e. one day), circa-semiseptan (i.e. 3.5 days) and circa-septan (i.e. one week). The determination of the survival fractions provides an optimum exploitation of radiation damages, when the ATP-concentration assumes a maximum value. This optimum is reached, when all three cycles exhibit an ATP maximum, which is only possible by accounting for the circa-septan rhythm.--------------------------------------Cite this article as: Ulmer W. Radiobiological investigations at tumor cell lines by exploiting aspects of chronological dose administration. Int J Cancer Ther Oncol 2014; 2(3):020312. DOI:10.14319/ijcto.0203.12
oai:ojs.ijcto.org:article/224
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.19
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Dosimetric dependence on the collimator angle in prostate volumetric modulated arc therapy
Isa, Muhammad; Department of Physics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada
Rehman, Jalil ur; Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, USA
Afzal, Muhammad; Department of Physics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
Chow, James; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada
Department of Radiation Oncology, University of Toronto, Toronto, Canada
2014-11-28 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.19
Medical Dosimetry; Medical Physics
VMAT; Dose-Volume Histogram; Collimator Angle; Organs-At-Risk
Treatment Planning
M Isa, Princess Margaret Cancer Center and Islamia University Bahawalpur Pakistan; J Rehman, UT MD Anderson Cancer Center and Islamia University Bahawalpur Pakistan; M Afazl, Islamia University Bahawalpur Pakistan; J Chow, Princess Margaret Cancer Center
en
Purpose: The purpose of this study is to investigate the dose-volume variations of planning target volume (PTV) and organs-at-risk (OARs) in prostate volumetric modulated arc therapy (VMAT) when varying collimator angle. The collimator angle has the largest impact and is worth considering, so, its awareness is essential for a planner to produce an optimal prostate VMAT plan in a reasonable time frame. Methods: Single-arc VMAT plans at different collimator angles (0o, 15o, 30o, 45o, 60o, 75o and 90o) were created systematically using a Harold heterogeneous pelvis phantom. The conformity index (CI), homogeneity index (HI), gradient index (GI), machine monitor units (MUs), dose-volume histogram and mean and maximum dose of the PTV were calculated and analyzed. On the other hand, the dose-volume histogram and mean and maximum doses of the OARs such as the bladder, rectum and femoral heads for different collimator angles were determined from the plans.Results: There was no significant difference, based on the planned dose-volume evaluation criteria, found in the VMAT optimizations for all studied collimator angles. A higher CI (0.53) and lower HI (0.064) were found in the 45o collimator angle. In addition, the 15o collimator angle provided a lower value of HI similar to the 45o collimator angle. Collimator angles of 75o and 90o were found to be good for rectum sparing, and collimator angles of 75o and 30o were found to be good for sparing of right and left femur, respectively. The PTV dose coverage for each plan was comparatively independent of the collimator angle. Conclusion: Our study indicates that the dosimetric results provide support and guidance to allow the clinical radiation physicists to make careful decisions in implementing suitable collimator angles to improve the PTV coverage and OARs sparing in prostate VMAT.
oai:ojs.ijcto.org:article/237
2015-03-29T11:59:33Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.21
2015-03-29T11:59:33Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Dose variation due to change in planned position for patients with carcinoma of the cervix undergoing high-dose-rate brachytherapy- 2D dose analysis
http://www.ijcto.org/index.php/IJCTO/article/download/237/2651
Talluri, Anil; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Yarrama, Aparna; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad
Ahamed, Shabbir; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Gudipudi, Deleep; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Madhusudhana Sresty, NVN; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Alluri, Krishnam; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Puriparthi, Lakshmi; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
2015-01-30 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.21
Medical Physics
Supine; Lithotomy; Time Dose Pattern; Bladder; Rectum
Brachytherapy
Nil
en
Purpose: To assess the dosimetry to organs at risk (OARs) in lithotomy position with a planned time-dose pattern obtained from supine position. Methods: The sample consists of thirty patients with carcinoma of the uterine cervix, Stage II and III. Patients often feel discomfort in supine position (S position) when compared to lithotomy position (M position) due to relaxation of pelvic floor muscles after the insertion of applicator (tandem and ovoids) or before delivery of the treatment. Each patient was imaged with orthogonal X- ray radiographs simultaneously in two positions, i.e. S position and M position. Dwell time and dwell position pattern obtained from the optimized plan in S position was used to generate plan in M position. Following dose reference points (point A, pelvic wall points, bladder points, rectal, anorectum (AR point) and rectosigmoid (RS point) points) were identified for analysis in S and M positions. The dosimetric data for reference points generated by the Brachyvision TPS was analyzed.Results: Pelvic wall points registered lower doses in M position when compared to S position. Mean doses for right pelvic wall point (RPW) and left pelvic wall point (LPW) were reduced by -10.02 % and -11.5% in M position, respectively. International Commission on Radiation Units and Measurements (ICRU) bladder point also registered lower doses in M position with a mean dose of -6.8%. Rectal point showed dose reduction by mean of -6.4%. AR and RS points showed an increased dose in M position by a mean of 16.5% and 10%, respectively. Conclusion: Current dosimetry procedure serves as a model with time-dose pattern planned for S position, but delivered in M position, without dose optimization. Prioritization of comfort and position can be considered in conjunction with optimization of dose.
oai:ojs.ijcto.org:article/323
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.12
2016-01-03T12:17:48Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 3 (2015): July - September
A Monte Carlo model for independent dose verification in IMRT and VMAT for the Varian Novalis TX with high definition MLC
http://www.ijcto.org/index.php/IJCTO/article/download/323/3190
Vazquez Quino, Luis; Department of Radiation Oncology, Alyzen Medical Physics Inc, Paragould
Huerta Hernandez, Claudia; Department of Radiation Oncology, Alyzen Medical Physics Inc, Paragould
Papanikolaou, Nikos; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio
Gutierrez, Alonso; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio
Esquivel, Carlos; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio
Eng, Tony; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio
Manciu, Marian; Department of Physics, University of Texas at El Paso, El Paso
Stathakis, Sotirios; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio
2015-07-06 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.12
Medical Physics
Monte Carlo simulations; BEAMnrc; MCSIM; Novalis TX; HD-MLC
en
Purpose: With intensity modulated radiation therapy (IMRT), the physician can prescribe, design and deliver optimized treatment plans that target the tumor and spare adjacent critical structures. The increased conformity of such plans often comes at the expenses of adding significant complexity to the delivery of the treatment. With volumetrically modulated arc therapy (VMAT), in addition to the modulation of the intensity of the radiation beam, other mechanical parameters such as gantry speed and dose rate are varied during treatment delivery. It is therefore imperative that we develop comprehensive and accurate methods to validate such complex delivery techniques prior to the commencement of the patient’s treatment. Methods: In this study, a Monte Carlo simulation was performed for the high definition multileaf collimator (HD-MLC) of a Varian Novalis TX linac. Our simulation is based on the MCSIM code and provides a comprehensive model of the linac head. After validating the model in reference geometries, treatment plans for different anatomical sites were simulated and compared against the treatment planning system (TPS) dose calculations. All simulations were performed in a cylindrical water phantom as opposed to the patient anatomy, to remove any complexities associated with density effects. Finally, a comparison through gamma analysis of dose plane between the simulation, the TPS and the measurements from the Matrixx array (IBA) was conducted to verify the accuracy of our model against both the measurements and the TPS. Results: Gamma analysis of ten IMRT and ten VMAT cases for different anatomical sites was performed, using a 3%/3 mm passing criterion. The average passing rates were 97.5% and 94.3% for the IMRT and the VMAT plans respectively when comparing the MCSIM and TPS dose calculations. Conclusion: In the present work a Monte Carlo model of a Novalis TX linac which has been tested and benchmarked to produce phase-space files for the treatment head of the linac was used to produce a input phase-space to calculated dose deposition phenomena in different geometries for IMRT and VMAT treatment modalities. The control points defined for the MLC were replaced by blocks with the same characteristics and materials of the linac MLC to speed up the simulation time. With this technique a simulation of a typical IMRT case can be performed with a 10 computer cluster in about 1.02 hours in average. If the number of computer used is increased the computing time can be reduced even more which make our model suitable for clinical use as a second check method to compare the TPS dose calculated. Our results showed that for IMRT and VMAT deliveries with a HD-MLC, there is an average of 95.9% of the points have a gamma index less than 1 with our chosen criterion between our Monte Carlo simulations and the corresponding measurements and TPS calculations in a cylindrical water equivalent phantom. This Monte Carlo code can be used as pre-treatment, independent dose calculation verification for IMRT and VMAT deliveries.
oai:ojs.ijcto.org:article/411
2016-07-16T06:23:17Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.3
2016-07-16T06:23:17Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 1 (2016): January - March
The role of pre- and post-SRS systemic therapy in patients with NSCLC brain metastases
http://www.ijcto.org/index.php/IJCTO/article/download/411/3754
http://www.ijcto.org/index.php/IJCTO/article/download/411/3755
http://www.ijcto.org/index.php/IJCTO/article/download/411/3756
http://www.ijcto.org/index.php/IJCTO/article/download/411/3757
http://www.ijcto.org/index.php/IJCTO/article/download/411/3758
Patel, Shyamal; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Mourad, Waleed; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Patel, Rajal; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Kabarriti, Rafi; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Young, Rebekah; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Yaparpalvi, Ravi; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Hong, Linda; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
LaSala, Patrick; Department of Neurosurgery, Montefiore Medical Center, Bronx, New York
Guha, Chandan; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Kalnicki, Shalom; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
Garg, Madhur; Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York
2015-12-07 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.3
Radiation Oncology
SRS and Chemotherapy, Lung Cancer Brain Metastases, SRS Chemotherapy Interval, SRS for NSCLC Brain Metastases
en
Purpose: We report our experience with stereotactic radiosurgery (SRS) for NSCLC brain metastases. We then assess the prognostic value of pre- and post-SRS systemic therapy (PrSST and PoSST) and evaluate the timing of PoSST.Methods: In this retrospective study, we analyzed 96 patients with lung cancer and ECOG PS ≤ 3 who underwent SRS during 2007-2013. Recorded factors included SRS treatment parameters, systemic status of disease (SDS) at time of SRS, and the use of PrSST and PoSST. SDS was designated as pulmonary disease or extrapulmonary disease. For analysis, the SRS-PoSST interval (SPI) was divided into ≤30 days and >30 days. Univariate and multivariate analyses were performed.Results: 85 patients with NSCLC were included in this analysis. 48% received PrSST and 48% received PoSST. 57% of patients had pulmonary disease while 40% had extrapulmonary disease. 46% of patients had synchronous metastases. At a median follow-up of 6 months, the median survival was 6.4 months and the actuarial overall survival at 3, 6, 12, and 36 months was 80%, 52%, 31%, and 6%. Extrapulmonary disease (p = 0.008) negatively predicted for survival while the receipt of any systemic therapy (p = 0.050) or PoSST alone (p = 0.039) positively predicted for survival. In patients receiving PoSST, an SPI >30 days positively predicted for survival (HR 0.28, 95% CI 0.13-0.62, p = 0.002) regardless of SDS.Conclusion: Our results indicate the prognostic importance of systemic therapy and specifically PoSST. Additionally, delaying the initiation of PoSST to >30 days seems beneficial. This finding was potentially influenced by neurotoxicity after SRS. Further investigation is warranted to define the optimal SPI.
oai:ojs.ijcto.org:article/495
2016-07-16T11:29:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.6
2016-07-16T11:29:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 2 (2016): April - June
Clinical characteristics of triple negative breast cancer in Egyptian women: a hospital-based experience
http://www.ijcto.org/index.php/IJCTO/article/download/495/4116
Gado, Nivine; Department of Clinical Oncology, Ain-Shams University, Cairo,
Ibrahim, Dina; Department of Clinical Oncology, Ain-Shams University, Cairo
Atef, Doaa; Department of Clinical Oncology, Ain-Shams University, Cairo
Kanaan, Ahmed; Department of Clinical Oncology, Ain-Shams University, Cairo
2016-06-30 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.6
Clinical Oncology
Breast cancer, Triple negative, Recurrence, Survival, Hormonal receptors, HER-2.
en
Purpose: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis despite the high rates of response to chemotherapy. We aim to study the clinical features, factors influencing recurrence and survival outcomes of TNBC patients.Methods: We retrospectively studied the charts of patients with biopsy proven TNBC treated at The Clinical Oncology Department Ain-Shams University between 2009 and 2012.Results: One hundred and forty five patients fulfilled the eligibility criteria. The incidence of TNBC was 10.5% - 15% with a mean of 12% of all breast cancer patients. The follow-up duration ranged from six months to four years. The age range was 26 to 78 years. Infiltrating ductal carcinoma represented 93.1% of the pathologic types. 87% of patients were free of metastases (M0) at presentation. Clinical stages II and III represented 38 and 39.5% of the patients. 66% of patients had modified radical mastectomy. Following surgery, 77.5% of patients received adjuvant chemotherapy while 61% of the patients had adjuvant radiation therapy. Anthracyclines based chemotherapy was given to 52% of patients. Disease-free survival (DFS) of the M0 patients at 20 and 30 months was 92% and 80% respectively. Relapse occurred in 23% of M0 patients. After a mean duration of DFS of 15.1 months, the most common sites of metastases for relapsed M0 patients were pulmonary (44.8%), bone (41.4%), and locoregional (13.8%). The median overall survival (ORS) of patients was 18 months (1 - 45 months), whereas for the M1 group of patients the median ORS was 9 months (2 - 29 months).Conclusion: The incidence, pathological characteristics, and clinical behavior of TNBC were similar to what is mentioned in the literature. Adding taxanes to the chemotherapy protocols and using postoperative radiotherapy were both associated with a significant increase in the mean period of DFS, while did not significantly affect the ORS.
oai:ojs.ijcto.org:article/546
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.5
2017-02-12T15:24:27Z
International Journal of Cancer Therapy and Oncology
Vol 4, No 4 (2016): October - December
Dosimetric analysis of 3D-conformal radiotherapy and intensity modulated radiotherapy for treatment of advanced stage cervical cancer: A comparative study
http://www.ijcto.org/index.php/IJCTO/article/download/546/4437
http://www.ijcto.org/index.php/IJCTO/article/download/546/4823
http://www.ijcto.org/index.php/IJCTO/article/download/546/4825
Sri Krishna, Gangarapu; 1Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad -500004, Telangana
Venkata Ramireddy, Marella; 1Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad -500004, Telangana
Ayyangar, Komanduri; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska
Yadagiri Reddy, Palreddy; Department of Physics, University College of Science, Osmania University, Hyderabad, Telangana-500007
2016-12-26 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.5
Medical Physics
Three dimensional conformal radiotherapy, Intensity modulated radiotherapy, Organs at risk, Uniformity index, Conformity index, Homogeneity index, Dose spillage index.
Medical Physics
en
Purpose: The purpose of this study is to analyze the dosimetric parameters of three dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT) with seven and nine fields (7F-IMRT, 9F-IMRT) in selected advanced stage cervical cancer cases.Methods: Fifteen cases of cervical cancer (IIB to IIIB) were selected for retrospective analysis. All the cases were previously treated with 3DCRT technique with prescribed dose of 50 Gy in 25 fractions. For this study, plans with seven fields IMRT and nine fields IMRT were generated for all patients following Radiation Therapy Oncology Group (RTOG) guidelines. The plans were compared on the basis of planning target volume (PTV) coverage (dose to 1%, 5%, 95% and 99% of target), maximum dose and mean dose to organs at risk (OARs) and also doses at different volumes of OARs. Apart from this, uniformity index (UI), homogeneity index (HI), conformity index (CI) and dose spillage index (R50%) were also calculated with respect to PTV coverage.Results: The average dose value of PTV coverage for all three techniques were comparable and all the DVH indices for 7field IMRT (UI (1.04±0.01), HI (0.07 ±0.02), CI (0.75±0.03) and R50% (4.47±0.36)) were better than 3DCRT and 9F-IMRT techniques. All OAR doses were significantly reduced in 7F- IMRT compared to 3DCRT and 9F- IMRT. The target volumes ranged from 769.2 ml to 1375.6 ml with average target volume of 1071.9 ml (SD: 205.38 ml).Conclusion: This study showed that significant dose reduction to OARs could be achieved with seven field IMRT plans by maintaining the PTV coverage compared to 3DCRT or 9F- IMRT for treating cervical cancer in advanced stages particularly from IIB to IIIB.
oai:ojs.ijcto.org:article/602
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.9
2017-12-17T14:56:15Z
International Journal of Cancer Therapy and Oncology
Vol 5, No 1 (2017): January - December
Clinical implementation of IMRT step and shoot with simultaneous integrated boost for breast cancer: A dosimetric comparison of planning techniques
http://www.ijcto.org/index.php/IJCTO/article/download/602/4756
http://www.ijcto.org/index.php/IJCTO/article/download/602/4757
http://www.ijcto.org/index.php/IJCTO/article/download/602/4758
http://www.ijcto.org/index.php/IJCTO/article/download/602/4759
http://www.ijcto.org/index.php/IJCTO/article/download/602/4760
http://www.ijcto.org/index.php/IJCTO/article/download/602/4761
http://www.ijcto.org/index.php/IJCTO/article/download/602/4762
Nastasi, Ugo; Department of Radiology and Radiotherapy, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
Gianusso, Laura; Department of Physics, Turin University, Turin, Italy
De Monte, Francesca; Department of Radiology and Radiotherapy, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
Cannizzaro, Alessandra; Department of Radiology and Radiotherapy, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
Rovea, Paolo; Department of Radiology and Radiotherapy, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
2017-08-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.9
Radiation Oncology, Medical Physics, Medical Dosimetry
Breast cancer, Radiotherapy, IMRT, Treatment planning, Dosimetry, Contralateral breast dose, Second cancer risk.
Original Article
en
Purpose: Radiotherapy post-lumpectomy with two coplanar tangent beams is the standard treatment for women with early stage breast cancer. Despite the use of wedges as tissue compensators, the resultant plans often contains a significant dose gradient and 'hot spots' in excess of 15% or more of prescribed dose. In recent years a field-in-field (FIF) dose-compensation technique, which use two standard tangent fields and one or two (rarely three) small beams within these, was developed. It allows to obtain a more uniform dose throughout the target volume in the majority of cases but not in all. This study presents our experience to develop optimal intensity modulated radiation therapy (IMRT) techniques to be applied clinically in those cases where the traditional technique with two tangent fields or its variant field in field (FIF) are unable to achieve a satisfactory planning target volumes (PTVs) coverage and dose objectives to the organs at risk (OARs). Methods: We investigated two pure IMRT plans (named 3F-IMRT and 4F-IMRT) and a hybrid one (H-IMRT). Treatment plans were performed for 7 left-sided and 4 right-sided breasts using simultaneously integrated boost (SIB) planned technique with inverse optimization. Results were compared with those obtained with FIF technique. Dose prescribed was 45 Gy/20 fractions to the breast and 50 Gy /20 fractions to the lumpectomy cavity delivered in 5 fr/week. Dose–volume histograms were generated and parameters as target dose coverage, conformity and homogeneity as well as OARs dose distribution were analyzed. Finally the secondary cancer risk to contralateral breast due to radiation was evaluated as a further parameter for the choice of the optimal plan. Results: Compared to the FIF, the three IMRT plans provided the same target coverage and a better dose conformation, but a worst dose homogeneity of the boost target. The volume of the OARs, receiving higher doses than 15 Gy was reduced but was increased the volume receiving low doses. This causes the increase of the risk of radiation induced cancer, especially for the contralateral breast. For this organ, the highest value of the excess absolute risk (EAR) was associated to the 4F-IMRT, while the lower, to the FIF. Conclusion: The intensity-modulated radiation therapy techniques 5F-IMRT and 4F-IMRT were the best to be applied clinically in those cases, where the traditional technique of irradiation of the breast is unable to achieve the PTVs coverage and dose objectives to the OARs. However, all the IMRT techniques showed an increased volume of healthy tissues receiving low doses, so they should not be used in extensive manner and in particular should be avoided in the cases of young women due to the excess of risk to develop a secondary cancer.
oai:ojs.ijcto.org:article/11
2014-03-16T14:23:21Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Moorthy
2014-03-16T14:23:21Z
International Journal of Cancer Therapy and Oncology
Vol 1, No 1 (2013): September - October
Dosimetric study of SIB-IMRT versus SIB-3DCRT for breast cancer with breath-hold gated technique
http://www.ijcto.org/index.php/IJCTO/article/download/11/44
http://www.ijcto.org/index.php/IJCTO/article/download/11/45
http://www.ijcto.org/index.php/IJCTO/article/download/11/0
http://www.ijcto.org/index.php/IJCTO/article/download/11/153
Moorthy, Suresh; Department of Oncology & Hematology, Salmaniya Medical Complex, Kingdom of Bahrain
Sakr, Hamdi; Department of Oncology & Hematology, Salmaniya Medical Complex, Kingdom of Bahrain
Hasan, Shubber; Department of Oncology & Hematology, Salmaniya Medical Complex, Kingdom of Bahrain
Samuel, Jacob; Department of Oncology & Hematology, Salmaniya Medical Complex, Kingdom of Bahrain
Al-Janahi, Shaima; Department of Oncology & Hematology, Salmaniya Medical Complex, Kingdom of Bahrain
Murthy, Narayana; Department of Physics, Acharya Nagarjuna University, Guntur, India
2013-10-10 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Moorthy
Radiation Oncology; Medical Physics; Medical Dosimetry
Intensity Modulated Radiation Therapy, Three Dimensional Conformal Radiotherapy, Simultaneous Integrated Boost, Breath-Hold, Technique, Breast Cancer
Breast cancer
en
Background and Purpose: 3-dimensional conformal therapy (3DCRT) is widely employed radiation therapy technique for breast cancer, but there is still need to minimize the doses to organ at risk (OAR) using 3DCRT. A few clinical studies have discussed using intensity modulated radiation therapy (IMRT) to address this shortfall. Simultaneous integrated boost (SIB) has been used in head and neck and prostate cancer, and there is a growing interest in using SIB for breast cancer too. This study aimed to compare SIB-IMRT versus SIB-3DCRT for breast cancer patients. Materials and Methods: SIB-3DCRT treatment plans were created for 36 consecutive patients. Dose was prescribed as 45 Gy in 25 fractions to the planning target volume (PTV)-1 and 60 Gy in 25 fractions to PTV-2. Treatment plans were normalized to 95% of PTV volume receiving 95% of the prescription dose. The conformity index (CI), homogeneity index (HI), lung dose, heart dose, left anterior descending artery(LAD) dose, and low dose volume and integral dose of normal healthy tissue were recorded and analyzed. Results: With the use of IMRT technique, there was an improvement in CI (0.14) when compared to CI of 3DCRT (0.18; p = 0.01). However, there was no significant difference in the HI (p = 0.45). On average, the V20Gy of ipsilateral lung was 37.9 % for 3DCRT and 22.4 % (p < 0.01) for IMRT, whereas the V20Gy of total lung (ipsilateral + contralateral) was 21.8% for 3DCRT and 12.14 (p < 0.01) for IMRT. Similarly, average V40Gy of heart was 7.5 % for 3DCRT and 2.13 % (p = 0.01) for IMRT. The LAD maximum dose to left side breast patients, on average, was 39.5 Gy for 3DCRT and 29.17 Gy (p = 0.03) for IMRT. The average number of monitor units was about 180 for 3DCRT and 1441 (p < 0.01) for IMRT. Conclusion: IMRT for breast cancer treatment is feasible. In comparison to 3DCRT, IMRT can reduce the maximum dose to the target volume, and dose to the OAR. However, 3DCRT technique is superior in terms of low dose volume, integral dose, and treatment time. With the use of breath-hold gated technique in IMRT, it can further improve the target coverage and reduction of doses to the heart, lung, and LAD. SIB technique could reduce the overall treatment duration by about one week.----------------------------------Cite this article as:Moorthy S, Sakr H, Hasan S, Samuel J, Al-Janahi S, Murthy N. Dosimetric study of SIB-IMRT versus SIB-3DCRT for breast cancer with breath-hold gated technique. Int J Cancer Ther Oncol 2013;1(1):010110. DOI: http://dx.doi.org/10.14319/ijcto.0101.10
oai:ojs.ijcto.org:article/72
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/Ekambaram
2014-08-16T18:42:03Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 3 (2014): July - September
Analysis of low dose level volumes in intensity modulated radiotherapy and 3-D conformal radiotherapy
http://www.ijcto.org/index.php/IJCTO/article/download/72/1159
http://www.ijcto.org/index.php/IJCTO/article/download/72/1160
http://www.ijcto.org/index.php/IJCTO/article/download/72/1161
http://www.ijcto.org/index.php/IJCTO/article/download/72/1162
http://www.ijcto.org/index.php/IJCTO/article/download/72/1163
http://www.ijcto.org/index.php/IJCTO/article/download/72/1164
http://www.ijcto.org/index.php/IJCTO/article/download/72/1165
http://www.ijcto.org/index.php/IJCTO/article/download/72/1166
http://www.ijcto.org/index.php/IJCTO/article/download/72/1167
http://www.ijcto.org/index.php/IJCTO/article/download/72/1168
http://www.ijcto.org/index.php/IJCTO/article/download/72/1169
http://www.ijcto.org/index.php/IJCTO/article/download/72/1170
http://www.ijcto.org/index.php/IJCTO/article/download/72/1171
http://www.ijcto.org/index.php/IJCTO/article/download/72/1172
http://www.ijcto.org/index.php/IJCTO/article/download/72/1173
http://www.ijcto.org/index.php/IJCTO/article/download/72/1174
http://www.ijcto.org/index.php/IJCTO/article/download/72/1175
http://www.ijcto.org/index.php/IJCTO/article/download/72/1176
Ekambaram, Varadharajan; Department of Radiation Oncology, Billroth Hospitals LTD, Chennai
Velayudham, Ramasubramanian; Nuclear and Medical Physics Division, VIT University, Vellore
2014-05-04 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/Ekambaram
Radiation Oncology; Radiotherapy
Intensity Modulated Radiotherapy; Three Dimensional Conformal Radiotherapy; Treatment Planning System; Analytical Anisotropic Algorithm; Low Dose Regions
Intensity Modulated Radiotherapy
Dr.Rajesh Jeganathan, Billroth Hospitals, Chennai; Shiyama Swaminathan,Billroth Hospitals, Chennai; Dr.Padmanabhan Loganathan,Billroth Hospitals, Chennai
en
Purpose: To analyze the low dose volume regions in four facets: Analysis 1: low dose volume regions were compared between 3-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) plans for each case; Analysis 2: the effect on low dose volume in 3DCRT as the number of fields are increased; Analysis 3: the same effect in IMRT, and Analysis 4: above two analysis were inter-compared between the two modalities. Methods: For this work 18 patients were taken for which both 3DCRT and IMRT plans with varying number of beams were planned using Anisotropic Analytical Algorithm (AAA) in Eclipse 10 Version Treatment Planning System with two to nine beams and five to nine beams, respectively. The plans were analyzed on the basis of conformity index and dose to the critical structures.Results: In Analysis 1, 5 Gy volume region was greater for IMRT than for 3DCRT but the 10 Gy, 15 Gy and 20 Gy volume regions were smaller for IMRT plans. In Analysis 2 and 3 shows that as the number of fields increases the low dose volume regions also increases. In Analysis 4, the effect pronounced due to increase in the beam portals is similar in 3DCRT as well as IMRT. Also it was seen that with same number of beams for both IMRT and 3DCRT, low dose volume region is higher in 3DCRT than IMRT. Conclusion: Low dose volume regions are a major concern in 3DCRT and IMRT plans with multiple beams because of its risk of secondary cancer incidence. This study concludes that by increasing number of beams low dose volume regions increases in 3DCRT and IMRT. It shows that the low dose volume regions are slightly higher in IMRT than 3DCRT, however with proper optimization the volume of tissue receiving 10 Gy, 15 Gy and 20 Gy can be reduced.-----------------------Cite this article as: Ekambaram V, Velayudham R. Analysis of low dose level volumes in intensity modulated radiotherapy and 3-D conformal radiotherapy. Int J Cancer Ther Oncol 2014; 2(3):02032. DOI: 10.14319/ijcto.0203.2
oai:ojs.ijcto.org:article/165
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0204.10
2014-12-13T14:36:24Z
International Journal of Cancer Therapy and Oncology
Vol 2, No 4 (2014): October - December
Efficacy and safety of transarterial chemoembolization combined to conformal radiotherapy for uninodular hepatocellular carcinoma
Merle, Philippe; Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon
Rode, Agnes; Radiology Department, Groupement Hospitalier Lyon Nord, Lyon
Benlaredj, Redouane; Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon
Cuinet, Marie; Radiology Department, Groupement Hospitalier Lyon Nord, Lyon
Said, Tammam; Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon
Bathaix, Fulgence; Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon
Enachescu, Ciprian; Radiotherapy Department, Centre Hospitalier Lyon Sud, Lyon
Mornex, Francoise; Radiotherapy Department, Centre Hospitalier Lyon Sud, Lyon
2014-10-02 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0204.10
Hepatology; Oncology; Radiotherapy
Hepatocellular carcinoma; Conformal Radiotherapy; Chemoembolization
Hepatocellular carcinoma
None
en
Purpose: A proportion of patients with uninodular hepatocellular carcinoma (HCC) cannot benefit from potential curative therapies such as liver transplantation, surgical resection or radiofrequency ablation. Thus, they are prone to receive transarterial chemoembolization (TACE) that is a palliative option with low probability of both complete response and prolonged local control. Herein, we assessed the combination of TACE and 3D-high dose conformal radiotherapy (3D-HDCRT) for efficacy and safety in HCC. Methods: We retrospectively analyzed the outcome of 35 consecutive patients with uninodular HCC ≤ 100 mm, treated by one course of TACE combined to 3D-HDCRT. The follow-up consisted on clinics, biology, hepatic CT-scan or MRI at month-1 and -3, and thereafter every 3 months. Results: Complete response was obtained in 80% of patients following mRECIST criteria (95% in HCC ≤ 50 mm, and 60% in HCC > 50 mm) with uncommon local recurrence (11%), overall survival rates of 79%, 59% and 44% at respectively 1, 2 and 3 years (median, 37.3 months), and 11.4% grade-3/4 toxicities. Pre-therapeutic α-fetoprotein level ≥ 200 ng/mL was found as a strong predictor of poorer outcome. Conclusion: We showed that TACE combined to 3D-HDCRT can be highly efficient to reach local control and interesting overall survival rates for uninodular HCC, with limited severe toxicities for Child-Pugh A patients. Subsequent prospective controlled trials are warranted for comparison with therapeutic standards.
oai:ojs.ijcto.org:article/151
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
v2
http://www.ijcto.org/index.php/IJCTO/article/view/0301.15
2015-03-29T11:59:32Z
International Journal of Cancer Therapy and Oncology
Vol 3, No 1 (2015): January - March
Treatment of skin and subcutaneous cancer diseases by hyperthermic methods
http://www.ijcto.org/index.php/IJCTO/article/download/151/1860
Kovziridze, Zviad; Department of Chemical and Biological Technologies, Georgian Technical University, Tbilisi
Menteshashvili, Guram; Institute of Clinical Oncology, Tbilisi
Khorava, Paata; Institute of Clinical Oncology, Tbilisi
Bluashvili, Khatia; Department of Chemical and Biological Technologies, Georgian Technical University, Tbilisi
2014-12-23 00:00:00
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
url:http://www.ijcto.org/index.php/IJCTO/article/view/0301.15
Controlled Local Hyperthermia; Necrosis; Ulceration; Metastasis
en
Purpose: The present work pursues perfection of highly efficient anticancer, principally new methodology and technology. It deals with the comparative study of anticancer activity of controlled local hyperthermia in animals and determination-de- velopment of optimal regimes and schemes. Furthermore, it also presents the work on new clinical device of high anticancer effect. Methods: Authors used controlled local hyperthermia for this study. In our experiments, we used 3 to 3.5 months-old non-pedigree (nonlinear) white mice (mass: 18-30 gram). After mice selection for the experiments, animals were placed in vivarium, in quarantine regime for 10 to 4 days. Individual protocols were drawn for each animal. Similar feeding and handling regimes were created for all animals. Transplantable malignant cancer strain, Erlich adenocarcinoma, was used. Results: Experiments on animals were successful. There are positive conclusions of pathological-anatomy laboratory “PathGeo”: Form # IV -200- 6A, for the examination # 3119-12 and # 15/02 and macro-morphological and micro-morphological description of the study # 15272-13. On the basis of the results of morphological study, it was proved that liver and lungs (the main target bodies) were intact, and secondary cancer injuries were not fixed. After three sessions of hyperthermia treatment, the decrease in sizes of cancer formations and necrosis of diseased sections were visualized, while massive necrosis was observed after seven sessions. In all cases, necrosis and ulceration of diseased places were observed, which refers to transition of cancer into phase of healing. After eight-ten sessions, necrosis of cancer and ulceration were observed, which refers to irreversibility of the process and efficiency of the applied method of hyperthermia. Conclusion: Anticancer effect of hyperthermia conditioned by temperature fields was proved, which was expressed in inhibition of cancer growth, resorption and increase of life length of experimental animals. The method of treatment was selected with maximum anticancer effect free of side effects and was offered as a new, perspective alternative or additional means for treatment of malignant cancers.
b37b3e987198d8a251fe57c17f9bf0bd